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2ii) Abstract
Recent advances in molecular genetics have enabled generation of sophisticated 
genetically-modified mouse models to study specific molecules and their biological 
function in vivo. Here, I investigated biochemical changes in two different genetically- 
modified mouse lines with previously described learning and memory phenotypes.
Firstly, I analysed biochemical changes in a mouse line carrying a threonine to alanine 
point mutation at Thr286 of alpha Ca2+/calmoduline-dependent kinase II (aCaMKII), 
which disenables this phosphorylation site. Autophosphorylation at Thr286 switches 
aCaMKII into an autonomous activity mode. The T286A mutant mice displayed 
changes in basal phosphorylation levels. In order to study biochemical changes after 
activity-dependent synaptic potentiation, an in vivo long-term potentiation (LTP) 
approach was established and validated by assessing activity-dependent changes in 
phosphorylation levels of well-characterised marker molecules including synapsin I and 
NR2B. Both aCaMKII and pCaMKII exhibited elevated levels of autophosphorylation 
after LTP stimulation in hippocampal area CA1 and dentate gyrus (DG). This finding 
indicates that pCaMKII may compensate for the loss of autonomous aCaMKII activity 
in T286A mutants. Furthermore, induction of LTP triggered phosphorylation of 
glycogen synthase kinase 3 (GSK3) at its inhibitory site suggesting a role for GSK3 in 
synaptic plasticity.
Secondly, I investigated a transgenic (TG) mouse line expressing the cyclin-dependent 
kinase (Cdk5) activator protein, p25, a protein previously linked to some aspects of 
Alzheimer’s disease (AD). The forebrain restricted expression of p25 started postnatally 
and stayed constant throughout the life-span of the TG mice. The expression of p25 
triggered constitutive over-activation of Cdk5 in the TG mice. The p25 TG mice 
displayed age-dependent hyperphosphorylation of the microtubule-associated protein
3tau and age-dependent alterations in the processing of amyloid precursor protein (APP). 
Furthermore, p25-induced over-activation of Cdk5 led to inhibition of GSK3. This 
negative regulation of GSK3 was lost in aged p25 TG mice and correlated with the 
increased tau hyperphosphorylation. The levels of tau phosphorylation in aged p25 mice 
were reduced after treatment with lithium, an inhibitor of GSK3. These results indicate 
that GSK3 directly mediates tau hyperphosphorylation, whereas Cdk5 acts indirectly via 
inhibitory control of GSK3.
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CHAPTER 1: Introduction
1.1) General introduction
Learning and memory are key aspects of human cognition and their improper 
functioning manifests in multiple severe cognitive deficits. Therefore, fully 
understanding the cellular and molecular mechanisms of how the nervous system 
acquires, transforms and stores information is a major goal in neurosciences. 
Anatomical, pharmacological and electrophysiological studies have provided general 
understanding of the processes important for learning and memory. First insights into 
the mechanism of learning and memory were gained by psychological examination of 
patients with lesions in specific brain regions and animal lesion studies. Recent 
advances in molecular and genetic techniques has helped greatly to broaden the 
understanding of learning and memory on a molecular and cellular level. Much research 
focused on neurons, which are the basic functional unit of the nervous system. The 
study of synapses, specialised sites of contact between neurons important for 
intemeuronal signalling helped greatly in identifying molecules that are involved in 
learning and memory, and in characterising their functions.
Previously, biochemical processes were investigated in in vitro systems, cellular 
cultures and in single-cellular organisms including bacteria and yeast. This work 
established many molecular mechanisms of basic biological functions, such as the 
metabolic mechanisms. However, the elucidation of the complex processes used in 
learning and memory from the molecular to the systems level required the development 
of novel methods and research strategies. Over the last decades the advances in 
biochemistry and molecular biology have made it possible to study biological processes 
in vivo in model organisms using spontaneous mutations, targeted genetic deletion or 
modification of specific molecules. These conventional transgenic and gene knockout 
technologies have become invaluable experimental tools for modelling genetic
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disorders, testing gene functions, evaluating drugs and toxins, and helping to answer 
fundamental questions in basic and applied research. These techniques helped greatly 
the advancement in the field of learning and memory research by enabling behavioural 
studies combined with targeted molecular manipulations in model organisms. Several 
model organisms including the worm (Caenorhabditis elegans), the fruit fly 
(Drosophila melanogaster) and the mouse (Mus musculus) have been exploited to 
explore the mechanisms underlying learning and memory,
1.2) Generation of genetically-modified mice and recent advances
Pharmacological approaches helped greatly to characterise molecular and cellular 
mechanisms important for learning and memory. However, the drawbacks of 
pharmacological studies are the lack of specificity of the drugs, the absence of 
pharmacological reagents for many targets, and the difficulty of confining the 
pharmacological manipulation. Over the last two decades advances in mouse molecular 
genetic techniques enabled the generation of knock-out (KO), knock-in, targeted point 
mutation, region-restricted and conditional transgenic mouse models (see for review 
Mayford & Kandel, 1999; Tonegawa et al., 2003). The generation of genetically- 
modified mice made it possible to investigate the effect of a specific molecule on 
learning and memory at different levels from the molecular and cellular to the systems 
level. Further, with the advent of region-restricted and conditional transgenic mouse 
models the function of a specific molecule can be analysed in distinct brain regions and 
tested at different points in time during life. Together, these approaches opened up new 
avenues to elucidate the molecular mechanisms underlying learning and memory.
The development of embryonic stem (ES) cell technology and gene targeting methods 
and their application in mice provided fundamental insights into gene function (see for 
review Bradley et al., 1998; Capecchi, 2005). This reverse genetic technique allows the
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introduction of a mutation into the genome of a mouse ES cell by homologous 
recombination. The genetically-modified ES cells are injected into blastocysts and then 
implanted into the uterus of foster mothers. The ES cells from the blastocyst develop 
into cells of all embryonic tissues resulting in chimeric mice. Chimeras are mice that 
consist of cells derived from the injected ES cells and from the host blastocyst. 
Chimeric mice, in which the mutation was transmitted to the germ line, are crossed with 
wild-type mice. In this way off-spring are generated that carry the mutation in every cell 
of the body.
As changes in synaptic efficacy are thought to underlie learning and memory, the first 
studies using conventional KO mice focussed on proteins that have been shown to affect 
the efficacy of synaptic transmission. Electrophysiological studies had implicated the
♦ 9 +proteins Ca /calmodulin-dependent protein kinase II (CaMKII) and tyrosine kinases in 
changes of hippocampal long-term potentiation of synaptic transmission (Malinow et 
al., 1989; O’Dell et al., 1991). Hence, conventional KO mice, where the expression of 
aCaMKII or the tyrosine kinase, fyn, was abolished, were studied to evaluate the effects 
of these proteins on learning and memory. Mutant mice lacking aCaMKII displayed 
deficits in hippocampal long-term potentiation that correlated with an impairment in 
spatial learning (Silva et al., 1992a and 1992b). Equally, transgenic mice lacking the 
expression of the protein kinase fyn were impaired in hippocampal long-term 
potentiation and spatial learning (Grant et al., 1992). However, these mice also had 
deficits in hippocampal development, which interfered with their cognitive capacity. 
Therefore, it was impossible to make conclusions about the involvement of fyn in 
learning and memory processes.
These studies using conventional KO mice showed that the introduction of genetic 
changes to the germ line of a mouse can be a powerful tool to track down the effects of 
a particular gene and a meaningful approach to dissecting the molecular mechanisms of 
learning and memory. However, they exposed also some of the shortfalls of the 
conventional genetically-modified mice generated by gene targeting techniques. One of
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the major problems is that the genetic changes are present throughout the entire life of 
the mouse. This makes it difficult to distinguish between acute, direct effects of the 
genetic changes on the phenotype and consequences elicited as a result of prolonged 
genetic alteration, developmental effects or compensatory mechanisms. Many proteins 
are implicated in developmental processes and hence, their genetic alteration may have 
severe developmental consequences, which complicate or even preclude an 
experimental analysis as demonstrated by, for example, embryonic lethal KO 
phenotypes (e.g. glycogen synthase kinase 3p (GSK3|3) KO mice (Hoeflich et a l , 2000) 
and presenilin 1/2 KO mice (Donoviel et a l , 1999)). Another restriction that arises from 
the constant presence of the genetic changes is adaptive gene expression. In this case the 
genetic changes trigger an up or down regulation of some other gene products, which 
may impinge on various cellular processes and may even lead to cytotoxicity and hence 
preclude an analysis of the effects mediated by the introduced genetic alteration. This 
has to be distinguished from a regular compensatory mechanism, where another isoform 
or a molecule with similar function can compensate for the function affected by the 
genetic changes. Interestingly, such compensatory mechanisms were observed in 
numerous KO mouse lines (e.g. microtubule-associated protein tau KO mice (Harada et 
a l , 1994) and presenilin 1 KO mice (Yu et a l , 2001)). Though the molecules were 
thought to be crucial for specific cellular processes, the elimination of their expression 
resulted in no or only mild phenotypic changes.
Another problem with conventional genetically-modified mice is that the genetic 
changes are present in every cell of the mouse. Because the genetic alteration of 
molecules might have a different effect in distinct cell types and tissues, this might 
impact on vital functions or even the viability of the mouse. For example, a transgenic 
mouse line expressing the Cdk5 activator p25 in all neuronal cells including the spinal 
cord displays paralysis and is therefore not suitable for learning and memory studies 
(Bian et a l , 2002). Further, the presence of the genetic changes in every cell makes it 
difficult to relate an observed alteration in cellular processes to the function in a whole 
tissue; let alone to a behavioural phenotype.
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To overcome these undesired limitations intrinsic to conventional gene targeting 
approaches more advanced genetic approaches have been developed (see for review 
Mayford & Kandel, 1999; Bockamp et al., 2002). These conditional transgenic 
strategies allow more precisely controlled gene expression or ablation of gene function 
in a spatio-temporal fashion. The Cre/loxP system is commonly used and has been 
successfully applied to generate mouse lines with tissue and cell type specific 
inactivation of genes (conditional KO mice), with temporal control of gene activation 
and with spatially and temporally controlled expression of transgenes (see for review 
Mayford & Kandel, 1999; Bockamp et al., 2002). Regulating the expression or 
inactivation of genes in a temporal manner helps to overcome the problems linked with 
developmental artefacts. The inactivation of genes within specific tissue or cell types is 
a unique tool for investigating the function of gene products in complex physiological 
system networks such as the brain. One disadvantage here is that few tissue and cell 
type specific promoters are known. The temporal control of transgene expression or 
inactivation can be achieved by the use of inducible Cre-recombinase strategies. 
Different systems are used including the tamoxifen system (see, for example, Danielian 
et al., 1998). This reversible inducible regulation by switching transgene expression on 
and off allows the study of the function of a single gene at various time points. This 
strategy is particularly helpful in investigating the involvement of gene products in 
learning and memory processes by performing behavioural tasks with or without 
induction of the transgene or inactivation of the target gene.
Furthermore, the Cre/loxP system can be used to generate mouse lines carrying targeted 
point mutations (see, for example, Giese et al., 1998). This so-called “point lox” 
strategy allows investigating the role of specific residues within a protein. This is 
particularly useful in the study of signalling pathways, where posttranslational 
modifications, such as phosphorylation, at single residues play an important role. 
Hence, with this strategy a specific function of a protein linked to the modification can 
be blocked while other functions remain intact. The use of mice with single point 
mutations has the advantage over total KO mice that complete loss of the gene product
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can lead to compensatory mechanisms, which may not result from the point mutation. 
For example, in KO mice lacking aCaMKII expression, the p-isoform has been 
suggested to compensate for the loss of aCaMKII, whereas in the aCaMKII point 
mutant mouse line T286A no compensation is observed (Giese et al., 1998; Elgersma et 
al., 2002; sec section 3.2).
Along with the gene-targeting techniques, another strategy that is often used for 
generation of transgenic mouse models is the introduction of genes into the mouse 
genome through random genomic integration (see for review Bockamp et al., 2002). 
This technique allows targeted expression of the transgene mRNA in different tissues or 
even cell types in the transgenic mouse by selection of a specific promoter to drive the 
expression. Other factors that affect the level of expression are the number of copies of 
the transgene that are integrated into the mouse genome and the chromosomal 
integration site of the transgene. Learning and memory studies commonly use 
transgenic mouse lines where the transgene is driven by promoters that target the 
expression exclusively to neurons including the neuron-specific enolase (NSE), platelet- 
derived growth factor (PDGF) and aCaMKII promoter. For example, the aCaMKII 
promoter targets the expression to excitatory glutamatergic neurons in the forebrain 
(see, for example, Lui & Jones, 1997). The aCaMKII promoter initiates the expression 
postnatally and maintains constant expression levels. Hence, the transgene is not 
expressed during embryonic development and developmental artefacts can be excluded. 
This makes the aCaMKII promoter an ideal promoter to drive transgene expression in 
transgenic mouse lines used for learning and memory studies.
The advantages of the transgene over-expression approaches over the conventional KO 
mice in the study of learning and memory are that the expression of the transgene can be 
restricted to specific brain regions, whereas in most KO mice the gene is deleted 
everywhere, and that the transgene expression can be initiated at different time points, 
for example postnatally. However, transgenic mouse models with random integration
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mediated over-expression have also their pitfalls. In transgene over-expression 
approaches the expression level of the transgene can only be partially regulated by 
selecting specific promoters and enhancers to drive the expression. But the level of the 
over-expressed transgene depends as well on other factors that can not be regulated, 
such as the site of transgene integration and the number of copies inserted. Further, the 
integration of the transgene into the genome occurs in a random fashion. Thus, the 
expression may be affected by insertion site artefacts. In addition, the insertion into the 
genome might confound the function of endogenous genes by disrupting their 
expression. One has to be cautious when comparing different transgene over-expressing 
mouse lines, because the number of transgene copies, the integration sites and 
subsequently the transgene expression can vary between mouse lines and may have 
different effects on the observed phenotype. Reliable results can be obtained by 
generating and analysing multiple transgenic mouse lines with the same transgene. 
Comparison of the different mouse lines with distinct transgene levels allows 
determining to what extent the insertion site and the transgene level contribute to the 
phenotype and help to distinguish these from the effects mediated by the expression of 
the transgene.
1.3) Memory processes: Short-term and long-term memory
Cognitive studies distinguish a number of different forms of learning and memory 
involving distinct neuronal systems. From the neuropsychological view, human memory 
is characteristically divided into non-declarative (or implicit) and declarative (or 
explicit) memory (see for review Squire et a l , 2004). Non-declarative memory involves 
unconscious recall and includes motor skills, reflexes and emotional responses. 
Declarative memory involves recollection of factual information through a conscious 
effort. This form of memory has been attributed to a neuronal circuit, including all
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association areas of the neocortex, the parahippocampal region and the hippocampus 
(see for review Squire et a l , 2004). Psychological examination of patients with 
hippocampal lesions revealed deficits in declarative memory, such as spatial cognition, 
whereas their non-declarative memory remained intact (see, for example, Scoville & 
Milner, 1957; see for review Squire et a l , 2004). These studies also demonstrated that 
memory formation is a step-wise temporal process involving distinct mechanisms and 
that memories pass through characteristic stages over time. Patients with hippocampal 
lesions can recall old declarative memories, which they acquired long before their 
lesion, but are unable to form new declarative memories.
In neuropsychology, two forms of memory storage are characteristically distinguished: 
short-term memory (STM) describes the first period after memory acquisition, whereas 
long-term memory (LTM) can last for days or years (see for review Milner et a l , 1998; 
McGaugh, 2000a). The study of retrograde amnesic patients suggests that the 
hippocampus plays a role in the consolidation of some forms of LTM (see for review 
Squire et a l , 2004). It is hypothesised that the hippocampus acts as a modulator that is 
implicated in the transformation of STM into LTM. One model of how the 
hippocampus achieves the transformation, is the transfer of acquired information and 
the relevant contextual associations to other areas of the brain, possibly the cortex, (see 
for review Frankland & Bontempi, 2005).
The hippocampus is an area of primitive cortex medially located on the underside of the 
temporal lobe (see for review Amaral & Witter, 1989). It is connected to several 
neighbouring cortical areas, including the perirhinal, entorhinal and parahippocampal 
cortices. The human hippocampus receives direct or indirect inputs from all of the main 
neocortical and thalamic areas, as well as from some limbic structures, including the 
amygdala. This high level of connectivity indicates a central role of the hippocampus in 
memory processes and is suggestive of a structure that might integrate high-order 
information processed in other brain regions.
CHAPTER 1: Introduction 26
From a neurobiological view, it is hypothesised that the molecular and cellular 
mechanisms underlying the different forms of memory may be temporally organised in 
a way similar to the neuropsychological concept described above (see for review 
McGaugh, 2000). Indeed, the molecular processes for memory formation can be 
grouped similarly in a STM and LTM phase. The main distinction between the two 
phases is that new memories are initially labile during the STM phase, until they are 
consolidated to form LTM. Hence, the two phases have been termed labile STM (1- 
STM), which can last from seconds to hours and is sensitive to disruption, and stable 
LTM (s-LTM), which lasts from hours to months (see for review McGaugh, 2000; 
McGaugh & Izquierdo, 2000). On a molecular level the stabilisation process is thought 
to involve changes in synaptic structure and consequently synaptic connectivity. 
Blocking experiments using inhibitors of transcription or protein synthesis inhibitors 
demonstrated that 1-STM does not require de novo protein synthesis (see for review 
Davies & Squire, 1984). In contrast, s-LTM can be blocked by application of such 
inhibitors demonstrating the requirement for transcription and protein synthesis. These 
results are consistent with the observation of changes in gene expression and de novo 
protein synthesis after learning. Hence, it was proposed that the changes in gene 
expression and protein synthesis occurring in s-LTM are a critical step to establishing 
and maintaining synaptic changes. However, once the s-LTM is established, the 
application of these inhibitors does not erase the memory. Thus, it was hypothesised 
that in a first phase memories are modulated, which requires transcription and protein 
synthesis. Once memories are established, they are permanently stored within the brain 
and depend no longer on transcription and protein synthesis.
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1.4) Behavioural studies of learning and memory
Psychological examination of patients with different brain lesions has revealed selective 
memory deficits (see for review Squire et al., 2004). Comparably, in animals including 
primates and rodents brain lesion studies combined with behavioural studies 
distinguished different forms of memory and helped to dissociate distinct memory 
systems (see for review Squire, 1992). This work identified the hippocampus as an 
important brain structure for the processes of learning and the formation of declarative 
memory both in humans and in animals. It has been found that the hippocampus, in 
humans and animals, is involved in the transition from immediate to permanent memory 
and supports specific domains of memory including spatial memory (see for review 
Eichenbaum, 2000). In common with the observation in amnesic humans, the sensory, 
motor, motivational and cognitive processes remained intact in animals after 
hippocampal lesion, as seen, for example, in the visible platform learning task (see for 
review Squire, 1992; Eichenbaum, 2000). Further, in common with observations in 
some human amnesic patients, animal studies showed that memories acquired shortly 
before the hippocampal damage/lesion were lost, whereas memories acquired a long 
time before the damage were intact. Taken together, these findings demonstrated the 
similarity of the main characteristics of hippocampal learning and memory processes 
between humans and animals such as primates and rodents (see for review Squire, 
1992). Hence, these studies validate the use of animal models in specific behavioural 
paradigms to further characterise the neural circuitry and to assess the mechanisms 
underlying learning and memory.
Hippocampal lesion studies in animals demonstrated that some behavioural tasks can be 
performed only when hippocampal function is normal (see for review Eichenbaum, 
2000; Squire et al., 2004). These tasks are called hippocampus-dependent tasks. 
Commonly used behavioural tasks to assess hippocampal-dependent learning and 
memory include the radial arm maze, novel object recognition, social transmission of
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food preferences and contextual fear conditioning (see, for example, Eichenbaum, 
2000).
1.4.1) Spatial learning in the Morris water maze
One of the most frequently used tasks to test hippocampus-dependent spatial learning in 
rodents is the Morris water maze (MWM) (see for review D’Hooge & De Deyn, 2001). 
In this place navigation task the mouse learns to escape from submersion in a pool by 
swimming towards an invisible platform located just underneath the surface. The animal 
uses visual cues positioned around the pool to locate the platform. The training protocol 
consists of several repeated trails over several days. The learning progress can be tested 
by comparing the escape latency and the length of the swim path of the individual trials. 
As the animal learns the location of the platform the latency to find the platform 
decreases and the swim path gets shorter. Memory retention and search strategy can be 
assessed in probe trials where the platform is removed. The amount of time the mouse 
spends looking for the platform in the target quadrant, where the platform is normally 
located, is indicative of memory. Further, memory can be assayed by reversal training in 
the MWM, where the platform is placed in a new location. At first, the animal searches 
specifically where the platform was previously located, but in the course of the trials 
learns the new location. Rats and mice with hippocampal lesions are impaired in the 
MWM implying the specific involvement of the hippocampus in the place learning 
component of the task (see for review Eichenbaum, 2000). However, the sensory-motor 
and procedural components of the task are independent of the hippocampal function as 
indicated by the normal performance in the MWM if a local cue is attached to the 
platform. Because animals with impaired hippocampal function may still be able to 
learn procedural aspects, they can develop a non-spatial strategy to locate the hidden 
platform. The search strategy of the animal is most appropriately assessed in a probe 
trial.
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1.4.2) Cued and contextual fear conditioning
Contextual fear conditioning is a single trial hippocampus-dependent learning task (see 
for review Anagnostaras et a l, 2001). The animals are placed in a novel environment 
(context) and given some time to explore and familiarise with it. Later, they receive a 
brief electric foot shock in this new context. Rats and mice trained in this manner 
associate the novel context with the aversive shock and develop fear for the context. 
This learned fear is expressed as defensive behaviour, where the animal displays 
freezing, increased heart rate and increased blood pressure. The time the animal spends 
freezing when re-exposed to the novel context is indicative of some forms of memory. 
Freezing is a natural response manifested in the presence of predators, in order to avoid 
being detected and becoming prey.
Lesion studies in rodents showed that the hippocampus and the amygdala are involved 
in the acquisition and expression of learned fear responses in the contextual fear 
conditioning paradigm (see for review LeDoux, 2000; Anagnostaras et al., 2001). 
However, the hippocampus is not essential for cued fear conditioning, where the animal 
has to associate a single cue, in this case a tone, with a foot shock. The animal is 
presented with a neutral tone (conditioned stimulus = CS), which is paired with a brief 
electric foot shock (unconditioned stimulus = US) in a novel context. The animals are 
expected to freeze in response to the tone presentation independently of the novel 
context. This form of memory is amygdala-dependent as indicated by lesion studies in 
rats that showed that the amygdala is required for both the acquisition and expression of 
learned fear responses to explicit cues or a context (see for review LeDoux, 2000).
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1.4.3) Behavioural tests in genetically-modified mice as tools for learning and memory 
research
The advent of gene targeting and transgenic technologies opened up new avenues for 
the examination of the molecular and cellular mechanisms underlying learning and 
memory. The generation of transgenic mice combined with their behavioural 
characterisation helped greatly to study the specific roles of gene products in learning 
and memory processes (see for review Martin & Morris, 2002; Silva, 2003). Initially, 
behavioural experiments in knockout mice lacking aCaMKII demonstrated that deficits 
in long-term potentiation (LTP) of synaptic transmission observed in the hippocampal 
area CA1 could be correlated with memory impairments as tested in the MWM (Silva et 
al., 1992a and 1992b). Since then, many more mutant mice have been generated and 
tested in behavioural tasks to assess the implication of the mutations on brain function. 
These studies demonstrate that many molecules which have been involved in synaptic 
plasticity, have also been implicated in the expression of behaviour (see for review 
Martin & Morris, 2002). Taken together, these studies established the behavioural 
analysis of transgenic mice as an important method to assess learning and memory 
mechanisms. The behavioural analysis of more sophisticated transgenic mouse models 
including region-restricted and inducible mouse lines will help to characterise the role 
of specific molecules in distinct brain regions and start elucidating the role of individual 
molecules in the various stages of learning and memory.
1.5) LTP: An experimental model for learning and memory
Neuroscience has long attempted to address questions concerning memory acquisition 
and storage at the level of individual neurons and synapses. One hypothesis for a simple 
neural model for learning and memory is Donald Hebb’s rule. It states: ’’When an axon 
of cell A is near enough to excite cell B and repeatedly or consistently takes part in
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firing it, some growth process or metabolic change takes place in one or both cells so 
that A’s efficiency, as one of the cells firing B, is increased.” (Hebb, 1949). One 
neurophysiological phenomenon in accordance with Hebb’s rule is LTP. LTP is a long- 
lasting increase in synaptic strength between two connected neurons, first discovered in 
the hippocampus by Bliss and Lomo (1973), resulting from a brief high-frequency 
electrical stimulation of the afferent fibres to ensure depolarisation of post-synaptic 
target neurons. Subsequently, it has been shown that LTP can be induced by pairing pre 
and post-synaptic depolarisation using intracellular patch-clamp electrophysiology 
techniques (see, for example, Wigstrom et al., 1986; Markram et al., 1997), 
demonstrating, in accordance with Hebb’s hypothesis, that it is a matching of 
depolarisation that governs LTP induction. LTP is characterised by four basic 
properties: Longevity, cooperativity, associativity and input-specificity (see for review 
Bliss & Collingridge, 1993). Longevity is an essential feature of any memory storage 
mechanism and LTP has been shown to last for long periods in animals, even up to one 
year (see, for example, Abraham et al., 2002). Cooperativity describes the existence of 
an intensity threshold for induction, so that stimulation at lower intensities does not 
elicit LTP because too few inputs are co-active (see, for example, McNaughton et al., 
1978). Associativity of LTP describes the phenomenon whereby a weakly activated 
input pathway can be potentiated, if it is simultaneously delivered with a strong 
stimulus to a separate but convergent input pathway (see, for example, McNaughton et 
al., 1978). Input-specificity of LTP means that only tetanised pathways induce 
potentiation but not other inputs to the same cell that are inactive at the time of 
stimulation (see, for example, Andersen et al., 1977).
LTP has been most extensively studied in the mammalian hippocampus, but has also 
been observed in neocortical regions, subcortical nuclei, such as the amygdala, and in 
the peripheral nervous system. The hippocampal trisynaptic circuit is an ideal system to 
investigate activity-dependent synaptic plasticities because of its laminar organisation 
(see for review Amaral & Witter, 1989; Fig. 1-1). Pre-synaptic pathways can be 
stimulated in an isolated fashion whilst simultaneously recording from the cell body of
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the post-synaptic target neuron or populations of post-synaptic neurons. LTP was first 
observed in the perforant pathway that connects the entorhinal cortex to the granule 
cells in the dentate gyrus (DG) (Bliss & Lomo, 1973). LTP has also been observed in 
the mossy fibre pathway from the DG to the CA3 pyramidal cells and the Schaffer 
collateral pathway arising from CA3 and contacting CA1 pyramidal cells (see, for 
example, Alger & Teyler, 1976). These electrophysiological studies demonstrated that 
different types of synapses exhibit mechanistically distinct forms of LTP, due to the 
involvement of different molecular mechanisms. In the hippocampus, LTP induction at 
Schaffer collateral-CAl pyramidal cell synapses (CA1 LTP) and at perforant path- 
granule cell synapses (DG LTP) requires N-methyl-D-aspartate (NMDA) receptors (see 
also section 1.6.2). Hence, CA1 LTP and DG LTP are termed NMDA receptor- 
dependent. In contrast, LTP induction at mossy fibre-CA3 pyramidal cell synapses 
(CA3 LTP) is NMDA receptor-independent. The molecular mechanisms underlying 
induction of NMDA receptor-independent LTP probably involve pre-synaptic changes 
including activation of kainate receptors and modulation of cAMP-dependent protein 
kinase (PKA) signalling.
LTP has several different phases, one transient phase maintained by protein 
phosphorylation, another longer phase by the synthesis of new proteins from existing 
mRNAs and another even longer-lasting phase dependent upon triggered gene 
transcription and subsequent de novo protein synthesis (see for review Bliss & 
Collingridge, 1993; Reymann & Frey, 2006). The transient form, or early LTP (E-LTP), 
can be induced by a single train of high-frequency stimulation. E-LTP can last 3-6 hours 
and is independent of gene transcription and protein synthesis. However, E-LTP 
requires protein phosphorylation, as it is blocked by kinase inhibitors. Several trains of 
tetanic stimulation induce late LTP (L-LTP), which can persist for days and requires 
protein synthesis and de novo gene transcription. It has been demonstrated that L-LTP 
can be blocked by inhibitors of protein synthesis and gene transcription (see, for 
example, Krug et al., 1984; Mackler et al., 1992; Impey et al., 1996). Interestingly,
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LTM formation can also be blocked by application of inhibitors of protein synthesis and 
gene transcription (see for review Davies & Squire, 1984).
Activity-dependent synaptic potentiation may persist from milliseconds to hours or days 
(see for review Bliss & Collingridge, 1993; Malenka & Bear, 2004). Based on their 
temporal characteristics, different forms of synaptic plasticity can be classified as short 
or long-term. Short-term varieties include paired pulse facilitation, which is a transient 
enhancement of synaptic responses after priming the response with an stimulatory pulse, 
and post-tetanic potentiation (PTP), describing the initial synaptic potentation after 
tetanic induction, which decays within minutes. Short-term potentiation (STP) can occur 
normally in the first 15 minutes and decays within one hour after stimultaion. Long­
term varieties include LTP and long-term depression (LTD), a plasticity resulting in a 
weakening of the efficacy of synaptic transmission either by prolonged, low frequency 
stimulation or mismatching of pre and post-synaptic depolarisation using intracellular 
recording techniques (see for review Braunewell & Manahan-Vaughan, 2001; Malenka 
& Bear, 2004).
Since its discovery, LTP of synaptic transmission in the hippocampus has been widely 
used as primary experimental model to study molecular processes in neurons. 
Electrophysiological LTP studies have demonstrated that the long-lasting enhancement 
in synaptic efficacy is a manifestation of multiple, complex molecular mechanisms. The 
elucidation of molecular and cellular processes involved in the induction, expression 
and maintenance of LTP potentially provides insight into the mechanisms underlying 
learning and memory. Recent advances suggest that many of the molecular mechanisms 
of synaptic plasticity are also engaged during learning and in memory formation (see, 
for example, Martin & Morris, 2002).
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1.6) Molecular basis of synaptic plasticity
In recent years electrophysiological, molecular and pharmacological studies have 
implicated over a hundred proteins in synaptic plasticity, learning and memory (Sanes 
& Lichtman, 1999). These proteins can be divided broadly into categories including 
neurotransmitter receptors and ion channels, signalling enzymes, cell adhesion 
molecules, cytoskeletal proteins and adaptor proteins. The proteomic characterisation of 
a multi-protein signalling complex has demonstrated the clustering of a network of 
proteins to the NMDA receptor (Husi et a l , 2000). Many proteins in this network are 
directly related to both synaptic plasticity, learning and memory. This work has revealed 
the complex structural and functional organisation of synapses in which there is a 
clustering of large numbers of molecules into macromolecular complexes both pre- and 
post-synaptically at precise zones. Membrane proteins, such as receptors, channels and 
adhesion molecules, are attached to a network of intracellular scaffold, signalling and 
cytoskeletal proteins. These synaptic complexes are specialized input devices for 
neurons, which allow them to detect and discriminate different patterns of neural 
activity and, in turn, regulate downstream events via discrete signalling pathways. One 
of the functions of the signalling cascades is to regulate de novo gene transcription and 
protein synthesis and thereby possibly initiate long-term changes in the organisation, 
structure and function of the synapse (see, for example, Dosemeci et a l , 2001). In 
dendritic spines activity-dependent morphological changes, such as enlargement of the 
spine head and shortening of the spine neck become apparent (see for review Yuste & 
Bonhoeffer, 2001). These recent findings on the molecular structure, organisation and 
regulation at the synapse begin to provide insight into the complex mechanisms 
involved in learning processes. However, further elucidation of the signal transduction 
mechanisms regulated via multiple protein kinases and the molecular mechanisms that 
drive the activity-dependent reorganisation and maintenance of synapses, both pre- and 
post-synaptically, are required for a deeper understanding of brain function and, 
potentially, cognition.
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1.6.1) Pre-synaptic mechanisms
It has been postulated that activity-dependent changes in synaptic strength are central to 
the processes of learning and memory. Much research has focussed on the events 
occurring post-synaptically that contribute to different forms of synaptic plasticity (see 
for review Kandel, 2001). The pre-synaptic mechanisms underlying synaptic 
modulation and synaptic plasticity are less well understood. This is partly due to 
methodological difficulties in discerning pre-synaptic from post-synaptic effects.
The arrival of an action potential at the pre-synaptic terminal triggers neurotransmitter 
release into the synaptic cleft, and thereby initiates the synaptic transmission (see for 
review Siidhof, 2004). An action potential induces the opening of voltage-gated calcium 
channels (VGCC) at the pre-synaptic terminal. The resulting Ca2+ influx into the pre- 
synaptic terminal triggers molecular mechanisms that lead to synaptic vesicle exocytosis 
and subsequent neurotransmitter release. These processes of vesicular exo- and 
endocytosis are regulated by an intricate protein machinery. A molecular complex 
including the SNARE proteins (including synaptobrevin, syntaxin 1, SNAP-25) is 
required for docking the vesicles close to the active zones in the pre-synaptic terminal 
(see for review Chen & Scheller, 2001). Furthermore, this complex prepares the vesicles 
for fusion with the plasma membrane, in a step called “priming”. The increase in Ca2+ 
levels promotes a conformational or electrostatic change of Ca -sensor proteins, which
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in turn trigger the fusion reaction with the plasma membrane. Several pre-synaptic Ca - 
binding proteins have been proposed to act as a Ca2+-sensor including synaptotagmins 
(see for review Chen & Scheller, 2001; Siidhof, 2004).
Different pools of synaptic vesicles can be distinguished. Vesicles of the immediate- 
releasable pool are docked close to the active zones in the pre-synaptic terminal. They 
can be either immature or already “primed”, which means that they are fully mature and 
ready for release. Vesicles belonging to the releasable pool are not yet docked and need 
to be recruited to the docking sites. This recruitment step is also Ca2+-dependent and 
involves multiple proteins including myosin light chain kinase (MLCK) (see, for
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example, Polo-Parada et al., 2005). Many pre-synaptic proteins associated with the 
vesicle release machinery are directly Ca2+-binding (e.g. Muncl3, rabphilin and RIM). 
Also, several pre-synaptic proteins important for neurotransmitter release and pre- 
synaptic plasticity are regulated via phosphorylation by protein kinases including PKA, 
protein kinase C (PKC), MLCK and CaMKII (see for review Leenders & Sheng, 2005). 
CaMKII has been found in pre-synaptic terminals associated with synaptic vesicles (see 
for review Lisman et al., 2002). Pre-synaptic activation of CaMKII is required for 
induction of synaptic plasticity in hippocampal cell cultures (Ninan & Arancio, 2004). 
A number of pre-synaptic proteins have been described as substrates of CaMKII. 
However, the precise processes mediated by CaMKII that are necessary for the 
induction of synaptic plasticity are unknown. One candidate substrate is synapsin I, 
which is persistently phosphorylated at its CaMKII phosphorylation sites after LTP 
induction (Nayak et al., 1996). Synapsins are involved in regulating the synaptic vesicle 
mobilisation and hence, controlling the number of vesicles available for exocytosis at 
pre-synaptic release sites. Synapsins bind simultaneously to synaptic vesicles and parts 
of the cytoskeleton, including actin and tubulin, and thereby retain the vesicles away 
from the vesicle release sites. During synaptic activation synapsins are phosphorylated 
by CaMKII and dissociate from the synaptic vesicles. This liberates the synaptic 
vesicles, which, in turn, get recruited to the vesicle release sites, where they are docked 
and primed for neurotransmitter release.
Several post-synaptic mechanisms have been proposed to enhance synaptic strength, 
including an increase in the number of synaptic neurotransmitter receptors or an 
enhancement of their single-channel conductance (see for review Malenka & Bear,
2004). Nevertheless, enhanced synaptic plasticity could also be attributed to alteration 
of pre-synaptic mechanisms, such as increased neurotransmitter release, structural 
changes of individual pre-synaptic terminals or the formation of new synapses involving 
de novo protein synthesis (see for review Leenders & Sheng, 2005). It is conceivable 
that changes in neurotransmitter release by modulation of synaptic vesicle dynamics 
might indeed be a major mechanism for regulating synaptic strength. This hypothesis is
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supported by the observation that retrograde messengers, such as nitric oxide (NO), 
carbon monoxide (CO) and arachidonic acid are involved in the generation of LTP by 
modifying pre-synaptic transmitter release (see for review Bliss & Collingridge, 1993). 
However, more research will be required to resolve the respective contribution of pre- 
and post-synaptic mechanisms to the molecular processes underlying synaptic plasticity.
1.6.2) Post-synaptic mechanisms
Much research has focused on NMDA-receptor dependent LTP in area CA1 and some 
of the underlying mechanisms are well-characterised. The excitatory Schaffer collateral- 
CA1 synapses use glutamate (L-glutamic acid) as a neurotransmitter. 
Electrophysiological stimulation of the Schaffer collateral fibres triggers pre-synaptic 
glutamate release. The released glutamate binds to post-synaptically located ionotrophic 
glutamate receptors, the a-amino-3-hydroxy-5-methyl-isoxazole-4-proprionic acid 
(AMPA) receptor and the NMDA receptor (see for review Hollmann & Heinemann, 
1994). Upon glutamate-binding, the AMPA receptor opens its ligand-gated ion channel, 
allowing post-synaptic Na+ and K* influx. This inward Na+-current depolarises the post- 
synaptic membrane and produces an excitatory post-synaptic potential (EPSP). The 
NMDA receptor is blocked by Mg2* at resting potential and its ligand-gated ion channel 
is opened only in response to glutamate binding if the post-synaptic membrane is 
depolarised. This post-synaptic depolarisation, triggered by either AMPA receptor 
activation or back-propagation of action potentials, removes the Mg2+ block of the 
NMDA receptor and allows Ca to enter post-synaptically. The rise in post-synaptic 
intracellular Ca2+ is the critical trigger for LTP induction (see for review Bliss & 
Collingridge, 1993; Malenka & Bear, 2004). The NMDA receptor thereby works as a 
coincidence detector, integrating the pre-synaptic glutamate release with the post- 
synaptic depolarisation. Consistent with the proposed role of the NMDA receptor in 
synaptic plasticity and memory, LTP is inhibited in area CA1 by pharmacological 
blockade of the NMDA receptor, which also affects learning and memory in the MWM
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(Collingridge et al., 1983; Morris et al., 1986). Furthermore, transgenic mice lacking the 
NMDA receptor in area CA1 display impaired LTP and hippocampus-dependent spatial 
learning (McHugh et al., 1996; Tsien et al., 1996).
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The importance of post-synaptic Ca -influx through the NMDA receptor in synaptic 
plasticity has been demonstrated by the finding that the addition of Ca2+-chelators to the 
post-synaptic cell prevents induction of LTP (see, for example, Malenka et al., 1988). 
Ca has been found to regulate many synaptic proteins, including CaMKII, PKC and 
fyn tyrosine kinase. Hence, it was hypothesised that some of these Ca2+-dependent 
kinases become activated and phosphorylate specific substrates, which in turn trigger 
biochemical pathways and initiate long-term changes in synaptic structure and function 
(see for review Soderling, 2000; Soderling & Derkach, 2000). In particular, CaMKII is 
a leading candidate in the search for the molecular basis of learning and memory (see 
for review Lisman et al., 2002; see also section 1.7.5). In response to NMDA receptor 
activation and subsequent intracellular Ca2+-elevation, CaMKII becomes activated by
04 -association with Ca /calmodulin (CaM) and translocates to the post-synaptic densities, 
where it binds to a number of structural and modulatory proteins. There are numerous 
substrates through which CaMKII may modify neuronal function and exert its influence 
on synaptic strength (Yoshimura et al., 2000 and 2002; see for review Lisman et al, 
2002). In addition, several other protein kinases, including extracellular signal-regulated 
kinase (ERK), mitogen-activated protein kinase (MAPK), PKC and the tyrosine kinases 
Src and fyn have been proposed to be important for signal transduction that contributes 
to synaptic plasticity and for initiation of long-term changes in synaptic structure and 
function (see for review Soderling & Derkach, 2000; Thiels & Klann, 2001).
1.6.3) Maintenance mechanisms involving gene transcription and protein synthesis
LTP maintenance early after synaptic stimulation is mediated by intracellular signalling 
cascades. Pharmacological studies have demonstrated that LTM and L-LTP require de
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novo transcription and protein synthesis (see for review Kandel, 2001). Therefore, it is 
thought that one important function of these signalling cascades is the activation of 
critical transcription factors and subsequently the transcription and synthesis of specific 
proteins. So far, several signalling pathways have been implicated in learning-related 
transcription.
One model proposes the involvement of the cyclic AMP (cAMP) signalling pathway in 
the activation of transcription (see for review Bailey et al., 2000; Kandel, 2001). Ca - 
influx and subsequent CaM binding activates adenylate cyclase isoforms, which are 
responsible for the synthesis of cAMP. Increased levels of cAMP can, in turn, activate 
PKA, which translocates to the nucleus, where it phosphorylates the transcription factor 
cAMP responsive element-binding protein (CREB). The phosphorylation of CREB at 
Seri 33 is required for its activation as a transcription factor. Upon activation, CREB 
binds to a specific motif within the promoter region of target genes, called the cAMP 
responsive element (CRE) and triggers CRE-mediated transcription. Evidence for the 
involvement of the cAMP signalling pathway in memory formation comes from studies 
of mutant mice lacking the Ca2+-regulated adenylate cyclase isoforms, AC1 and AC8 
(other isoforms are regulated via the activation of G-protein coupled receptors) (Wong 
et al., 1999). These KO mutants display both impaired LTM and L-LTP in hippocampal 
area CA1. Furthermore, cAMP agonists trigger L-LTP in hippocampal slices without 
tetanic stimulation, whereas cAMP antagonists block L-LTP (Frey et al., 1993). In 
addition, CREB phosphorylation and CRE-mediated transcription can be induced in 
hippocampal slices by tetanic stimulation that induces L-LTP, as well as by activation 
of adenylate cyclase and PKA (Impey et al., 1996).
Other studies implicate alternative signalling pathways in the activation of the 
transcription factor CREB. The Ca2+/calmodulin-dependent kinase IV (CaMKIV) has 
been found to mediate CREB phosphorylation and CRE-mediated transcription after 
synaptic stimulation. Studies on transgenic mice expressing a dominant negative 
isoform of CaMKIV have revealed an impairment of CREB phosphorylation and CRE-
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mediated transcription coinciding with impaired LTM formation in hippocampus (Kang 
et al., 2001). Interestingly, consistent with a role for CaMKIV in the initiation of 
transcription and the finding that the early phase of LTP is independent of transcription, 
hippocampal L-LTP was impaired in these mice, whereas E-LTP was normal (Kang et 
a l, 2001).
Along with the phosphorylation of CREB at Seri33, the recruitment and subsequent 
binding of the transcriptional co-activator CREB binding protein (CBP) is required to 
trigger CRE-mediated transcription (see for review Johannessen et al., 2004). CBP is 
thought to link CREB to the other components of the transcriptional machinery. CREB 
regulates the transcription of genes harbouring the CRE motif within their promoter 
region. A multitude of genes are under the control of the CRE promoter, including ion 
channels, growth factors and immediate-early genes (see for review Lonze & Ginty, 
2002). Importantly, CREB initiates the expression of immediate-early genes, such as the 
transcription factors c-fos and c-jun, and thereby triggers a transcriptional cascade. The 
synthesis of these immediate-early transcription factors leads in turn to expression of 
late-effector genes that encode for proteins that could be important for the regulation of, 
for example, synaptic structure. Such changes in the organisation, structure and function 
of synapses could lead to increased synaptic strength and could be the basis of cellular 
learning and memory mechanisms.
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1.7) Ca /calmodulin-dependent protein kinase II
1.7.1) General characteristics o f Ca2+/calmodulin-dependent protein kinase II
Ca2+/calmodulin-dependent protein kinase II (CaMKII) is a multifunctional 
serine/threonine kinase, which requires binding of CaM for activation (see for review 
Hudmon & Schulman, 2002; Lisman et a l , 2002; Colbran & Brown, 2004). In 
mammals, CaMKII is encoded by four alternatively spliced genes (a, P, y and 8), which 
give rise to approximately 30 similar isoforms. Specific functions have been 
characterised for only a few of the alternatively spliced sequences including a domain 
for SR-membrane targeting, a nuclear localisation signal and an SHh-binding site. The 
different CaMKII isoforms have distinct tissue, cellular and subcellular localisations 
(see for review Hudmon & Schulman, 2002). In the brain, aCaMKII (Swiss 
Prot|P11798|KCC2A_MOUSE) and PCaMKII are the predominant isoforms; the a- 
isoform displaying high levels in neurons of the forebrain, and the P-isoform having 
high levels in the cerebellum. The aCaMKII is almost exclusively restricted to 
excitatory, glutamatergic neurons, whereas the p-isoform is found in neurons and glial 
cells (Liu & Jones, 1997). Further, the expression of aCaMKII starts postnatally, 
whereas pCaMKII is already expressed embryonally. The CaMKII y- and 8-isoforms 
are broadly expressed in the brain, but at a much lower level than the a- and P-isoforms. 
In addition, the subcellular distribution of the isoforms is also different. The aCaMKII 
isoform is enriched at synapses and constitutes the major postsynaptic density protein. 
The pCaMKII isoform associates with actin filaments, which confers a localisation at 
the dendritic shaft.
All CaMKII isoforms comprise an amino-terminal catalytic domain, an autoinhibitory 
domain and a self-association domain (see for review Lisman et a l , 2002; Fig. 1-2). The 
catalytic domain contains the ATP-pocket and the substrate-binding site. The self­
association domain is required for the formation of a holoenzyme composed of 12
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subunits grouped in two stacks of hexameric rings. The autoinhibitory domain contains 
a pseudosubstrate region, a CaM binding site, as well as interaction sites for anchoring 
proteins and regulatory phosphorylation sites (Fig. 1-2). The function of the 
autoinhibitory domain is the regulation of the kinase activity. Under basal conditions, 
CaMKII is inactive because the pseudosubstrate region is binding to the catalytic site
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and thereby inhibiting its enzymatic activity (Fig. 1-3). A rise in intracellular Ca - 
levels leads to association of the CaM complex, which can subsequently bind to 
CaMKII on a site overlapping with the pseudosubstrate region. This interaction evokes 
a conformational change of CaMKII that exposes the catalytic domain and renders the 
kinase active. In this Ca -activated state the Thr286 on the autoinhibitory domain of 
aCaMKII (respectively Thr287 on PCaMKII) can be autophosphorylated by 
neighbouring subunits (see, for example, Miller & Kennedy, 1986; see for review 
Lisman et al., 2002). Once this site is phosphorylated CaMKII can not revert back to the 
original, inactive conformation, even after Ca2+-levels drop and CaM dissociates from 
the kinase. This results in a persistent, autonomous activity that is Ca2+-independent. 
This persistently activated state of CaMKII is maintained until the subunits are 
dephosphorylated by phosphatases, including PP1 and PP2A. Further, control of 
CaMKII activity occurs via the (auto)phosphorylation of the regulatory sites 
Thr305/306 that block activation of CaMKII via CaM by hindering the CaM-binding 
site and prevents the translocation of CaMKII to the PSD (see, for example, Miller & 
Kennedy, 1986; Elgersma et al., 2002).
1.7.2) CaMKII as a putative sensor o f Ca2+ oscillations
The autoregulatory properties of CaMKII subunits combined with the structural 
properties of the holoenzyme complex make CaMKII a specialised sensor of 
intracellular Ca -concentration and oscillations (see for review Lisman et al. 2002; Fig. 
1-4). In order for autophosphorylation of one subunit to occur, the coincident binding of 
two CaM molecules at adjacent subunits is required. With low frequencies of
CHAPTER 1: Introduction 43
intracellular Ca2+-oscillations, which evoke only a minor rise in Ca2+-levels, the 
probability of two CaM molecules binding to neighbouring subunits is low. As the 
frequency of oscillation increases, the probability of coincident binding becomes higher, 
until one subunit within the holoenzyme is persistently activated by the 
autophosphorylation. Once a subunit is autonomously activated the coincident binding 
is no longer essential and propagation of autophosphorylation can proceed more easily 
within the holoenzyme. Any subunit, adjacent to an already autonomously activated 
subunit, can now also be autophosphorylated simply by binding CaM. Therefore, the 
propagation can occur in response to lower levels of Ca than in the initial step, where 
coincident binding is required. Different frequencies of intracellular Ca -oscillations 
will thereby result in distinct levels of autophosphorylated subunits within the 
holoenzyme.
1.7.3) Synaptic functions o f aCaMKII
Post-synaptic Ca2+ influx triggers the activation of aCaMKII by association with CaM 
and leads to translocation of the activated aCaMKII from the synapse into the post- 
synaptic densities (Ouyang et a l , 1997). There, aCaMKII interacts with numerous 
proteins including the Cdk5 activator p35, a-actinin, densin-180, SynGAP and NMDA 
receptor subunits (see for review Colbran, 2004). In the active state aCaMKII can 
associate with the cytoplasmic carboxy-terminus of the NMDA receptor subunits NR2B 
and with less affinity, NR1 and NR2A. Next to the autophosphorylation at Thr286, this 
association is another important mechanism by which aCaMKII can be persistently 
activated even after Ca2+ levels drop and CaM dissociates (Fig. 1-3). The association of 
aCaMKII to proteins located within the post-synaptic densities brings the kinase into 
proximity with numerous substrates (Table 1-1.; see, for example, Yoshimura et a l , 
2000 and 2002). Dephosphorylation of Thr286 by protein phosphatase 1 (PP1), which is
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immobilized in the PSD, and PP2A, which is excluded from the PSD, is critical for 
terminating the autonomous activity of CaMKII (Shen et al., 1998).
Table 1-1. CaMKII substrates
Receptor and 
channel proteins
Scaffold
proteins
Cytoskeletal 
and associated 
proteins
Motor
proteins Enzymes
Proteins involved 
in neurotrans­
mitter release
Others
AMPA receptor Densin-180 a-actinin Caldesmon CaMKII Synapsin I Insulin receptor kinase
GABA-modulin Homer lb Clipin C C protein Calpain Synaptotagmin TOAD64
GABA receptor, 
type A
PSD95-
associated
protein
a-intemexin Myosin IIB
Cyclic nucleotide 
phosphodiesterase Synaptophysin
TNF receptor- 
associated factor 
3
GluRl subunit PSD95 Myosin V Calcineurin
IP? receptor SAP90 MAP2 Dynamin 1
NMDA receptor SAP97 Neurofilaments 
H, M and L Phospholipase A2
NR2B tau Nitric oxide 
synthase
N-type Ca2+- 
channel a/p-tubulin SynGAP
VDAC1
LRP4
Abbreviations: AMPA, a-amino-3-hydroxy-5 methyl-isoxazole-4-proprionic acid; GABA, y-amino 
butyric acid; GluR, glutamate receptor; IP3, inositol triphosphate; LDL, low-density lipoprotein; LRP4, 
LDL receptor-related protein 4; MAP, microtubule-associated protein; NMDA, N-methyl-D-aspartate; 
NR2B, NMDA receptor subunit 2B; PSD-95, post-synaptic density 95 kDa; SAP, ; TNF, Tumor 
necrosis factor; TOAD64, turned on after division 64 kDa; VDAC1, voltage-dependent anion channel 
protein 1 (After Yoshimura et al, 2002).
The phosphorylation o f specific substrates by aCaMKII is thought to modify neuronal 
function and exert an influence on synaptic plasticity. CaMKII activity was shown to 
strengthen synaptic transmission by several mechanisms. One of them involves the 
direct phosphorylation o f the AMPA receptor subunit GluRl, which in turn increases 
the single-channel conductance o f homomeric GluRl AMPA receptors (Derkach et a l,
1999). Another mechanism involves the addition o f AMPA receptors to synapses, 
which is thought to depend on changes in receptor trafficking and on the organised 
addition of anchoring sites for AMPA receptors (see for review Malinow & Malenka, 
2002). Moreover, autophosphorylation increases the affinity o f CaMKII for CaM by 
approximately thousand fold. Hence, it has been proposed that the autophosphorylated
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CaMKII pool within the post-synaptic densities might function as a CaM sink (Lisman 
et al., 2002). However, despite the extensive research there is only a limited knowledge 
on the specific substrates of aCaMKII and the molecular processes that are regulated 
specifically by autonomous aCaMKII activity.
1.7.4) CaMKII in synaptic plasticity, learning and memory
The first evidence supporting a role for CaMKII in synaptic plasticity demonstrated that 
induction of LTP could be blocked by application of CaMKII inhibitors, including 
peptide inhibitors designed from the autoinhibitory domain of CaMKII (Malinow et a l , 
1989; Otmakhov et a l , 1997). Further it was shown that induction of LTP leads to 
activation of CaMKII and in turn to autophosphorylation, which results in autonomous, 
Ca2+/CaM-independent activity (Fukunaga et a l , 1993, Ouyang et a l , 1997). Studies in 
different genetically-modified mouse lines demonstrated an important role of CaMKII 
and its autophosphorylated state in synaptic plasticity, learning and memory processes 
(see for review Elgersma et a l , 2004). KO mice lacking aCaMKII show impairment in 
CA1 LTP (Silva et a l , 1992a; Elgersma et a l , 2002). However, some residual CA1 
LTP persists in these aCaMKII null mice, which could be attributed to a compensatory 
translocation of the p-isoform of CaMKII to the post-synaptic density (Hinds et a l , 
1998; Elgersma et al., 2002). In the aCaMKII T286A point mutant mouse line the 
autophosphorylation at residue Thr286 is disenabled by replacing endogenous 
aCaMKII with a mutated form carrying an alanine at residue 286, instead of a threonine 
(Giese et a l , 1998). In these aCaMKII T286A mutants induction of CA1 LTP is 
completely abolished indicating that the autophosphorylation of aCaMKII is 
fundamental for the induction of CA1 LTP. Further studies in the aCaMKII T286A 
mutants implicated aCaMKII in the induction of neocortical LTP (Glazewski et a l , 
2000; Hardingham et a l , 2003). CA1 LTP is also completely absent in the aCaMKII 
T305D point mutant mouse line, where activation of the kinase by CaM and
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translocation to the PSD have been disenabled (Elgersma et al., 2002). No pCaMKII 
compensation occurs in these T305D mutants (Elgersma et al., 2002). Interestingly, in 
aCaMKII T305V/T306A point mutant mice, where these inhibitory sites can not be 
phosphorylated, a 10 Hz tetanus readily induces marked LTP suggesting that the 
Thr305/Thr306 site is implicated in the control of the threshold of LTP induction 
(Elgersma et al., 2002). Together, these results indicate that aCaMKII and specifically 
autophosphorylation of aCaMKII on Thr286 are essential for the induction of NMDA 
receptor-dependent CA1 LTP and might play an important role in other forms of 
synaptic plasticity.
The study of aCaMKII KO mice in hippocampus-dependent learning and memory tasks 
revealed a gross impairment in spatial learning (Silva et al., 1992b; Elgersma et a l , 
2002). However, as in the LTP studies, it is conceivable that the compensatory 
mislocalisation of pCaMKII is responsible for the residual learning in the aCaMKII KO 
mice. The aCaMKII T286A mutants exhibit severely impaired hippocampal learning 
and memory as tested in the MWM that can not be rescued by over-training (Giese et 
al., 1998). These results indicate that the autophosphorylation of aCaMKII is essential 
for hippocampal spatial learning. However, the aCaMKII T286A mutants performed 
normally in several non-hippocampus-dependent learning tasks including the visible 
platform water maze suggesting that aCaMKII is not essential in all brain areas (Giese 
et al., 1998). Investigation of place cell activity in the aCaMKII T286A mutants found 
that spatial selectivity and stability of place cells require autophosphorylation of 
aCaMKII on Thr286 (Cho et al. 1998). Consistent with an important role for functional 
aCaMKII in learning processes, the aCaMKII T305D mutants also displayed 
hippocampal learning and memory impairments (Elgersma et al., 2002). The analysis of 
the aCaMKII T305V/T306A mutants showed that these inhibitory phosphorylation sites 
on aCaMKII are not essential for all spatial learning tasks, but in fact are required for 
flexible fine-tuning in some tasks (e.g. reversal learning in the MWM; Elgersma et al., 
2002). Together, these findings demonstrate a central role for aCaMKII and the
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autophosphorylation of aCaMKII on Thr286 in learning processes and the formation of 
memories. However, the molecular mechanisms engaged by aCaMKII activation are 
poorly understood and no convincing link to other processes important for learning and 
memory has yet been found.
1.7.5) The CaMKII hypothesis for the storage o f synaptic long-term memory
A fundamental question in neuroscience is how memory is stored at the molecular and 
cellular level. The study of LTP, a promising candidate mechanism for cellular learning 
and memory, helped greatly to further the understanding of the molecular basis of 
memory. In line with these advances John Lisman formulated an influential hypothesis 
suggesting that CaMKII acts as a molecular switch that is capable of storing long-term 
synaptic memory (Lisman, 1985 and 1994; Lisman et al., 2002). He proposed that, 
following a synaptic event a group of kinase molecules becomes activated, so that they 
can autophosphorylate each other. The autophosphorylation switches the kinase into an 
autonomously active mode, which can persist for prolonged periods even after the 
synaptic event is over. In this autophosphorylated, autonomous mode the group of 
kinase molecules could perpetuate its phosphorylation state, even though 
dephosphorylation by phosphatases occurs or some kinase molecules are replaced by 
newly synthesised molecules. This group of autonomously active kinase molecules 
could hence form the basis of stable long term memory of the triggering synaptic event. 
The molecular and structural characterisation of aCaMKII showed that its properties are 
in agreement with the hypothesis and hence made it a prime candidate for the molecular 
storage of memory. aCaMKII is the major postsynaptic density protein in glutamatergic 
neurons and it requires association of CaM for activation. In the activated state 
aCaMKII can undergo autophosphorylation. The autophosphorylation switches 
CaMKII into a Ca -independent, autonomously active mode which can persist for 
prolonged periods even after the Ca2+-concentration decreases. The structural properties
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of the CaMKII holoenzyme complex even suggest that this autophosphorylated state 
could outlast continuous dephosphorylation and protein turnover (Rosenberg et al., 
2005).
Results from electrophysiological and behavioural experiments further support the role 
of CaMKII as a candidate protein mediating memory storage. Autophosphorylation and 
autonomous kinase activity of aCaMKII are prolonged following induction of LTP 
(Ouyang et al., 1997; Fukunaga et al., 1993). Enhanced CaMKII activity partially 
mimics and/or facilitates LTP (Mayford et al., 1996; Bejar et al., 2002). The T286A 
point mutant mice, where the autophosphorylation switch is disenabled, display 
impaired LTP and deficits in spatial learning and memory in the Morris water maze 
(Giese et al., 1998). These experiments consistently demonstrated that the enzymatic 
activity of aCaMKII is required for the induction of LTP. However, it is still not known 
whether persistent, autonomous CaMKII activity is essential for the maintenance of 
stored information. It is possible that CaMKII acts only as a trigger and that other 
downstream events are responsible for the maintenance of memory storage. Recent 
advances have identified novel mechanisms that could serve as memory storage, 
including atypical PKC isoform, PKM£, prion-like proteins, gene expression and local 
protein synthesis (see, for example, Bliss et al., 2006; Si et al., 2003; Dudai, 2004).
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1.8) Neurodegenerative diseases
1.8.1) Dementia: decline o f cognitive functions
Dementia is generally used to describe a chronic and significant decline of cognitive 
functions (see for review Knopman, 1998; McKeith & Cummings, 2005). Dementia 
patients show a decline in more than one of the five broad neuropsychological domains 
including learning and memory, attention and concentration, thinking, language, and 
visuospatial functioning. In contrast, for example, amnesic patients show a striking 
deficit only in the area of memory, or aphasic patients in the area of language. Dementia 
is a collection of diverse conditions evoked by different causes that manifest in similar 
fashion with the decline of cognitive functions. Many causes have been linked to 
dementia including brain injury, brain tumors, drug toxicity, syphilis, encephalitis, 
meningitis, Creutzfeld-Jakob disease (CJD), Huntington disease and Alzheimer’s 
disease (AD). The onset and the progression of the cognitive decline vary between the 
different types of dementia. Most dementias are progressive, however some are non­
progressive (e.g. alcoholic dementia). Further, most dementias, including AD and 
Huntington disease, have an insidious onset which is followed by a slow and gradual 
progression of the cognitive decline. In many dementias specific brain regions are 
affected and characteristic cognitive deficits appear in these dementia patients. Early in 
the disease memory impairment is often the only clinical sign in dementia patients. With 
progression of dementia the cognitive decline aggravates and social and occupational 
functioning is affected. In general, the likelihood of onset of dementia becomes higher 
with increasing age. Individuals that show first signs of memory impairment are classed 
as patients with mild-cognitive impairment (MCI), which describes a condition that may 
or may not eventually lead to dementia (see for review Gauthier et al., 2006).
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1.8.2) Neurodegenerative tauopathies
Many sporadic and familial neurodegenerative diseases are characterised 
neuropathologically by brain lesions that are accompanied by abnormal filamentous 
depositions of brain proteins (see for review Buee et al., 2000; Lee et al., 2001; Goedert 
& Jakes, 2005). The so-called neurodegenerative tauopathies consist of a group of 
heterogeneous dementias and movement disorders including AD (see Table 1-2 for list 
of diseases). Neurodegenerative tauopathies are characterised by intracellular 
accumulation of fibrils formed by the microtubule-associated protein tau. The cognitive 
decline in the tauopathies correlates with the progressive accumulation of the 
filamentous tau depositions. The study of sporadic and, especially, familial (i.e. 
genetically-linked) forms of neurodegenerative tauopathies helped greatly to 
characterise some of the underlying molecular mechanisms. The observation that the 
frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), a 
familial form of tauopathy, was caused by a series of mutations within the tau gene, 
provided evidence that alteration in tau structure and expression are sufficient for the 
expression of neurodegenerative diseases (see for review Lee et al., 2001; Goedert & 
Jakes, 2005). These findings inspired further studies to elucidate the physiological 
functions of tau and its role in the mechanisms of brain dysfunction and 
neurodegeneration. Much research focussed on the abnormal changes of tau that were 
characteristically observed in AD and that are not linked to genetic alterations (see also 
section 1.8.3). It was shown that the filamentous tau deposits, termed neurofibrillary 
tangles (NFT), consist mainly of aberrantly phosphorylated and proteolytically 
fragmented tau (see, for example, Grundke-Iqbal et al., 1986a and 1986b; see, for 
review Buee et al., 2000). Hence, it was proposed that increased tau phosphorylation 
interferes with the physiological role of tau and triggers the formation of fibrillar tau 
complexes, called paired helical filaments (PHF). The PHF aggregate subsequently into 
NFT.
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Table 1-2. Diseases exhibiting neurofibrillary tangle (NFT) pathology
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Disease NFT as main feature
Alzheimer’s disease (AD)
Amyotrophic lateral sclerosis (ALS)/ 
parkinsonism-dementia complex +
Argyrophilic grain dementia +
Corticobasal degeneration +
Creutzfeldt-Jacob disease (CJD)
Dementia pugilistica +
Diffuse neurofibrillary tangles with calcification +
Down’s syndrome
Frontotemporal dementia with parkinsonism linked 
to chromosome 17 (FTDP-17) +
Gerstmann-Straussler-Scheinker disease
Hallervorden-Spatz disease
Myotonic dystrophy
Niemann-Pick disease, type C (NPC)
Non-Guamanian motor neuron disease with 
neurofibrillary tangles
Pick’s disease +
Postencephalitic parkinsonism (PEP)
Prion protein cerebral amyloid angiopathy
Progressive subcortical gliosis +
Progressive supranuclear palsy (PSP) +
Subacute sclerosing panencephalitis
Tangle only dementia +
(After Buee et a l, 2000 and Lee et al., 2001)
Several protein kinases and phosphatases have been implicated in the regulation of tau 
phosphorylation and are thought to be important in the pathogenesis of 
neurodegenerative tauopathies (see for review Billingsley & Kincaid, 1997; Buee et al.,
2000). It was believed that the accumulation of hyperphosphorylated tau and
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aggregation into NFT are toxic processes for neurons and therefore might be responsible 
for the neurodegeneration and subsequently the cognitive deficits observed in patients 
with tauopathies. A recent study, however, demonstrated that viability of neurons and 
memory function are not affected by continuous NFT accumulation (SantaCruz et al., 
2005). Transgenic mice expressing a repressible human tau variant developed 
progressively NFT, neuronal cell loss and impaired spatial learning as tested in the 
MWM. Suppression of the transgenic tau expression resulted in stabilisation of the 
neuronal cell numbers and recovery of memory deficits, despite the continuous 
accumulation of NFT. Taken together, these results suggest that NFT are not directly 
cytotoxic and do not severely impact on memory functions. This is consistent with 
pathological examinations showing that many older individuals display NFT 
accumulation in the brain, but did not exhibit any obvious signs of cognitive deficits 
prior to death (Takayama et a l , 2002). Based on these studies, it was hypothesised that 
it is not the presence of hyperphosphorylated tau and NFT, but more likely the absence 
of sufficient functional tau supporting its physiological role that impacts on the viability 
of the neurons (Trojanowski & Lee, 2005).
The study of genetically-linked forms of neurodegenerative tauopathies identified 
several molecular targets thought to be involved in the ontogeny of the disease. The 
identification of these molecular targets has been subsequently exploited to generate 
genetically-modified animal models of tauopathies, characterise the* function of these 
target molecules and explore therapeutic strategies (see for review Lee et al., 2005).
1.8.3) Alzheimer’s disease
Alzheimer’s disease (AD), a neurodegenerative tauopathy, is the most common cause of 
dementia (see for review Selkoe, 2001). The prevalence of AD is directly related to age. 
AD affects about 10% of the population aged over 65 years and rises to at least 25% of 
the population aged over 85 years. The neuropathological hallmarks of AD are the
CHAPTER 1: Introduction 53
senile plaques, NFTs and neuronal cell loss. Senile plaques are extracellular deposits of 
p-amyloid (A0) peptide. The Ap-peptide is produced by proteolytic cleavage of the 
amyloid precursor protein (APP) (Fig. 1-7). NFTs are mainly composed of 
hyperphosphorylated tau at proline-directed serine/threonine sites (see, for example, 
Grundke-Iqbal et al., 1986b; Paudel et a l, 1993; Morishima-Kawashima et al., 1995). 
NFTs accumulate with the progression of AD (see, for example, Braak & Braak, 1991; 
Augustinack et al., 2002a). How the accumulation of plaques and NFT interferes with 
the viability of the neurons is, so far, not known. But there is a striking temporal and 
spatial relationship between the accumulation of these filamentous deposits and 
neuronal loss, which is ultimately responsible for the cognitive impairments seen in AD. 
In the early stages of AD, the areas displaying neuropathological changes spread 
progressively from the hippocampal formation to the anterior, inferior and mid temporal 
cortex (Braak & Braak, 1991). In these patients the changes manifest as mild cognitive 
impairments. With the progression of the disease the association areas of the temporal, 
parietal and frontal cortex are affected and the patients show increasingly loss of 
cognitive functions. The last brain regions to be affected are the primary motor area and 
sensory areas.
AD is broadly classified into an early-onset form (before the age of 50) and a late-onset 
form (after the age of 65) (see for review Selkoe, 2001; Tanzi & Bertram, 2001). The 
study of the inherited familial forms of AD has associated several molecules with the 
early-onset of the disease. Mutations in the genes APP, as well as presenilin 1 (PS1) and 
presenilin 2 (PS2) have been identified as a cause of familial AD (FAD). Over 100 
mutations in these three genes can each trigger the early-onset of AD (see for review 
Tanzi & Bertram, 2001). It is thought that most of these mutations trigger the aberrant 
overproduction of Ap-peptides. Interestingly, the APP gene is located on chromosome 
21, and consistently with this the prevalence of AD is increased in patients with Down’s 
syndrome carrying three copies of the chromosome 21. Allelic variation within the 
apolipoprotein E (APOE) gene on chromosome 19 were linked to the late-onset form of
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AD (see for review Herz & Beffert, 2000). Patients that carry the APOE e4 allele have a 
predisposition for the late-onset form of AD and hence the s4 allele acts as a risk factor. 
Further genetic linkage studies found additional molecules that were weakly linked with 
the late-onset form of AD, including LDL receptor-related protein and FE65 (see for 
review Herz & Beffert, 2000). Sporadic AD with a late-onset accounts for the vast 
majority of AD cases. However, the molecular factors underlying sporadic AD remain 
unknown and aging is the only known risk factor. Hence, many processes displaying 
age-related alterations have been proposed to contribute to AD pathogenesis including 
oxidative stress, changes in gene expression, and altered metabolism (see for review 
Selkoe, 2001). Because the cognitive deficits are detected before tangle and plaque 
formation become apparent, it is hypothesised that synaptic dysfunction precedes tangle 
and plaque formation and could trigger the onset of molecular changes in AD (Selkoe, 
2002). A recent study implicated deficient axonal transport in early stages of the 
pathogenesis of AD long before disease-related pathology was observed (Stokin et a l , 
2005). The impairment of axonal transport was accompanied by swellings with 
accumulation of abnormal amounts of microtubule-associated proteins, including tau, 
molecular motor proteins, organelles and vesicles (Stokin et a l , 2005). Interestingly, 
several molecules associated with the pathogenesis of AD including APP and tau have 
also been functionally linked to axonal transport. Therefore, it is hypothesised that 
disruption of proteins with functions important for axonal transport are at the basis of 
AD (Morfini et a l , 2004). Accordingly, tau hyperphosphorylation and increased 
proteolytical processing of APP could directly affect axonal transport or else may be 
manifestations of impaired axonal transport. Precise regulation of phosphorylation of 
tau is important for its proper functioning, for example, for binding to microtubules and 
hyperphosphorylation of tau could disrupt these functions important for axonal transport 
(see for review Johnson & Stoothoff, 2004). Interestingly in this context, the proline- 
directed kinases Cdk5 and GSK3 have been implicated in the regulation of kinesin- 
driven axonal transport and are prime candidates for mediating tau 
hyperphosphorylation (Morfini et a l , 2004).
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APP was found to regulate vesicular transport by linking vesicles to the motor protein 
kinesin. Proteolytical cleavage of APP is thought to be involved in the release of the 
vesicles. Further, presenilin 1 and 2, that have also been associated with AD, are 
implicated in the proteolytical cleavage of APP. Deficits in axonal transport have also 
been shown to induce oxidative stress and lead to neurodegeneration, characteristic 
features of AD (Stamer et al., 2002). Future research promises to elucidate the 
mechanisms involved in axonal transport, which might help greatly to further the 
understanding of molecular processes underlying AD.
1.9) Microtubule-associated protein tau
The tau protein belongs to the microtubule-associated protein (MAP) family and is 
evolutionarily conserved amongst invertebrate species including worm and fly as well 
as vertebrate species such as frog, mouse and human (see for review Buee et al, 2000; 
Lee et al., 2001). Tau is widely expressed in the mammalian nervous system, but also at 
low-levels in other tissues including kidney. In the adult human central nervous system 
(CNS), six different isoforms are generated by alternative splicing from one single gene 
(Fig. 1-5; Swiss Prot|P10636|TAU_HUMAN). In addition, a peripheral nervous system 
(PNS) tau isoform and a fetal-tau isoform can be generated from the same gene (Fig. 1- 
5). The tau protein contains two major functional domains: a projection domain and a 
microtubule-binding domain (Fig. 1-6). The projection domain is located at the amino- 
terminal and contains an acidic region and a proline-rich region (Fig. 1-6). The different 
tau isoforms vary from each other by alternative splicing of two amino-terminal inserts 
encoded by exons 2 and 3 (Fig. 1-5). The presence or absence of these inserts is thought 
to affect tau interactions and hence regulate distinct functions of the different isoforms. 
The carboxy-terminal microtubule-binding domain of tau consists either of three 
microtubule-binding repeats (3R) or four repeats (4R) (see, for example, Goedert et a l ,
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1989; Goedert & Jakes, 1990). Three of the isoforms lack microtubule-binding repeat 
number 2 encoded by exon 10 and thus contain 3R, whereas the other three isoforms 
have 4R (Fig. 1-5). The expression ratios between the tau isoforms vary during 
development and is different for specific cell types (see, for example, Goedert et al., 
1989a and 1989b). The spatio-temporal regulation of tau expression suggests distinct 
physiological roles of the different isoforms. In contrast to the six tau isoforms 
generated via alternative splicing in the adult human brain, the homologous mouse tau 
gene is spliced only into 4R isoforms in adult murine brain (Swiss 
Prot|P10637|TAU_MOUSE). Thus, mice lack the 3R tau isoforms. Furthermore, mouse 
tau has a different splicing ratio between the isoforms and the amino-terminal region of 
tau contains an additional 14 amino acid insert (Appendix I).
The tau protein interacts with numerous molecules (see for review Buee et al, 2000). 
The projection domain is probably important for the interaction with cytoskeletal 
proteins and the plasma membrane. Interaction of tau with actin filaments and spectrin 
are thought to interconnect microtubules with other cytoskeletal components and 
thereby restrict the flexibility of the microtubules (see, for example, Matus, 1994). The 
amino-terminal proline-rich region of tau has been implicated in the association with the 
non-receptor tyrosine kinase, fyn (SH3 binding motif (PxxP) residues 231-237, as per 
441aa tau isoform), and phospholipase C-y (PLC-y) (see, for example, Lee et al., 1998; 
Hwang et al., 1996). The carboxy-terminal three or four microtubule-binding repeats of 
tau bind microtubules. Interestingly, the 4R isoforms exhibit a far higher binding 
affinity to microtubules than 3R isoforms (see, for example, Goedert & Jakes, 1990; 
Panda et al., 1995). In addition, the microtubule-binding domain of tau interacts with 
PP2A (residues 224-236, as per 441aa tau isoform) and presenilin 1 (Sontag et al., 
1999; Takashima et a l , 1998).
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Tau undergoes characteristic post-translational modifications, including glycosylation 
and phosphorylation (see for review Buee et al, 2000; Johnson & Stoothoff, 2004; Fig. 
1-7). These post-translational modifications are differentially regulated in specific cell 
compartments, cell types and during development. Moreover, post-translational 
modifications at specific sites were found to alter the function of tau and may play a role 
in subcellular localisation and degradation of tau. For example, phosphorylation of tau 
at KxGS motifs within the microtubule-binding domain reduces the affinity for 
microtubule binding (see, for example, Drechsel et a l , 1992). There are 79 serine and 
threonine residues within the 441 tau isoform (Fig. 1-7). Over thirty of these sites have 
been found phosphorylated on tau (Fig. 1-7). Many of these sites are proline-directed 
serine/threonine phosphorylation sites and are modified by proline-directed kinases. The 
proline-directed kinases include cyclin-dependent kinases (Cdks; e.g. Cdc2, Cdk2 and 
Cdk5), glycogen synthase kinase 3 (GSK3), mitogen activated protein kinases (MAPKs; 
e.g. ERK and MEK) and stress-activated protein kinases (SAPKs; e.g. c-jun N-terminal 
kinase (JNK)). Amongst others the following proline-directed phosphorylation sites 
have been found modified within the 441 residue human tau isoform (Fig. 1-7): Ser46, 
Thr50, Thr69, Thrl53, Thrl75, Thrl81, Serl99, Ser202, Thr205, Thr212, Thr217, 
Thr231, Ser235, Ser396, Ser404 and Ser422. However, the function of the 
phosphorylation at these sites is not yet understood, but it is believed to be important for 
the association with the microtubules (see for review Johnson & Stoothoff, 2004). 
Interestingly, none of the proline-directed phosphorylation sites is directly located 
within a microtubule-binding repeat indicating additional putative functions for these 
phosphorylation sites. The level of tau phosphorylation is balanced by antagonistic 
action of phosphatases including PP1, PP2A PP2B and PP5 (see, for example, Liu et a l ,
2005). Interestingly, both, kinases as well as phosphatases, have been found directly or 
indirectly associated with microtubules and/or tau, suggesting that the regulation of the 
phosphorylation levels of tau may be important for its function.
CHAPTER 1: Introduction 58
There is still only limited knowledge on the physiological roles of tau and tau 
phosphorylation. One well-characterised function of tau is the binding and stabilisation 
of microtubules (for review, see Buee et al., 2000; Johnson & Stoothoff, 2004). Tau 
interacts directly with microtubules and subsequently promotes their polymerisation 
(see, for example, Drechsel et al., 1992). Increasing levels of phosphorylation on tau at 
KxGS motifs within the microtubule-binding domain have been found to induce 
dissociation of tau from the microtubules and in turn destabilisation of the microtubules 
(see, for example, Biemat et al., 1993). The interaction of tau and microtubules is also 
important in the regulation of microtubule-dependent axonal transport (see, for example, 
Stamer et al., 2002; Mandelkow et al., 2003 and 2004). It has been proposed that local, 
intermittent dissociation of tau from the microtubules is required to enable the 
progression of motor-molecules such as kinesin and dynamin (Mandelkow et al., 2004). 
The dissociation of tau is thought to be regulated via its phosphorylation, specifically 
mediated by microtubule-affinity regulating kinase (MARK) (at KxGS motifs) and 
GSK3 (see, for example, Mandelkow et al., 2003 and 2004; Cho & Johnson, 2003; 
Tatebayashi et al., 2004). These observations prompted the notion that the precise 
regulation of phosphorylation of tau is important for its normal cellular functions. In 
contrast, increased tau phosphorylation disrupts cellular processes including 
microtubule stability and axonal transport. Moreover, tau has been implicated in neurite 
outgrowth (Caceres & Kosik, 1990). Interestingly, a recent study in a transgenic mouse 
line expressing mutant tau-P301L reported that LTP is increased in DG, but not in 
hippocampal area CA1 of young P301L mice before the onset of hyperphosphorylation 
and tauopathy (Boekhoom et al., 2006). The increased DG LTP coincided with a higher 
preference in the novel object recognition task after 3.5h in the P301L mice. In contrast 
to this finding, old P301L mice exhibit learning and memory impairments, probably due 
to incipient neuronal cell loss (Ramsden et a l , 2005). The changes in LTP and memory 
in the young P301L mice were not due to alterations in tau phosphorylation, 
neurogenesis, dendritic morphology or hippocampal morphology (Boekhoom et al.,
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2006). These results suggest that expression of mutant tau-P301L directly affects 
neuronal processes and implicate tau in synaptic plasticity and memory formation.
Much research has focussed on tau and the regulation of its phosphorylation levels, 
because tau is characteristically hyperphosphorylated in the filamentous aggregates 
found in many patients with neurodegenerative tauopathies including AD (see, for 
example, Grundke-Iqbal et al., 1986b; see for review Buee et al, 2000; Lee et a l , 2001; 
Table 1-2). Hence, it was hypothesised that the abnormal phosphorylation of tau may be 
responsible for their aggregation into intraneuronal filamentous inclusions in 
neurodegenerative tauopathies. However, many of the sites that are 
hyperphosphorylated in aggregated filamentous tau, have also been found 
phosphorylated on fetal and native adult tau (see, for example, Kenessey & Yen 1993; 
Brion et a l , 1993; Matsuo et a l , 1994). In addition, despite the fact that fetal tau is 
highly phosphorylated, no tau aggregation could be observed (see, for example, Matsuo 
et al., 1994). Furthermore, recombinant tau forms filamentous structures without being 
phosphorylated in the presence of polyanions (see, for example, Goedert et a l , 1996). 
These findings indicate that phosphorylation of tau may not be involved in the 
aggregation of tau or additional factors are required. Some results suggest that 
glycosylation, oxidation, faulty degradation and truncation of tau might trigger the 
assembly of filaments (see for review Buee et a l , 2000). Other studies demonstrate the 
involvement of co-factors such as glycosaminoglycans, metal ions (i.e. Aluminium) and 
polyanions (i.e. RNA and lipids) in tau filament formation (see for review Buee et a l , 
2000).
Native tau and aggregated tau from pathological filaments can be unequivocally 
distinguished by biochemical means indicating fundamental differences between the 
two states (see for review Lee et a l , 2001). Separation of aggregated filamentous tau by 
SDS-PAGE produces characteristic electrophoretic profiles. These electrophoretic 
profiles vary between the different diseases, but are often characteristic within a specific 
disease. The differences in electrophoretic mobility might result from post-translational
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modifications and subsequent conformational changes of tau. Interestingly, the prolyl 
isomerase Pinl, a molecule that catalyses conformational conversion of proline-directed 
phosphorylation sites, has been implicated in hyperphosphorylation of tau and 
neurodegeneration (see for review Lu et a l , 2002). Phosphorylation at some proline- 
directed sites induces a conformational change in the backbone of proteins and thereby 
restricts the accessibility for phosphatases. Pinl activity can restore the function of 
some phosphorylated proteins by reverting the conformation and thereby promoting its 
dephosphorylation. A KO mouse line lacking Pinl expression exhibits age-dependent 
motor and behavioural deficits, tau hyperphosphorylation, tau filament formation and 
neurdegeneration (Liou et al., 2003). These results indicate that Pinl plays a role in 
preventing tau hyperphosphorylation and protecting against neurodegeneration.
1.10) Amyloid-^ precursor protein and A|3-peptides
1.10.1) Amyloid-Pprecursor protein
The amyloid-p precursor protein (APP) is the product of a single gene located on 
chromosome 21 and is widely expressed in many tissues (see for review Turner et a l , 
2003; Swiss Prot|P05067|A4_HUMAN and Swiss Prot|P12023|A4_MOUSE). Three 
major APP isoforms including APP695, APP751 and APP770 are generated by 
alternative splicing (Fig. 1-8). The name indicates the number of amino acids within the 
APP isoforms (i.e. 695, 751 or 770 amino acids). The expression ratio between the three 
APP isoforms varies within different cell types and tissues. APP is a single membrane- 
spanning protein with a large extracellular amino-terminal domain and a short 
intracellular carboxy-terminal portion (Fig. 1-8 and 1-9). The extracellular part contains 
a kunitz protease inhibitor domain (lacking in APP695), a domain with a 
neuroprotective function and domains binding copper, zinc, heparin and collagen (Fig.
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1-8). The heparin and collagen binding domains of APP are thought to mediate cell 
adhesion. The short intracellular portion has binding sites for the proteins Fe65, Ibl 
(Jiplb), Dabl, PAT1, she A, she C and X I1 (Fig. 1-9). These protein interactions with 
the intracellular tail of APP may be involved in various functions (see for review, 
Turner et al., 2003; Kerr & Small, 2005). Interaction with Fe65 has been implicated in 
gene transcription, actin binding and protein trafficking. Interestingly, phosphorylation 
within the binding domain of Fe65 at Thr6 6 8  on APP (as per APP695 or Thr743 as per 
APP770) inhibits the binding of Fe65, but not Dabl and X I1 (see, for example, Ando et 
al, 2001). The phosphorylation at this proline-directed Thr6 6 8  site of APP is mediated 
by Cdk5 and might be important for the localisation of APP in axons and conferring a 
specific function on APP (Iijima et a l, 2000). Further, association of the APP carboxy- 
terminus with Ibl, Dabl, she A and she C might regulate kinase activation (see for 
review, Kerr & Small, 2005). Binding of X I1 with APP was found to reduce its 
processing and may be involved in modulation of protein trafficking and synaptic 
vesicle release (Borg et a l, 1998). In addition, APP may function as a cell surface G- 
protein-coupled receptor, as Go was found to associate with APP (Okamoto et al, 
1995). Together, APP has been implicated in diverse processes such as axonal transport, 
cell adhesion, gene transcription and synaptic vesicle release (see for review Turner et 
al, 2003). Moreover, the study of APP KO mice revealed impaired LTP and memory 
deficits (Dawson et a l, 1999). These findings link APP to synaptic plasticity and 
memory processes.
The three alternative splice variants of APP undergo extensive post-translational 
modifications, including glycosylation and phosphorylation, and complex proteolytic 
processing that gives rise to a large number of APP isoforms and APP fragments (see 
for review Turner et a l, 2003; Fig. 1-9 and 1-10). APP is processed by several 
proteases, including secretases and caspases. The secretases cleave APP at two 
extracellular sites in the vicinity of the transmembrane domain. The a-secretase 
(possibly the metalloproteases: ADAM 10, TACE (or ADAM 17) and MDC9) cleaves 
between the residues 687/688 and the p-secretase (BACE1 and BACE 2) between the
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residues 671/672 of the APP770 (All further numberings refer to APP770). The 
proteolytic cleavage site of the y-secretase complex (including presenilin 1 and 2, Aph- 
1, Pen-2, and nicastrin) is within the transmembrane domain between residues 711/712, 
713/714 or 720/721. Processing at these sites results in the production of a large 
extracellular domain fragments and smaller fragments composed of the transmembrane 
domain and the intracellular tail of APP. Depending on the activation pattern of the 
different secretases, distinct APP fragments are generated. The processing of APP by 
the a-secretase and P-secretase are thought to be mutually exclusive. The consecutive 
cleavage of APP by p- and y-secretases results in the production of the Ap-peptides, 
with the predominant fragments APmo (residues 672 to 711) or Api_42 (residues 672 to 
713) and the y-carboxy-terminal fragments (y-CTFs; depending on cleavage site, the y- 
CTF fragment is 59, 57 or 50 aa long). First, the p-secretase cleaves APP within the 
extracellular domain and releases the soluble APPp amino-terminal part (sAPP-P) and 
the p-carboxy terminal fragment (p-CTF or C99; 99aa long). In a second step, the p- 
CTF can be cleaved by the y-secretase within the transmembranal domain and produces 
the Ap-peptides and the y-CTFs.
In addition, APP can be cleaved by the a-secretase within the AP-peptide domain and 
thus precluding formation of Ap-peptides (Esch et al., 1990). Processing by the a- 
secretase generates the soluble APPa amino-terminal part (sAPP-a) and the a-carboxy 
terminal fragment (a-CTF or C83; 83aa long). Subsequent processing of a-CTF by the 
y-secretase leads to the production of the y-CTFs and the p3 peptides (depending on the 
cleavage site the p3 fragment is 24, 26 or 33aa long). This pathway, involving the a- 
secretase and the y-secretase, is thought to be the major secretory pathway. It does not 
produce Ap-peptides and hence is not amyloidogenic (Esch et al., 1990). Furthermore, 
caspases have been shown to cleave APP at several sites within the cytosolic domain 
giving rise to many more different cleavage products (Ayala-Grosso et a l , 2002). For 
example, during neuronal apoptosis caspases cleave APP at the residues 739/740 and
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release the neurotoxic C31 peptide. Most of the APP cleavage products listed above 
seems to have physiological cellular functions, however very little is known about their 
precise roles. It was demonstrated that sAPPp is neuroprotective and regulates cell 
excitability and synaptic plasticity (see for review Turner et a l , 2003). Further, the y- 
CTFs, also called APP intracellular domain (AICD), were found to relocalise to the 
nucleus (see, for example, Cao & Sudhof, 2004). Because the y-CTFs bind the protein 
Fe65, which interacts with transcription factors, it is thought to be a mechanism to 
regulate gene transcription (Cao & Sudhof, 2004). Little is known about the 
downstream mechanisms that regulate the cleavage of APP into AP-peptides. One study 
reported that the production of Ap-peptides is regulated by GSK3a activity (Phiel et al., 
2003). There, it is shown that therapeutic concentrations of lithium, a GSK3 inhibitor, 
block the production of AP-peptides by interfering with APP cleavage at the y-secretase 
step. Further, in transgenic mice with over-expression of APP, the accumulation of Ap- 
peptides is also blocked by lithium administration (Phiel et al., 2003; Ryder et a l , 
2003). Another study confirms the involvement of GSK3 in APP processing (Ryder et 
a l , 2003). However their results implicate the p-isoform of GSK3 in the cleavage of 
APP. In addition, this study shows that application of roscovitine, a Cdk5 inhibitor, or 
Cdk5 antisense oligonucleotides stimulates the production of Ap-peptides. These results 
indicate that GSK3 activity is increasing the level of Ap-peptides, possibly by 
regulating y-secretase activity, whereas Cdk5 activity is inhibiting Ap-peptide 
production. It is thought that Cdk5 regulates the processing of APP via the 
phosphorylation at Thr6 6 8  within the carboxy-terminus of APP. It was observed that in 
cell cultures over-expression of p35 and subsequent over-activation of Cdk5 led to 
phosphorylation of both mature and immature APP at Thr6 6 8 , whereas over-expression 
of p25 led predominantly to phosphorylation of immature APP (Liu et a l , 2003). 
Curiously, this study implicates increased APP phosphorylation and Cdk5 over­
activation with elevated APP processing resulting in enhanced secretion of sAPP-a, 
sAPP-p and Ap-peptides contradicting previous findings (see, for example, Ryder et al, 
2003).
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1.10.2) A p-peptides
Much research was focused on the production and function of AP-peptides, AP1-40 and 
Api-42, because of their involvement in Alzheimer’s disease (see for review Selkoe,
2001). The Ap-peptides are the main component in the extracellular senile plaques 
characteristically found in AD patients. Some early-onset forms of FAD could be 
directly linked to point mutations near the APP cleavage sites (e.g. Swedish mutation: 
K670N/M671L, Dutch mutation: E693Q), which alter the processing of APP and lead 
to increased production of Api.42. It was hypothesised that an age-dependent 
accumulation and aggregation of Ap-peptides, triggered by increased production and 
reduced Ap-peptide clearance, are the primary cause of FAD, as well as sporadic AD. 
However, the extend to which Ap-peptides are responsible for the cognitive decline in 
AD is controversial. Insoluble Ap-peptide aggregation correlates only poorly with the 
cognitive state of AD patients. In contrast, NFT formation reflects more accurately the 
cognitive decline of patients (Braak & Braak, 1991). However, it has been found that 
the levels of soluble Ap-peptide oligomers correlate better than senile plaques with the 
severity of the dementia (Lue et al., 1999). These findings are supported by behavioural 
studies in transgenic mice expressing human APP 695 carrying the Swedish mutation 
(Tg2576), where cognitive impairment is observed long before aggregates of Ap- 
peptides are found (Chapman et al., 1999). Further, intraventricular injection of soluble 
mutated Ap-peptides inhibited the induction of CA1 LTP in anaesthetised rats (Klyubin 
et al., 2004). Interestingly, application of Api-42 peptides impaired DG LTP and 
mediated inhibition of the phosphorylation of CaMKII at Thr286 and of the AMPA 
receptor subunit GluRl at Ser831 (Zhao et al., 2004). These results suggest that Ap- 
peptides interfere with molecular mechanisms important for hippocampal synaptic 
plasticity and thereby induce memory deficits as observed in AD patients.
Furthermore, Ap-peptides have been implicated in cholinergic neurotransmission. Api- 
42 peptides associate with nicotinic acetylcholine receptors and thereby possibly alter
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their conductance (Wang et al., 2000). The dysfunction of acetylcholine receptors and 
AD is well established and cholinergic neurons are particularly prone to degeneration in 
AD (see for review Selkoe, 2001). This provides a further possible mechanistic link 
between the Ap-peptides and cognitive dysfunction in AD. Moreover, Api.42 was linked 
to increased Ca2+ influx through L-type VGCC (see, for example, Ueda et al., 1997).
04 -Increased Ca influx triggers many molecular processes important for the induction of 
synaptic plasticity (see section 1.6). Hence, the activation of L-type VGCC by Ap- 
peptides could lead to the induction of some forms of synaptic plasticity. However, 
increased Ca influx over long periods or at high levels could also induce 
neurotoxicity.
Api.42 has a higher tendency to self-association than APmo and was shown to be more 
toxic to neurons (see for review Selkoe, 2001). Interestingly, a study using transgenic 
mice carrying the Dutch mutation in APP (E693Q) crossed with transgenic mice 
producing mutated presenilin 1 demonstrated the importance of the ratio of ApMo and 
AP1-42 peptides for the formation of amyloid pathology at the brain vasculature or in the 
parenchyma (Herzig et al., 2004). This study demonstrates that neuronally-produced 
APmo is key for the vascular amyloid pathology observed in cerebral amyloid 
angiopathy and emphasises the different roles of APmo and APm2 peptides in amyloid 
pathology.
In summary, Ap-peptides play an important role in the pathology of AD and are 
possibly involved in the cognitive deficits observed in AD. However, recent results 
indicate that Ap-peptides serve a physiological role and are not solely a toxic by­
product (see, for example, Wang et al., 2004). The basic cellular functions of the Ap- 
peptides are not well understood. Therefore, it is important to elucidate the precise 
biological roles of the Ap-peptides and its precursor molecule APP, in order to better 
understand the processes involved in AD.
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1.11) Cyclin-dependent kinase 5
Cyclin-dependent kinase 5 (Cdk5) is a multifunctional serine/threonine kinase of the 
cyclin-dependent kinase (Cdk) family (see for review Dhavan & Tsai, 2001; Swiss 
Prot|P49615|CDK5_MOUSE). Cdk5 is expressed in all tissues with the highest level of 
expression and kinase activity found in post-mitotic neuronal cells (Hellmich et al., 
1992). Cdk5 is a proline-directed kinase, which means that it can phosphorylate 
serine/threonine residues only immediately upstream of a proline residue resulting in the 
consensus phosphorylation motif x-(S/T)-P-x. Cdk5 has a broad range of substrates with 
diverse functions (see Table 1-3).
Tablel-3. Cdk5 substrates
Trans-
membranal
proteins
Scaffolding
proteins
Cytoskeletal
and
associated
proteins
Proteins 
implicated in 
transcription
Protein kinases 
and phosphatases
Proteins involved 
in neurotrans­
mitter release
Others
APP P-catenin Filamin P-catenin
Apoptosis- 
associated tyrosine 
kinase
Amphyphysin I Cables
ErbB
(neuregulin
receptor)
PSD95 MAP IB and MAP2 Histone HI CPRK
Dynamin I Canoe
NCAM Neurofilame nt H and M MEF2
DARPP-32
Munc-18 (Seel or 
P67)
cGMP phospho­
diesterase
NR2A NUDEL mSds3 FAK Synapsin I Disabled 1
Presenilin-1 tau p53 JNK3 synaptojanin Ezrin
VGCC
(P/Q-type and L- 
type)
Rb MEK1 Trio nestin
STAT3
p35 and p39 (Cdk5 
activator)
Pctaire 1
PAK1 (a-Pak) RasGRF2
PP1 inhibitor-1 and 
2 (I-1/1-2)
Tyrosine
hydroxylase
Src
Abbreviations: APP, amyloid precursor protein; CPRK, Cdk5/p35 regulated kinase; DARPP-32, 
dopamine and cAMP-regulated phosphoprotein molecular mass 32 kDa; FAK, focal adhesion kinase; 
JNK, c-jun N-terminal kinase 3; MAP, microtubule-associated protein; MEF2, myocyte enhancer 
factor 2; mSds3, mammalian suppressor of defective silencing 3; NR2A, NMD A receptor subunit 2 A; 
PSD-95, post-synaptic density 95 kDa; RasGRF2, Ras protein-specific guanine nucleotide-releasing 
factor 2; Rb, ; Src, ; STAT3, signal transducer and activator of transcription 3;VGCC, voltage-gated 
calcium channel (After Shelton & Johnson, 2004 and Angelo et al. 2006).
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Cdk5 activity has been implicated amongst other functions in the regulation of the 
cytoskeleton, axon guidance, axonal transport, apoptosis and synaptic plasticity (see, for 
example, Morfini et al., 2004; Li et al., 2001; see for review Dhavan & Tsai, 2001). 
Despite similar substrate specificity to other mitotic Cdks, no function of Cdk5 in cell- 
cycle regulation was observed (Van den Heuvel & Harlow, 1994). The role of Cdk5 in 
the development of the CNS is well-established. There it is essential for regulating 
neuronal migration, axo-dendritic organisation and the development of cortical laminar 
architecture (Nikolic et al., 1996; Ohshima et al., 1996; Chae et al., 1997). Another 
intensively studied function of Cdk5 is the phosphorylation of neuronal cytoskeletal 
proteins, including neurofilaments and the microtubule-associated proteins MAP IB, 
MAP2 and tau and its potential involvement in neurodegenerative diseases including 
AD (see for review Shelton & Johnson, 2004). Furthermore, recent studies provide 
compelling evidence for a role in synaptic plasticity and memory formation (see for 
review Angelo et al., 2006; see section 1.11.5).
1.11.1) Cdk5 activation requires association with activator proteins
As other members of the Cdk family, Cdk5 alone has no enzymatic activity and requires 
the association with a regulatory subunit for activation. Several activators of Cdk5 have 
been identified, including p35 and p39 (Ishiguro et al., 1994; Lew et al., 1994; Tsai et 
al., 1994; Humbert et al., 2000; Swiss Prot|P61809|CD5Rl_MOUSE). The interaction 
of Cdk5 with one of these regulatory subunits is sufficient to activate the kinase (Lew et 
al., 1994; Tsai et al., 1994). The Cdk5 activators, p35 and p39, are myristoylated at the 
N-terminus and are in turn membrane-bound (see, for example, Patrick et al., 1999). 
This restricts the Cdk5 activity to distinct subcellular compartments in the vicinity of 
membranes. Hence, many Cdk5 substrates are likely to be transmembranal, membrane- 
bound or membrane-clustered proteins (Table 1-3). So far, it is not clear whether p35 
and p39 target Cdk5 activity to a similar or to distinct subsets of substrates. Studies in 
p3 9-null mutant mice that lack any specific phenotype indicate that p35 can compensate
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for p39 function (Ko et al., 2001; Table 1-4). In contrast, in p35-null mutants p39 can 
compensate only for some functions of p35 (Chae et a l , 1997; Ko et a l , 2001).
1.11.2) Formation o f the Cdk5 activator p25 by cleavage ofp35
The Ca -dependent protease calpain can cleave the Cdk5 activator p35 into the 
carboxy-terminus fragment, p25 and the amino-terminus fragment plO (Kusakawa et 
al., 2000). The protein fragment p25 acts also as an activator of Cdk5. Because p25 is 
more stable than p35, formation of p25 leads to over-activation of Cdk5. The half-life of 
p35 is short with about 20-30 minutes (Patrick et al., 1998). The degradation of p35 is 
directly regulated via Cdk5 activity. Phosphorylation of p35 by Cdk5 in the amino- 
terminal portion leads to degradation of p35 via the ubiquitin-proteosome pathway 
(Patrick et al., 1998). This negative feedback regulation restricts the formation of the 
active p35/Cdk5 complex to a limited period of time and constitutes an elegant 
mechanism to control the kinase activity of Cdk5. The amino-terminus part containing 
the degradation-inducing phosphorylation site is lacking in p25 and hence it is not 
subjected to the feedback regulation resulting in longer half-life.
Furthermore, p25 lacks also the amino-terminus myristoylation site of p35 that confers 
membrane localization. Consequently, p25 displays a broad distribution throughout the 
cell. Thus, formation of p25 has been suggested to alter the localization of active Cdk5 
within the cell (Patrick et al., 1999). In addition, association of Cdk5 with either p35 or 
p25 may confer discrete substrate specificities to Cdk5. This is indicated by the finding 
that expression of p25 in p3 5-null mutants could rescue the phenotypical deficits only 
partially (Patzke et al., 2003; Table 1-4). In addition, association of Cdk5 with either 
p35 or p25 resulted in differential phosphorylation of the amyloid precursor protein 
(APP) and microtubule-associated protein IB (MAPIB) (Liu et al., 2003; Kawauchi et 
al., 2005).
Table 1-4. Mouse models with altered expression of Cdk5 or p35.
M ouse line; 
Reference
M utation;
Genetic
background
Phenotype/ A ppearance AD-like molecular phenotype Rem arks
Cdk5 (-/-)
(Ohshima et al., 
1996)
KO mouse line; 
C57BL/6
Lesions in brain and spinal cord, not in other 
tissues, lack of cortical laminar structure and 
cerebellar foliation; perinatal death
Accumulation of NF immunoreactivity 
in neuronal cell bodies suggesting 
defective transport of NF
Heterozygous Cdk5 (+/-) mice appear 
normal.
p35 (-/-)
(Cha ee ta l., 1997)
KO mouse line; 
129/Sv and C57BL/6
Cortical lamination defects, altered cell 
orientation, dendritic and axonal trajectories; 
sporadic adult lethality and seizures
Not assessed Study links the Cdk5 activator p35 to proper neuronal migration
p39 (-/-) and 
p35/p39 (-/-)
(Ko et al., 2001)
p39 KO mouse line 
and p35/p39 double 
KO mouse line; 
C57BL/6
p39 KO mice have no phenotypic 
abnormalities, loss of p39 produced no 
changes in p35 and Cdk5 levels and Cdk5 
activity;
Double KO mice are perinatal leathal and 
display similar phenotype as Cdk5 KO mice, 
double KO display no Cdk5 activity in brain,
No changes in tau phosphorylation 
during development; Phosphorylation of 
NF-H is unaltered; Changes in cellular 
NF-H localisation in spinal cord
Study shows distinct roles for p35 
and p39; Regulation of p39 levels by 
p35 expression; p35 and p39 seem to 
be only Cdk5 activators important 
during CNS development.
p35 (-/-)
(Hallows et al., 
2003)
KO mouse line; 
C57BL/6
Cortical lamination defects, axonal 
derangement, redistribution of Cdk5 and 
cytoskeletal proteins, Cdk5 activity reduced 
by approx. 60 %.
Increased phosphorylation of NF, 
MAP2B and tau at Ser202, Ser235, 
Ser396/404; Increased GSK30 activity
Results indicate a role in neuronal 
trafficking for CdK5/p35.
p35 (-/-) 
expressing p25
(Patzke et al., 
2003)
Crossing of transgenic 
p25 mice (Ahlijanian 
et al., 2000) and p35 (- 
/-) mice (Chae et al., 
1997);
C57BL/6
Partial rescue of the p35 (-/-) phenotype, 
phosphorylation of disabled-1 is partially 
restored.
No tau hyperphosphorylation, 
p25 levels increase with age; 
(spongiform degeneration in the 
cortex at 2 years)
Study shows that p25 can substitute 
some but not all functions of p35.
Abbreviations: CNS, central nervous system; GSK3p, glycogen synthase kinase 3p; KO, knock-out; MAP2B, microtubule- 
associated protein 2B; NF, neurofilament; (Taken from Giese et a l, 2005)
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1.11.3) Formation o f p25 under pathological conditions and in disease models
The formation of the Cdk5 activator p25 has been observed so far only under neurotoxic 
and pathological conditions (see, for example, Lee et al., 2000; see for review Dhavan 
& Tsai, 2001; Shelton & Johnson, 2004). It is thought that under pathological 
conditions an alteration in cellular calcium homeostasis occurs, as proposed for example 
in AD. Changes in intracellular calcium levels would in turn induce calpain activation, 
and lead to the subsequent cleavage of p35 into the protein fragments p25 and plO. 
Several post-mortem studies describe the accumulation of the protein fragment p25 in 
patients with sporadic AD patients, but not in healthy control patients (Patrick et a l , 
1999; Tseng et al., 2002; Swatton et al., 2004). One problem encountered in post­
mortem studies is the spontaneous generation of p25 due to pathological activation of 
calpain. Other studies did not detect p25 production in AD patients (Yoo & Lubec, 
2001; Takashima et a l , 2001; Tandon et a l , 2003) and hence, there is still controversy 
as to whether p25 is formed specifically in AD.
However, further support for the specific p25 production in AD comes from the findings 
that calpain and Cdk5 activity are increased in post-mortem AD brain tissue (Veeranna 
et a l , 2004; Taniguchi et a l , 2001; Lee et a l , 1999). In addition, the formation of p25 
has been described in the transgenic mouse line Tg2576 that models familial AD by 
expressing the APP carrying the Swedish mutation K670N and M671L (Otth et a l ,
2002) and in the conditional presenilin double KO mouse line (Saura et a l , 2004) 
(Table 1-5). Interestingly, in patients with Niemann-Pick type C disease, another 
neurodegenerative tauopathy, accumulation of p25 was observed. Consistent with this, a 
transgenic mouse line modelling Niemann-Pick type C disease by expressing a mutant 
form of the protein npc-1 displayed also p25 accumulation (Bu et a l , 2002).
T able 1-5. Disease models in which p25 formation occurs.
Mouse line; 
Reference
M utation; Mouse 
genetic background
p25 levels; 
Cdk5 activity
(AD-like) phenotype; 
Neurodegeneration Phenotype O ther rem arks
Amyotrophic lateral 
sclerosis model; 
(Nguyen et al., 2001)
Mutant SOD (G37R); 
C57BL/6
Ratio of p25/p35 is about 
1:2 to 1:3;
2-fold increase in Cdk5 
activity in spinal cord.
Hyperphosphorylation of 
tau and NF proteins.
Mislocalization of Cdk5 
in motor neurons; 
accumulation of NF in 
the perikarya
Recent studies indicate p25 
expression is not responsible for 
motomeuronal degeneration in 
this ALS mouse model 
(Takahashi et al., 2004)
Niemann-Pick type 
C model;
(Bu et al., 2002)
npc-1 mutation;
p35 signal is several fold 
stronger than p25;
Cdk5 activity is 1.5 to 
2-fold increased.
Hyperphosphorylation of 
NF, M AP2 and tau. 
Elevated NF levels; 
neuronal cell loss
Extensive lipid storage 
accumulation, 
neuroaxonal dystrophy, 
neuronal cell loss
p25 formation also observed in 
human NPC patients; 
Heterozygous npc-1 (+/-) show 
no cytoskeletal pathology.
APP transgenic 
Tg2576 mice; 
(Otth et al., 2002)
Human APP with Swedish 
mutation;
Mix of C57B1/6 and SJL
p35 signal is several fold 
stronger than p25;
Cdk5 activity is about 
1.5-fold increased.
Hyperphosphorylated tau; 
small-clustered core 
plaques in hippo-campus 
and cortex; dystrophic 
neurites and astrogliosis
Cdk5 colocalizes with plaques
Presenilin double 
mutant;
(Saura et al., 2004)
Conditional presenilin 
double KO mouse line; 
C57BL6/129 hybrid mice
p35 signal is several fold 
stronger than p25;
Cdk5 activity not 
assessed.
Age-dependent tau 
hyperphosphorylation and 
neurodegeneration
Memory impairment and 
altered synaptic plasticity
Presenilins are components of 
the y-secretase protein complex 
and are thought to affect cellular 
levels of calcium.
Rat ischemia model; 
(Wang et al., 2003) N/A
Ratio of p25/p35 is about 
1:2 to 1:3;
At different times after 
ischemia Cdk5 activity 
was 2 to 4-fold 
increased.
Apoptosis, neuronal cell 
loss
Study shows that production of 
p25 is mediated via Ca2+ influx 
through AMPA receptor 
channels in ischemic 
hippocampal CA1 neurons.
Abbreviations: ALS, amyotrophic lateral sclerosis; APP, amyloid precursor protein; KO, knock-out; NF, neurofilament; NPC, 
Niemann-Pick type C disease; SOD, superoxide dismutase. (Taken from Giese et al., 2005)
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Further, p25 formation was detected in a transgenic mouse line modelling amyotrophic 
lateral sclerosis (ALS; also known as motor neuron disease) by expressing superoxide 
dismutase carrying a point mutation (G37R) (Nguyen et a l, 2001). However, recently it 
was demonstrated that p25 and Cdk5 activation are not involved in the ALS-like 
pathogenesis (Takahashi & Kulkami, 2004). Finally, ischemic insult in rat after 
occlusion of cerebral arteries was shown to trigger generation of p25 and a subsequent 
increase in Cdk5 activity in the hippocampal area CA1 (Wang et al., 2003). This study 
further demonstrated that the p25 production is mediated via Ca2+-influx through the 
AMPA receptor channels. For a summary of disease models in which p25 formation 
occurs, see Table 1-5.
1.11.4) Implication o f Cdk5 in tau hyperphosphorylation, tangle formation and 
neurodegeneration
Enhanced phosphorylation of the microtubule-associated protein tau at proline-directed 
serine/threonine sites is characteristic for many neurodegenerative diseases including 
AD (Paudel et a l, 1993; Morishima-Kawashima et al., 1995; see for review Lee et al,
2001). Cdk5 has been identified as a prime candidate for mediating tau 
hyperphosphorylation at proline-directed phosphorylation sites; because Cdk5 co- 
localizes with the filamentous tau depositions and shows enhanced activity in some 
neurodegenerative diseases including AD (Patrick et al., 1999; Augustinack et al., 
2002b; see for review Shelton & Johnson, 2004). Furthermore, Cdk5 has been involved 
in phosphorylation of other neuronal cytoskeletal proteins, including neurofilaments 
MAP IB and MAP2. In addition, Cdk5 activity was found to be detrimental to cell 
survival. In cultured primary neurons treatment with agents that induce neurotoxicity, 
such as glutamate, ionomycin and H2O2, trigger production of p25, which in turn leads 
to over-activation of Cdk5 (Lee et al., 2000). Expression of p25 in cultured primary 
cortical neurons was shown to increase Cdk5 activity and produced drastic effects, 
including collapse of microtubules and apoptosis (Patrick et al., 1999).
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In order to study the physiological effect of p25 formation and Cdk5 over-activation 
several TG mouse lines expressing p25 have been generated (For a summary of TG 
mouse lines expressing p25, see Table 1-6). In fact, the reported accumulation of p25 in 
AD and the possible involvement of Cdk5 in tau hyperphosphorylation made these p25- 
expressing TG mice an interesting model to test the implication of p25-induced Cdk5 
over-activation in neurodegenerative diseases. The study of the different p25-expressing 
TG mouse lines yielded inconsistent results; for example, on tau hyperphosphorylation. 
This might be explained by the different strategies that were used to generate the TG 
mice. In some TG lines, where the transgene was active during embryonic development, 
paralysis and motor abnormalities were observed (Ahlijanian et al., 2000; Takashima et 
al., 2001; Bian et al., 2002). This precluded an analysis of memory formation and might 
have induced artifacts. In all TG mouse lines the expression of p25 led to an over­
activation of Cdk5 (Table 1-6). Hence, all studies investigated the impact of the p25- 
induced over-activation on the phosphorylation levels of tau and neurodegeneration. 
Most of the studies observed tau hyperphosphorylation and increased phosphorylation 
of neurofilaments as tested in immunoblot and immunohistological studies (Table 1 -6 ). 
However, the onset and the level of tau hyperphosphorylation varied markedly between 
the different TG p25 mouse lines (Table 1-6; for further discussion see section 4.3.3). 
Interestingly, a transgenic mouse line over-expressing the Cdk5 activator p35 did not 
detect increased tau phosphorylation (Van den Haute et al., 2001). This result suggests 
that p25 and p35 direct the Cdk5 activity towards distinct substrates and that the active 
complex p35/Cdk5 is not involved in the phosphorylation of tau (see also Patrick et al., 
1999). Two of the TG p25 mouse lines exhibited aggregates of hyperphosphorylated 
tau, similar to neurofibrillary tangles (NFT) observed in AD patients (Nobel et al., 
2003; Cruz et al., 2003). Moreover, in an inducible p25 mouse line immunoblot and 
immunohistological studies revealed signs of neurodegeneration and gliosis (Cruz et al.,
2003).
Table 1-6. Mouse models with p25 expression.
Mouse Line; 
Reference
Transgene; 
Promoter; Mouse 
genetic background
Expression pattern, 
Expression levels; 
Cdk5 activation
Appearance/ Behaviour/ 
Synaptic plasticity
AD-like molecular phenotype; 
Neurodegeneration Other remarks
p25 TG mice; 
(Bian et al., 2002)
Human p25;
PDGF B chain promoter; 
FVB/N
Brain and spinal cord; Ratio o f 
p25/p35 is 5:1 ; 1 .5-2 -fo ld  
increase in Cdk5 activity
Hindlimb semiparalysis and mild 
forelimb dyskinesia beginning at 3 
months o f age
Hyperphosphorylated tau, axonal 
swelling; no NFTs.
Sciatic nerve and leg muscle 
do not show axonal 
abnormalities.
p25 TG mice; 
(Ahlijanian et al., 
2000)
Human p25;
Rat NSE promoter; 
FVB/N
Brain (tested only);
Ratio o f p25/p35 is 1:1 (lower in 
cerebellum);
Up to 2-fold increase in Cdk5 
activity;
At 4-9weeks o f age whole body 
exertion tremors/ increased 
locomotor activity more time spent 
on open arms o f  elevated plus- 
maze test
Hyperphosphorylation of tau and NF 
detected by IHC, but not IB, positive 
Bielschowsky staining; axonal swelling 
in amygdala.
axonal swelling in spinal cord
p25 TG mice; 
(Takashima et al., 
2001)
Bovine p25;
pCMV or PDGF promoter
Cortex, cerebellum and pituitary 
gland; 3 - 5-fold increase in p25 
expression; 2 - 5-fold increase in 
Cdk5 activity,
Unable to stand upright at 5 
month, died at 6 month
No tau hyperphosphorylation 
(Ser202,Ser396, and Ser404 tested), No 
neuronal cell loss and apoptosis.
Enlarged pituitary gland with 
high level o f  p25 expression, 
possibly inducing cell 
proliferation.
p25/mutant tau 
double TG mice; 
(Nobel et al., 
2003)
p25 mouse line (Ahlijanian et 
al., 2000) crossed with TG 
mice expressing mutant 
(P301L) human tau
Amygdala (tested only);
Ratio o f  p25/p35 is about 1:2 to 
1:4;
Approx. 2-fold increase in Cdk5 
activity
Pre-paralysis and early-stage 
degeneration mice were analysed
Tau hyperphosphorylation, tau aggregates 
in sarkosyl-insoluble fractions, NFT as 
detected by silverstain
P301L TG mice develop NFTs 
in the brainstem, spinal cord, 
telencephalon and 
diencephalons; Neuronal cell 
loss in spinal cord
Inducible p25 TG
mice;
(Cruz et al., 2003)
Human p25, GFP and c-myc 
tagged; TetO-p25 mice 
crossed with CamKII-tTA TG 
mice; C57BL/6
Inducible, restricted to forebrain; 
Ratio o f  p25/p35 is about 2:1 to 
3:1;
2.3-fold increase in Cdk5 
activity
Not assessed
Tau hyperphosphorylation, accumulation 
o f sarkosyl-insoluble tau, NFTs; 
Neurodegeneration and gliosis tested with 
antibodies in IHC and IB
Raised under presence o f  
doxycycline for 4 - 6 weeks; 
Leaky transgene; Different 
substrate specificity o f  
p25/Cdk5 detected.
p25 TG mice; 
(Angelo et al., 
2003; Ris et al., 
2005)
Mouse p25; 
alpha CaMKII; 
C57BL6 or 129B6F1
Restricted to forebrain; Ratio o f 
p25/p35 is 1:3 in hippocampus;
Normal appearance/ Altered fear 
conditioning and spatial memory 
formation/ altered hippocampal 
LTP
Hyperphosphorylation of NF-M 
No neurodegeneration or gliosis
Sexual dimorphisms in 
behavioural phenotype and 
hippocampal LTP
Abbreviations: CamKIIalpha, calcium/calmodulin kinase II alpha; CamKII-tTA, tetracycline-sensitive transactivator driven by CamKIIalpha promoter; 
CMV, cytomegalovirus; GFP, green fluorescence protein; IB, immunoblot; IHC, immunohistochemistry; NF, neurofilament; NFTs, neurofibrillary tangles; 
NSE, neuron-specific enolase; PDGF, platelet derived growth factor; TetO, tetracycline operon; TG, transgenic. (Taken from Giese et al., 2005)
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Taken together the analysis of the different p25 mouse lines indicates that the protein 
kinase complex p25/Cdk5 plays an important role in the phosphorylation of tau at 
proline-directed sites. However, the variation of the onset and level of tau 
hyperphosphorylation within the different p25 mouse lines suggest that tau 
hyperphosphorylation is regulated via an intricate molecular mechanism. As there is yet 
no good evidence that p25/Cdk5 directly mediates tau hyperphosphorylation, it is 
possible that p25/Cdk5 is indirectly involved in tau phosphorylation by regulating other 
kinases or phosphatases. Furthermore, it remains to be tested in how far the over­
activation of Cdk5 is involved in the aggregation of hyperphosphorylated tau and 
neurodegeneration. It is likely that additional factors are required to cause tau 
aggregation, as demonstrated by a study using TG mice expressing p25 and a mutated 
human tau isoform (Nobel et a l, 2003). Expression of p25 alone was not sufficient to 
induce aggregation of hyperphosphorylated tau and only in combination with expression 
of a mutated tau isoform NFT-like inclusions were observed.
1.11.5) Cdk5 in synaptic plasticity, learning and memory
Cdk5 and its activators, p35 and p39, are abundant in synaptic terminals in mature 
neurons. Hence, multiple studies investigated a possible role for Cdk5 in synaptic 
plasticity, learning and memory (see for review Angelo et al., 2006). Cdk5 has been 
suggested to influence synaptic plasticity by affecting pre- and post-synaptic processes. 
Cdk5 is thought to affect pre-synaptic mechanisms including ion channel conductance 
via phosphorylation of P/Q-type VGCC, exocytosis via phosphorylation of Munc 18 as 
well as synapsin I and endocytosis via phosphorylation of amphiphysin I, dynamin I and 
synaptojanin (see for review Angelo et al, 2006). Cdk5 mediates phosphorylation of 
several post-synaptic proteins including the NMDA receptor subunit NR2A and PSD-95 
(Wang et a l, 2003; Morabito et a l, 2004). Phosphorylation of NR2A at Seri232 by 
Cdk5 has been linked to increased NMDA receptor conductance and phosphorylation of 
PSD-95 has been reported to negatively regulate its clustering, possibly with NMDA
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receptors. Furthermore, Cdk5 has been involved in the regulation of several signalling 
pathways including MAPK and PKA pathways (Sharma et al., 2002; Bibb et al., 1999). 
These signalling pathways have been shown to be important for synaptic plasticity, 
especially in a post-synaptic context. The regulation of the PKA pathway by Cdk5 has 
important implications for dopaminergic signalling in striatum and in turn has been 
associated with drug addiction and might as well be of importance for learning and 
memory (see for review Bibb, 2001). Cdk5 phosphorylates dopamine and cAMP- 
regulated phosphoprotein 32 kDa (DARPP-32), a neostriatum-specific protein known to 
modulate dopamine signalling (Bibb et al., 1999). Phosphorylation of DARPP-32 by 
Cdk5 turns it into an inhibitor of PKA and prevents it from acting as a PP1 inhibitor. 
Phosphorylation of DARPP-32 by PKA makes it an inhibitor of PP1, which in turn 
triggers dopamine-induced phosphorylation of PKA substrates. Interestingly, Cdk5 has 
also been reported to regulate the PP1 inhibitors, 1-1 and 1-2 (Bibb et al., 2001; 
Agarwal-Mawal & Paudel, 2001).
A direct role for Cdk5 in learning and memory has been investigated for the first time 
by testing the effect of butyrolactone I, a Cdk5 inhibitor, on contextual fear conditioning 
in mice (Fischer et al., 2002). Intra-hippocampal and intra-septal injection of 
butyrolacetone I immediately before or after training has been found to impair 
contextual, but not cued, fear conditioning. These results suggest that Cdk5 is required 
for associative learning and memory formation in the hippocampus and septum. As 
Cdk5 KO mice are perinatal lethal and p35 as well as p39 KO mice have developmental 
disturbances of the brain, only little insight on the role of Cdk5 learning and memory 
could be gained through the study of these KO mouse lines (Table 1-4). In fact, the 
analysis of transgenic mouse lines expressing the Cdk5 activator p25 allowed 
investigation of the role of Cdk5 in synaptic plasticity, learning and memory (see for 
review Angelo et a l , 2006). First studies analysed a transgenic mouse line expressing 
postnatally low levels of p25 predominantly in excitatory forebrain neurons (Angelo et 
al., 2003; Ris et al., 2005). These studies demonstrated that low-level p25 expression 
does not effect basal glutamatergic synaptic transmission, or short-term synaptic
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plasticity. However, p25 expression was associated with enhanced CA1 LTP in female 
p25 TG mice, whereas CA1 LTP was reduced in male p25 TG mice (Ris et al., 2005). 
Spatial learning as tested in the MWM was improved in female p25 TG mice, but not 
affected in male p25 mice (Ris et al., 2005). Moreover, tone fear conditioning was 
improved in female p25 TG mice in the 129B6F1 background, as well as in male and 
female p25 TG mice in the C57BL/6 background. A recent study investigating an 
inducible p25 TG mouse line is in support of these results (Fischer et al., 2005). There, 
contextual fear conditioning was enhanced by transient high level p25 expression, 
possibly more in females than in males. The improvement in fear conditioning also 
coincided with enhanced CA1 LTP in the inducible p25 TG mice. However, after six 
weeks of high level p25 expression these inducible TG mice develop severe 
neurodegeneration, which consequently results in impaired fear conditioning and 
deficient CA1 LTP.
Together these observations indicate that expression of p25 and subsequent over­
activation of Cdk5 enhances CA1 LTP, possibly in a sex-dependent manner. The 
enhanced CA1 LTP could be correlated with improvements in spatial learning and in 
fear conditioning. These findings indicate that the activated p25/Cdk5 holoenzyme is 
involved in synaptic plasticity, learning and memory. Further, the effects of p25- 
induced Cdk5 activation suggest that the formation of p25 is a physiological process 
with importance for synaptic plasticity, learning and memory.
CHAPTER 1: Introduction 78
1.12) Glycogen synthase kinase 3
Glycogen synthase kinase 3 (GSK3) is a serine/threonine kinase, which exists in two 
isoforms, termed a  and p (see for review Grimes & Jope, 2001; Swiss 
Prot|Q9WV60|GSK3B_MOUSE). The isoforms are products from two distinct genes, 
but are highly homologous. GSK3a consists of 482 amino acids and GSK3p of 420 
amino acids. GSK3 is widely expressed in all tissues and is found at high levels 
specifically in brain. GSK3 is subject to several regulatory mechanisms. GSK3 can be 
inhibited by phosphorylation at Ser9 in the P-isoform and at Ser21 in the a-isoform 
(Stambolic & Woodgett, 1994). The inhibitory phosphorylation of GSK3a/p at the 
serine residue (Ser21/9) is regulated by antagonistic kinase and phosphatase activity 
(see for review Grimes & Jope, 2001). Several kinases have been implicated in this 
inhibitory regulation of GSK3 including AKT (also known as protein kinase B), 
p90Rsk, p70 S6  kinase, cyclic AMP-dependent protein kinase A (PKA) as well as some 
isoforms of protein kinase C (PKC). Further, some phosphatases have been shown to 
counterbalance the inhibitory phosphorylation, including PP1 and PP2A (Grimes & 
Jope, 2001; Morfini et al., 2004). The multitude of enzymes that can regulate the 
inhibitory control of GSK3 indicate the central role of GSK3 by integrating many 
signalling cascades. Impairment of this inhibitory control of GSK3 results in 
abnormally high GSK3 activity. In contrast, it was proposed that phosphorylation at 
Tyr216 in the p-isoform and at Tyr279 in the a-isoform is essential for activation of 
GSK3 (Hughes et a l , 1993). Another mechanism, by which GSK3 activity might be 
regulated, is the interaction of GSK3 with specific complexes. For example, it was 
suggested that association of specific GSK3p-binding proteins including FRAT 1 and 
axin leads to inactivation of GSK3p (see for review Grimes & Jope, 2001).
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Table 1-7. Substrates of GSK3
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Metabolic and 
signalling proteins Structural proteins Transcription factor
acetylCoA carboxylase Axin AP-1 (jun family)
APP dynamin-like protein P-catenin
APC MAP1B C/EBPa
ATP-citrate lyase MAP2 CREB
PKA NCAM glucocorticoid receptor
cyclin D1 neurofilaments HSF-1
eIF2B ninein c-myc
glycogen synthase tau NFAT
IRS-1 NFkB
myelin basic protein
NGF receptor
protein phosphatase 1 (PP1)
PP1 inhibitor-2 (1-2)
pyruvate dehydrogenase
Abbreviations: AP-1, activatior protein-1; APC, adenomatous polyposis coli gene 
product; APP, amyloid precursor protein; C/EBPa, CCAAT/enhancer binding protein 
alpha; CREB, cyclic AMP response element binding protein; eIF2B, eukaryotic 
initiation factor 2B; HSF-1, heat shock factor-1; IRS-1, insulin receptor substrate-1;
MAP, microtubule-associated protein; NCAM, neuronal cell adhesion molecule; NFAT, 
nuclear factor of activated T-cells; NFkB, nuclear factor kB; NGF, nerve growth factor;
PP1, protein phosphatase 1 (After Grimes & Jope, 2001)
GSK3 is a proline-directed protein kinase and phosphorylates substrates at 
serine/threonine residues that are directly followed by a proline residue. In addition, 
GSK3 phosphorylates substrates at so-called “primed” phosphorylation sites (see, for 
example, Sengupta et al., 1997; Cho & Johnson, 2003). This means GSK3 recognises 
on substrates a serine/threonine residue only when the residue located four residues 
upstream prior has been phosphorylated by a priming kinase. This forms the recognition 
motif -S/T-x-x-x-S/T(phospho)-. The phosphorylated residue is essential for the
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recognition motif and enables the binding of GSK3 to the substrate and its subsequent 
phosphorylation. GSK3 is a multifunctional protein kinase and has a broad range of 
substrates including metabolic, signalling and structural proteins, as well as 
transcriptions factors (Table 1-7). The diversity of the substrates indicates a 
fundamental role of GSK3 in many cellular processes. Indeed, GSK3 has been 
implicated in a variety of processes including axonal transport, embryonic development, 
metabolism, apoptosis and transcriptional regulation (see for review Grimes & Jope, 
2001).
1.12.1) Involvement o f GSK3 activity in neurodegenerative diseases
Much research focussed on the involvement of GSK3 in the phosphorylation of the 
microtubule-associated protein tau (see for review Imahori & Uchida, 1997; Grimes & 
Jope, 2001). GSK3 has been isolated as a protein kinase that associates with 
microtubules (see, for example, Ishiguro et al., 1993; Agarwal-Mawal et al., 2003). The 
co-localisation with aggregates of hyperphosphorylated tau (Ishizawa et al., 2003) and 
increased GSK3 levels in AD patients make it a prime candidate to mediate tau 
hyperphosphorylation in tauopathies (see for review Imahori & Uchida, 1997; Lee et 
al., 2001). GSK3 is known to phosphorylate proline-directed serine/threonine sites 
similarly to Cdk5 (Mandelkow et al., 1992; Reynolds et a l , 2000) and generate disease- 
associated phospho-epitopes on tau (Nishimura et al., 2004). Further, GSK3 has been 
shown to induce hyperphosphorylation of tau, which subsequently resulted in the loss of 
microtubule-binding (Hanger et a l , 1992; Lovestone et a l , 1996). Consistently, 
pharmacological inhibition of GSK3P with lithium or ATP competitive inhibitors 
reduced the phosphorylation levels of tau and affected the stability of microtubules (see, 
for example, Hong et a l, 1997; Lovestone et a l, 1999).
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TG mice conditionally over-expressing GSK3P in adulthood developed tau 
hyperphosphorylation and neurodegeneration in hippocampal neurons; however, no 
formation of tau filaments was observed (Lucas et al., 2001; Hernandez et al., 2002). A 
recent study suggests that GSK3 is involved in kinesin-driven axonal transport and 
hence, disruption of regulation of GSK3 could represent a molecular mechanism 
underlying neurodegenerative tauopathies (Morfini et al., 2004). Interestingly, this 
study proposes that GSK3 activity is regulated by Cdk5 as demonstrated by 
pharmacological in vitro assays.
GSK3 has also been linked to other neuropathological mechanisms that are thought to 
underlie neurodegenerative diseases including AD. GSK3 has been implicated in the 
regulation of Ap-peptide production (Phiel et al., 2003; Ryder et al., 2003). 
Accumulation of Ap-peptides could be blocked by inhibition of GSK3 activity. 
Interestingly, it has been reported that Ap-peptides activate GSK3 and thereby induce 
tau hyperphosphorylation (Takashima et a l , 1996). Further, increased GSK3 activity 
was implicated in reduction of acetylcholine synthesis by inactivating pyruvate 
dehydrogenase, which could explain the loss of cholinergic signalling in AD (Hoshi et 
al., 1997; see for review Imahori & Uchida, 1997). In addition, GSK3 interacts directly 
with presenilin 1, a molecule associated with FAD (Takashima et al., 1998).
1.12.2) GSK3 in synaptic plasticity and memory
Because of the presence of GSK3 at the synapse and its involvement in diverse 
processes including axonal transport and transcription, it is a candidate for regulating 
processes involved in synaptic plasticity, learning and memory. Studies in TG mice 
conditionally over-expressing GSK3p in hippocampus and cortical neurons showed that 
increased GSK3 activity resulted in impaired spatial learning in the MWM (Hernandez 
et al., 2002). Interestingly, increased GSK3 activity also impairs activation of CREB
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(Grimes & Jope, 2001). Therefore, it is likely that GSK3 is involved in synaptic 
plasticity and learning and memory processes via the regulation of transcription factors, 
such as CREB, nuclear factor of activated T-cells (NFAT) and activator protein-1 (AP- 
1; i.e. group of transcription factors including c-jun, c-fos and ATF family members). 
Consistent with this, over-expression of GSK3 attenuates brain-derived neurotrophic 
factor (BDNF) induced CREB phosphorylation. Application of lithium and 
carbamazepine can revert this effect and facilitate activation of CREB (Mai et a l ,
2002). Further, a pharmacological study demonstrates that serotonergic activity 
regulates the inhibitory phosphorylation of GSK3p in mouse brain in vivo (Li et a l ,
2004). These results link impaired inhibitory control of GSK3 to conditions in which 
serotonergic activity is deregulated, such as in mood disorders. This finding is 
consistent with studies implicating the mood stabilising effect of lithium with its 
function as a general GSK3 inhibitor (see, for example, Phiel & Klein, 2001).
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1.13) Overview
This is the end of the introductory Chapter 7, which should give the reader a short 
summary of basic knowledge relevant for the research presented in this doctoral thesis. 
The following Chapter 2 contains the materials and methods section. During my 
doctoral studies I analysed two different genetically-modified mouse lines with 
previously described learning and memory phenotypes. In Chapter 3, the results of the 
investigation of the aCaMKII T286A point mutation mouse line are shown. 
Furthermore, Chapter 3 describes the establishment of an in vivo LTP approach in the 
mouse hippocampus to study activity-dependent molecular changes. Chapter 4 contains 
the analysis of a transgenic mouse line expressing the Cdk5 activator p25. Finally, 
Chapter 5 is a short general discussion looking at aspects of the analysis of both 
genetically-modified mouse lines and an outlook on putative follow-up studies in these 
two genetically-modified mouse lines.
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2.1) Materials
All chemicals were from Sigma, unless stated otherwise. All buffers were prepared 
using the water purified by the Elix system (Millipore). The Milli-Q system (Millipore) 
was used to generate ultra-pure water.
2.2) Genetically-modified mouse lines
2.2.1) The aCaMKlI T286A point mutant mouse line
The aCaMKII T286A knock-in point mutant mouse line was generated in the 129 
genetic background by Dr K. Peter Giese in the laboratory of Dr Alcino Silva in the 
Cold Spring Harbour Laboratories, USA (Giese et al., 1998). The aCaMKII T286A 
point mutant mice and WT control littermates were bred with at least 10 backcrosses in 
the C57BL/6 genetic background. The genotype was determined by polymerase chain 
reaction (PCR) analysis using 0.2 pM 5 '-primer (loxl: 5'-
CTGACCAGCAGATCAAAGC-3') and 0.2 pM 3'-primer (lox2: 5'-
ATCACTAGCACCATGTGGTC-3') The PCR generated a 200 bp WT fragment and a 
300 bp fragment from mutants. The mice were housed in groups of 2-5 and treated 
according to the Animals (Scientific Procedures) Act 1986, UK.
2.2.2) The p25 transgenic mouse line
The p25 transgenic mouse line was generated in the C57BL/6 genetic background by Dr 
Marco Angelo in the laboratory of Dr K. Peter Giese at the Wolfson Institute for 
Biomedical Research, University College London (Angelo et al., 2003). Heterozygous
CHAPTER 2: Material and methods 85
p25 transgenic mice (TG) and wild-type (WT) control littermates were bred in the 
C57BL/6 genetic background. The genotype was determined by PCR analysis (220 bp 
WT fragment with primers sp2: 5 -GACAAGAAGCGACTCCTCCT-3' and WT3: 5'- 
TTCGCGCAAGGTTCATCAGT-3' ; 320 bp TG fragment with primers sp2: 5'- 
GACAAGAAGCGACTCCTCCT-3' and TG3: 5 -TGCTCCCATTCATCAGTTCC-3 '). 
The mice were housed in groups of 2-5 in the animal facilities of the Wolfson Institute 
for Biomedical Research, University College London, and treated according to the 
Animals (Scientific Procedures) Act 1986, UK.
2.2.3) Genotyping o f genetically-modified mouse lines
For identification the mice were marked by different combinations of holes in their ears. 
The tip of the mouse tails was desensitised with ice-spray and a piece of approximately 
3 mm was cut off. The protein content of the tail was digested in lysis buffer (0.1 M 
Tris-HCl pH8 , 0.2% sodium dodecyl sulfate (SDS), 0.2 M sodium chloride, 5 mM 
EDTA and 0.1 pg/pl of Proteinase K) at 55°C overnight. Undigested parts were pelleted 
by centrifugation and the supernatant removed. One volume of isopropanol was added 
to precipitate the genomic DNA. The DNA was pelleted by centrifugation, washed with 
70% ethanol and air dried. The dried DNA pellet was suspended in 100 pi of 10 mM 
Tris-HCl, pH 7.6. One microlitre of DNA solution was added to 25 pi PCR mix (PCR- 
reaction mix: 10% of lOx PCR buffer, 2 mM magnesium chloride, 0.1 mM deoxy 
nucleotide tri-phosphate (dNTP), Taq-polymerase (Invitrogen) and primer quantities 
specific to mutant mouse type). The GeneAmp® PCR system 9700 (Applied 
Biosystems, USA) was used for the PCR run with the following program: 2 minutes at 
93°C, followed by 32 cycles of 30 seconds at 93°C, 30 seconds at 58°C and 30 seconds 
at 72°C. The PCR products were separated on a 1.2% agarose gel containing ethidium 
bromide (4 pi /100 ml of gel) on a Mini-Sub Cell® system (BioRad). The bands were 
visualised by UV light and a picture of the gel taken on a imaging system with the 
software Alphalmager 1220 (Alpha Innotech corporation, USA).
CHAPTER 2: Material and methods 86
2.3) Lysate preparation
2.3.1) Hippocampal dissection
After removal from the scull the brain was placed in a 40 mm Petrie dish filled with 5ml 
of ice-cold P2-buffer (10 mM Tris-HCl pH 7.6, 320 mM sucrose and 0.025% sodium 
azide) containing phosphatase inhibitors (1 mM EDTA, 1 mM EGTA, 50 mM sodium
fluoride, 2 mM sodium ortho pervanadate, 0.1 mM ammonium molybdate, 0.2 mM
(£*)phenylarsine oxide) and protease inhibitor tablets Complete EDTA-free (1 tablet in 25 
ml) (Roche). The cerebellum was removed and the brain halved along the midline. The 
underlying thalamic structures were removed. The hippocampus rolled out and detached 
from the cortex.
2.3.2) Lysate preparation
Whole hippocampal protein lysate from mutant mice and WT littermates were prepared 
using P2-buffer containing phosphatase and protease inhibitors (see above) to preserve 
the integrity and phosphorylation state of hippocampal proteins. The mice were killed 
using carbon dioxide in accordance to the Animals (Scientific Procedures) Act 1986, 
UK. After decapitation, the head was immediately washed in ice-cold TBS buffer (10 
mM Tris-HCl pH 7.6 and 150 mM sodium chloride) containing phosphatase and 
protease inhibitors and the brain quickly removed. The hippocampus was dissected in 
ice-cold P2-buffer as described above. The hippocampi were dounce homogenised in 
700 jul ice-cold P2-buffer, snap-frozen on dry ice and stored at -80°C. After defrosting 
the samples on ice, detergents (1% TritonX-100 and 1% CHAPS) were added.
2.3.3) Synaptosomes
The preparation of crude synaptosomal fractionation from hippocampus was performed 
as described in Whittaker (1984). Briefly, the hippocampi were dissected as described
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above and dounce homogenised in ice-cold P2-buffer (10 mM Tris-HCl pH 7.6, 320 
mM sucrose, 0.025% sodium azide) containing phosphatase and protease inhibitors. The 
homogenate was centrifuged at 1,000 xg for 15 minutes. The resulting pellet (PI) was 
snap-frozen and the supernatant re-centrifuged at 30,000 xg for 15 minutes. The 
resulting supernatant was removed and the pellet fraction (P2) resuspended in P2-buffer 
containing detergents (1% TritonX-100 and 1% CHAPS) snap-frozen on dry ice and 
stored at -80°C.
2.3.4) Determination o f protein concentration
The protein concentrations of the lysates were determined using the BCA assay 
(Perbio). In brief, 4 pi of lysate were added to 1 ml of BCA solution in 1.5 ml cuvettes 
(Fisher). In parallel different amounts (0, 5, 10, 15 20 and 25 pi) of bovine serum 
albumin (BSA) solution (lmg/ml) were added to 1ml of BCA solution in 1.5 ml 
cuvettes. Each experiment was carried out in duplicate. The cuvettes were incubated at 
RT under shaking for 90 minutes. The optical density at 562 nm wavelength of each 
sample was evaluated with a UV-VIS spectrophotometer (UV mini 1240; Shimadzu). 
The values of the BSA samples was used to establish a standard curve, from which the 
protein concentration of the individual lysates was calculated.
2.4) Protein separation
2.4.1) Sodium dodecy sulfate polyacryl gel electrophoresis
Sodium dodecy sulfate polyacryl gel electrophoresis (SDS-PAGE) was performed after 
Laemmli (1970). Equal amounts of protein were denatured in SDS sample loading 
buffer ( 8  x SDS sample loading buffer: 1 M Tris-HCl pH 6 .8 , 16% SDS, 40% glycerol, 
8 % p-mercaptoethanol and trace of bromophenol blue) for 15 minutes at 90°C and
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separated on 4-16% polyacrylamide gels (BioRad). The gel was placed in the 
electrophoresis chamber (Ready Gel® Precast Gel System, BioRad) containing running 
buffer (25 mM Tris, 0.2 M glycine and 0.1% SDS) and the samples loaded. The SDS- 
PAGE was run with the current set at 10 mA for 30 minutes with constant voltage and 
thereafter at 20-30 mA for 3-4 hours. The gel was either Coomassie or silver stained or 
the proteins- were transferred from the gel onto polyvinylidene di-fluoride (PVDF) 
membranes (BioRad) in ice-cold transfer buffer (25 mM Tris, 0.2 M glycine and 20% 
methanol) at 50 V with constant current for 90 minutes.
2.4.2) Tris tricine gels
Proteins in the low molecular weight range were separated on tris tricine gels according 
to the protocol from Schagger and von Jagow (1987). Equal amounts o f protein were 
denatured in 2x sample buffer (0.9 M Tris-HCl pH 8.5, 8% SDS, 24% glycerol, 0.1% 
Coomassie and 0.1% phenol red) at 90°C for 15 minutes. The samples were loaded on 
16% tris tricine gels (BioRad) and the chamber filled with tris-tricine running buffer 
(500 mM Tris base, 100 mM tricine and 0.1% SDS; the buffer is approximately pH 8.3 
without adjusting). The proteins were separated at constant voltage with 10 mA current 
for 30 minutes and thereafter at 20-30 mA for 4-5 hours. The gels were blotted onto 
PVDF membrane or silver stained.
2.4.3) Two-dimensional electrophoresis (2DE)
Separation o f protein according to their isoelectric point (pi) was carried out using 
thirteen centimeter immobilized pH 3-10 nonlinear gradient strips (Amersham) in the 
Multiphor IEF cell (Amersham). The strips were rehydrated in 250 pi sample buffer (2 
M thiourea, 6 M urea, 4% CHAPS, 100 mM dithiothreitol (DTT), 0.5% Biolytes and 
trace o f bromophenol blue) containing 100 pg o f protein for 12 hours at RT. Voltage 
was gradually increased to 3500 V in the course o f 12 hours and then kept constant for
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24 hours for isoelectric focussing. The temperature was kept constant at 20°C. After the 
run the strips were stored at -20°C. For the second dimension run the strips were 
equilibrated for 10 minutes in equilibration buffer (6 M urea, 4% SDS, 375 mM Tris- 
HCl pH 8.8, 20% glycerol) containing 130 mM DTT and for 10 minutes in equilibration 
buffer substituted with 250 mM iodacetamide. The equilibrated strips were quickly 
dried on a tissue, placed on top o f 4-16% polyacrylamide gels and embedded in lx  SDS 
sample loading buffer containing 1.5% low-melt agarose. Electrophoresis was carried 
out with constant current at 20 mA for one hour and thereafter at 30-40 mA for 4 hours. 
The 2DE gel was either silver stained or the proteins transferred to a PVDF membrane. 
The separation o f complex protein lysates from whole tissues on 2DE is difficult to 
achieve, because the proteins tend to precipitate or do not show good electromotility 
during the first dimension run. In order to evaluate the applied 2DE methodology, I 
separated hippocampal synaptosome lysate by 2DE and silver stained the gel (Fig. 2-1). 
The results show that the proteins displayed a good separation in the range o f 20-90 kDa 
and between the pi o f 4 and 8 and indicates that the 2DE methodology is adequate to 
separate proteins from complex lysates.
2.5) Protein detection
2.5.1) Antibodies and reagents
All primary antibodies used for immunoblotting are listed in Table 2-1. Horseradish 
peroxidase-conjugated secondary antibodies donkey anti-rabbit IgG (H+L; #31458), 
mouse anti-goat IgG (H+L; #31400) and goat anti-mouse IgG (H+L; #31430) and goat 
anti-mouse IgM (#31440) were from Perbio.
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Table 2-1. Antibodies used for immunoblotting
Antibody Epitope Isotype Buffer Dilution Source
CaMKIIa total CaMKIIa mouse IgG milk 1:100000 Chemicon
22B1 phospho-CaMKIIa (Thr286) mouse IgG milk 1:2000 Affinity BioReagents
06-881 phospho-CaMKHa/p (Thr286/287) rabbit IgG BSA 1:1000 Upstate
13-9800 total CaMKIip mouse IgG milk 1:1000 Zymed
9196 phospho-CREB (Seri 33) mouse IgG milk 1:2000 Cell Signaling Technology
44-297G phospho-CREB (Seri 29/133) rabbit IgG BSA 1:1000 Biosource
38-7000 phospho-NR2B (Tyrl472) rabbit IgG BSA 1:2000 Zymed
36-9600 phospho-Synapsin I (Ser603) rabbit IgG BSA 1:2000 Zymed
Cdk5 (C-8) Cdk5 C-terminus rabbit IgG milk 1:200 Santa Cruz
p35 (C-19) p35 and p25 C-terminus rabbit IgG milk 1:200 Santa Cruz
2321
phospho-Cdk/MAPK substrate 
(x-T/S-P-x)
mouse IgM BSA 1:5000 Cell Signaling Technology
9611
phospho-AKT/CaMKII substrate 
(R/K-x-R/K-x-x-S/T(phospho))
rabbit IgG BSA 1:1000 Cell Signaling Technology
9411 Phospho-Tyrosine (PY-100) mouse IgG BSA 1:1000 Cell Signaling Technology
4G-1E total GSK3a/p mouse IgG milk 1:1000 Upstate
9331 phospho-GS K3 a/p(Ser21 /9) rabbit IgG milk 1:1000 Cell Signaling Technology
9332 total GSK3p rabbit IgG milk 1:1000 Cell Signaling Technology
5G-2F phospho-GS K3 a/p(T yr279/216) mouse IgG milk 1:1000 Upstate
AT-8 tau phospho-S202/205 mouse IgG milk 1:1000 Pierce
AT-100 tau phospho-Thr212/Ser214 mouse IgG BSA 1:2000 Innogenetics
PHF1 tau phospho-Ser396/404 mouse IgG milk 1:100 P. Davies
TG3
tau phospho-Thr231/Ser235; 
conformation-dependent
mouse IgM BSA 1:100 P. Davies
BR134 pan-tau rabbit IgG milk 1:750 M. Goedert
TAU-5 pan-tau (residues 220-240) mouse IgG milk 1:1000 Chemicon
SMI31
phospho-neurofilament antibody 
crossreacting with PHF-1 site on tau
mouse IgG milk 1:1000
Stemberger Monoclonals, 
Inc.
2451 phospho-APP (Thr668) rabbit IgG BSA 1:1000 Cell Signaling Technology
2452 APP (around Thr668) rabbit IgG BSA 1:1000 Cell Signaling Technology
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1
CT-15 APP carboxy-terminus rabbit IgG BSA 1:500 B.M. Austen
ab15272 APP N-terminal (residues 44-62) rabbit IgG BSA 1:400 Abeam
ab2084 APP N-terminal (residues 44-63) goat IgG BSA 1:1000 Abeam
9562 P-catenin rabbit IgG BSA 1:1000 Cell Signaling Technology
06-182 total ERK1/2 mouse IgG Milk 1:1000 Upstate
9101 phospho-ERKl/2 (Thr202/Tyr204) rabbit IgG BSA 1:1000 Cell Signaling Technology
4377
phospho-p44/42 MAPK 
(Thr202/Tyr204)
rabbit IgG BSA 1:1000 Cell Signaling Technology 1
9121 phospho-M EK1 /2 (Ser217/221) rabbit IgG BSA 1:1000 Cell Signaling Technology
9251
phospho-SAPK/JNK
(Thrl83/Tyrl85)
rabbit IgG BSA 1:1000 Cell Signaling Technology
1 9271 phospho-AKT (Ser473) rabbit IgG BSA 1:1000 Cell Signaling Technology
1 9275 phospho-AKT (Thr308) rabbit IgG BSA 1:1000 Cell Signaling Technology
I 9344 phospho-p90RSK (Thr359/Ser363) rabbit IgG BSA 1:1000 Cell Signaling Technology
I PP2Ac catalytic subunit o f  PP2A1 mouse IgG milk 1:1000 S.M. Dilworth
PR65/A
scaffolding/regulatory subunit o f  
PP2A
mouse IgG milk 1:1000 S.M. Dilworth
sc-7482 catalytic subunit o f  PP1 mouse IgG milk 1:4000 Santa Cruz
2581 phospho-PPl (Thr320) rabbit IgG BSA 1:500 Cell Signaling Technology
Clone 42 a-synuclein mouse IgG milk 1:1000 BD Biosciences
flag-tag Rabbit IgG milk 1:200 K. Brickley
1 A5441 P-actin mouse IgG milk 1:50000 Sigma
[ S2177 synaptotagmin rabbit IgG milk 1:40000 Sigma
2.5.2) Immunoblot analysis
After the transfer the PVDF membranes were incubated in blocking buffer consisting of 
TBS with either 3% milk or 3% BSA. Cross-reactivity o f phospho-specific antibodies 
with milk was avoided by using 3% BSA in the blocking buffer. The blots were 
incubated overnight at 4°C in blocking buffer containing primary antibodies (Table 2- 
1). After washing in several volumes of TBS with 0.05% Tween-20 (TBST) for 90
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minutes, the blots were incubated with horseradish peroxidase-conjugated secondary 
antibodies in blocking buffer at room temperature for 2-4 hours and washed again in 
several volumes o f TBST for 90 minutes. The signals were visualised with the enhanced 
chemiluminescent (ECL) system (Perbio), captured by apposing the blots to x-ray film 
(Amersham) and the films were developed with a compact X4 film processor (X-ograph 
Imaging Systems). The films were scanned with the Densitometer GS800 (BioRad) and 
band intensities quantified with the software Densitometer Quantity One (BioRad) in 
the linear range. The immunoblots were stripped with stripping buffer (Perbio) and 
reprobed with anti-p-actin and anti-synaptotagmin antibody to normalise for amount of 
loaded protein. After adjusting the immunoblotting protocols, it was assessed whether 
the ECL system is suitable to detect different protein amounts in the linear range. 
Further, it was checked whether the stripping affects the quality o f the signal on the 
blots and hence impacts on the reproducibility o f the results. The findings show that the 
ECL system can be used to detect reliably changes in protein concentrations and that the 
stripping does not affect the quality o f the blots (Fig. 2-2).
2.5.3) Colloidal Coomassie staining and silver staining
For the colloidal Coomassie staining the SDS-PAGE gels were rinsed two times with 
ultra-pure water and fixed in 20% (w/v) trichloroacetic acid fixing solution for 12 hours 
at RT. The fixing solution was removed and the colloidal Coomassie stain added for 3-4 
hours under shaking. The colloidal Coomassie staining solution was prepared by adding 
0.1% (w/v) Coomassie blue G250 to 37% water and 37% 1 M sulfuric acid and let 
dissolve for 3 hours while stirring at RT. The staining solution was filtered to remove 
any insoluble material and the sulfuric acid neutralised by carefully adding 8% of 10 M 
sodium hydroxide solution while stirring. After 15 minutes 18% (w/v) o f trichloroacetic 
acid were added to the solution. The Coomassie stain was removed and the gels were 
washed several times in ultra-pure water for at least 2 hours at RT under shaking. The 
gels were stored in ultra-pure water.
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For silver staining the SDS-PAGE gels the Silver stain plus kit (Biorad) was used 
according to manufacturer’s suggestions (Appendix II). The gels were stored in 5% 
acetic acid.
2.6) Kinase assays
2.6.1) Cdk5 activity assay
Lysate containing 200 pg protein was diluted in 350 pi IP-buffer (150 mM sodium 
chloride, 10 mM Tris-HCl pH 7.6, 1% Triton-100, 0.025% sodium azide) containing 
protease and phosphatase inhibitors, centrifuged and the supernatant transferred to a 
new tube. Five pi anti-Cdk5 antibody (1 pg) were added per tube and incubated for 2 
hours at 4°C under constant shaking. Thirty microlitres Protein-A bead slurry was added 
and incubated for 90 minutes. After settling o f the beads the supernatant was discarded 
and the beads were washed three times with 400 pi IP-buffer. Forty microlitres o f the 
kinase reaction mix (20 mM Tris-HCl pH 7.6, 25 mM magnesium chloride, 1 mM 
EDTA, 0.5 mM (3-glycerol phosphate, 0.2 mM sodium orthovanadate) containing 20 pg 
of the Cdk5 substrate Histone 1 (Upstate) and the inhibitor cocktail (Upstate) with 5 pM 
PKC inhibitor peptide, 0.5 pM PKA inhibitor peptide (PKI) and 0.5 pM Compound 
R24571 were added to the beads. The reaction was initiated by addition of 10 pi o f 100 
pM ATP solution containing 5 pCi o f radioactive-labelled [y-32P] ATP (GE 
Healthcare). The samples were incubated for 30 to 60 minutes at 30°C. The reaction 
was stopped by spotting 25 pi assay mix on p81 nitrocellulose paper (Upstate). The 
paper was washed 3-times in 0.75% phosphoric acid and once with acetone. The 
radioactivity was measured by Cherenkov counting using 25 ml polyethylene 
scintillation vials filled with 12ml H2 O. Cdk5 activity was calculated as the difference 
between the activity with and without the presence o f 10 pM roscovitine, a Cdk5 
inhibitor.
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2.6.2) GSK3 activity assay
The GSK3 p activity assay was performed similarly to the Cdk5 activity assay with the 
following changes: Lysate containing 100 jug protein was immunoprecipitated with 1 pi 
of anti-GSK3p antibody (1 pg; Cell signalling technology #9332). The kinase reaction 
mix was completed with 5 pg o f the GSK3 substrate phospho-glycogen synthase 
peptide-2 (Upstate), 0.2 pM okadaic acid, a PP1 inhibitor and the inhibitor cocktail 
(Upstate). The kinase reaction mix was incubated for 90 minutes at 30°C. The 
radioactivity count was performed as described above. GSK3p activity was calculated 
as the difference between the activity with and without the presence o f 10 mM lithium 
chloride, a GSK3 inhibitor.
2.7) Immimoprecipitation
Hippocampal lysate was defrosted on ice and lysate with a protein content o f 0.8 to 1 
mg was diluted up to 1 ml with ice-cold immunoprecipitation (IP) buffer (150 mM 
sodium chloride, 10 mM Tris-HCl pH 7.6, 1% Triton X-100, 0.025% NaN3) containing 
protease and phosphatase inhibitors. The IP mix was vortexed and centrifuged at 7,000 
xg for 1 minute at 4°C. The supernatant was transferred to a new eppendorf tube and 5- 
10 pg o f antibody were added. The IP mix was incubated for 2-3 hours on a rotator at 
4°C. Fifty to one hundred microlitres o f Protein-A bead slurry or IgG bead slurry were 
added and incubated for 2-3 hours on a rotator at 4°C. After settling o f the beads the 
supernatant was carefully removed and the beads were washed 3-5 times with 1 ml ice- 
cold IP-buffer containing protease and phosphatase inhibitors. After the last wash 50 pi 
o f lx  SDS sample loading buffer was added to the bead pellet. The sample was 
vortexed, spun down and denatured at 90°C for 15 minutes. Then the IP sample was 
separated on a SDS-PAGE as described in section 2.5.1. After the washing o f the beads, 
50 pi o f H2 O were added to the bead pellet and denatured at 70°C for 15 minutes in 
preparation for separating IP samples on 2DE gels. The IP sample was vortexed,
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centrifuged and 200 pi rehydration buffer without DTT and Biolytes (Amersham) was 
added. This solution was directly loaded onto the immobilized pH 3-10 non-linear 
gradient strips (Amersham) and 2DE was carried out as described in section 2.5.3.
2.8) Chronic lithium administration
Aged p25 transgenic mice of twenty months (n= 4) were chronically treated with 
lithium for one month. For the injection a 0.1 M lithium chloride solution was prepared 
and filter sterilised. The first two days the mice were injected intraperitoneally with 1.5 
meq/kg lithium chloride (corresponding to 10.4 mg/kg). From days 3 to 7 a dose o f 3 
meq/kg lithium chloride was administered. Control aged p25 transgenic mice (n= 4) 
were injected with saline solution. Thereafter, the mice were fed with powdered chow 
containing 1.7 g lithium chloride per kg o f chow for three weeks. Control aged p25 
transgenic mice were given regular powdered chow. To prevent hyponatremia, water 
and 400 mM sodium chloride solution were available ad libitum to the mice.
2.9) Contextual and tone fear conditioning
Two to three month-old female aCaMKII T286A mutants (n= 2) and WT littermates 
(n= 2) were trained for contextual and tone fear conditioning. Each mouse was placed 
into the conditioning chamber (Campden Instruments, Loughborough, UK) in a 
soundproof box. Following a 2 minutes “acclimatisation” period, a tone (80dB, 2.8 kHz) 
was presented for 30 seconds. The last 2 seconds of the tone presentation coincided with 
a mild foot-shock (0.7 mA). After the tone/foot-shock pairing the mouse was left for an 
additional 30 seconds in the conditioning chamber and then was returned to its home 
cage. The mouse was killed by cervical dislocation one minute after the mouse was 
taken out o f the conditioning chamber. As naive controls 2-3 month-old female 
aCaMKII T286A mutants (n= 2) and WT littermates (n= 2) were exposed to the
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conditioning chamber without a foot-shock for 3 minutes. The mice were returned to the 
home cage and killed by cervical dislocation one minute later. Hippocampal 
synaptosome lysate was prepared as described in section 2.3.
2.10) Electrophysiology in the anaesthetised mouse
The in vivo LTP experiments were carried out by Dr Sam Cooke from the laboratory o f  
Dr Tim Bliss at the National Institute fo r  Medical Research, Mill Hill, London, UK.
All electrophysiological experiments were carried out according to the Animals 
(Scientific Procedures) Act 1986, UK. Three to six month old mice were anaesthetized 
with an intraperitoneal injection o f urethane (1.8 mg/g). For experiments in area CA1 of 
the hippocampus, the recording electrode was placed in the stratum radiatum, with the 
stimulating electrode positioned near the midline in the contralateral ventral 
hippocampal commissure. In the DG, a concentric bipolar stimulating electrode was 
positioned in the perforant path, and a glass micropipette was lowered into the hilus o f  
the ipsilateral DG to record evoked field responses. In both cases input-output 
relationships were assessed using a range of stimulus intensities from 0 pA through to a 
stimulus strength that evoked a maximal response. Three responses were collected at 
each intensity and averaged. Pairs o f pulses (inter-pulse intervals, 10-100 ms) were used 
to study paired-pulse interactions at two intensities, one to evoke a pure excitatory 
postsynaptic potential (EPSP) and the other a population spike o f approximately 1 mV. 
Again, three responses were collected at each intensity and averaged. Test responses 
were evoked by monophasic stimuli (0.033 Hz; 70-300 pA, 60 ps). Pulse width was 
doubled during the tetanus. The LTP-inducing tetanus in CA1 consisted o f 2 trains o f 50 
pulses at 100 Hz, with an inter-train interval o f 30 seconds. In the DG the tetanus 
consisted o f 6 series o f 6 trains o f 6 stimuli at 400 Hz, 200 ms between trains, 20 
seconds between series. The slope of the field EPSP was expressed as a percentage
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change relative to the mean response in the 10 minutes prior to tetanic stimulation in 
both cases.
The mice were killed by decapitation 15 minutes or one hour after LTP induction in 
either DG or CA1. The relevant hippocampal subfield was micro-dissected in ice-cold 
P2-buffer containing protease and phosphatase inhibitors under a magnifying glass 
using ice-cold steel implements. Lysate was prepared as described in section 2.4 and 
samples were stored at -80°C. For the DG LTP experiments the contralateral DG was 
isolated as unstimulated control tissue, whereas for the CA1 LTP experiments control 
tissue was isolated from another unstimulated mouse or from a stimulated mouse treated 
with the NMDA antagonist, 3-(2-Carboxypiperazin-4-yl)propyl-1 -phosphonic acid 
(CPP).
2.11) Data acquisition and analysis
Immunoblot films were scanned with the Densitometer GS800 (BioRad) and band 
intensities quantified with the software Densitometer Quantity One (BioRad) in the 
linear range. Band intensities were normalised to amount o f loaded protein to band 
signals from anti-p-actin and/or anti-synaptotagmin antibodies. All changes in band 
intensities are indicated as x% of 100% control unless stated otherwise.
Images were prepared in Photoshop (Adobe) and assembled into figures in Microsoft 
PowerPoint. Statistical analysis was performed using one-way analysis o f variance 
(ANOVA) on the Microsoft Excel software. All data are expressed as mean ± S.E.M. 
unless stated otherwise.
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CHAPTER 3: Biochemical analysis of the aCaMKII T286A point mutant 
mouse line 
3.1) Introduction
3.1.1) The aCaMKII T286A point mutant mouse line
Dr K. Peter Giese generated the aCaMKII T286A point mutant mouse line by using 
knock-in technology (Giese et al., 1998). A mutation was introduced in the endogenous 
aCaMKII gene resulting in the substitution of threonine at residue 286 by alanine. This 
mutation disenables the autophosphorylation at Thr286 and in turn prevents aCaMKII 
from switching into an autonomously active state. For technical reasons, the generation 
o f the T286A knock-in mutants included the introduction o f a silent point mutation that 
gives rise to a diagnostic restriction site and an insertion o f a loxP site in an intron o f the 
endogenous aCaMKII gene. As the genetic modifications were directly introduced in 
the endogenous aCaMKII gene, the expression is still driven by the endogenous 
promoter, which ideally results in identical expression patterns and levels. Accordingly, 
the expression pattern o f aCaMKII in the hippocampus o f the T286A mutants was not 
altered (Giese et al. 1998). Furthermore, identical levels o f aCaMKII were detected in 
the hippocampus o f T286A mutants and WT controls (Giese et al. 1998; Hardingham et 
al., 2003). These results show that the point mutation and the intronic insertion o f a 
loxP site into the aCaMKII gene did not impact on the expression pattern of aCaMKII 
and its protein levels in the hippocampus of aCaMKII T286A mutants. However, in 
somatosensory cortex aCaMKII protein levels were markedly reduced, which is 
possibly due to interference of the introduced loxP site with the splicing efficiency of 
the aCaMKII gene (Hardingham et al., 2003). The genetic modification in the T286A
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mutants did not affect the expression levels o f the p-isoform of CaMKII (Giese et al. 
1998). The level o f Ca2+/CaM-dependent activity o f aCaMKII was also not altered by 
the mutation (Giese et al. 1998). In contrast, the Ca2+-independent aCaMKII activity 
was significantly reduced in the T286A mutants (Giese et al. 1998). 
Immunohistochemical analysis of the brain did not detect any morphological differences 
between the brains o f T286A mutants and WT mice (Giese et al., 1998). 
Electrophysiological characterisation of the T286A mutants revealed the importance of 
the aCaMKII autophosphorylation at Thr286 for the induction of LTP in hippocampal 
area CA1 and neocortex (Giese et al. 1998; Hardingham et al., 2003; Cooke et al., 
2006; see also section 1.7.4). Induction of LTP was abolished in the CA1 of T286A 
mutants (Giese et al. 1998; Cooke et al., 2006). This striking LTP phenotype was 
correlated with severe impairments in hippocampal learning and memory, as assayed in 
the MWM, and altered place cell activity in the T286A mutants (Giese et al. 1998; Cho 
et al., 1998). Importantly, the T286A mutants were able to learn the visible platform 
version o f the MWM indicating that they had the vision, motivation, and motor 
coordination required to perform this task (Giese et al. 1998). Interestingly, a recent 
study showed that LTP induction was reduced in the DG of the T286A mutants, and not 
completely abolished as observed with CA1 LTP (Cooke et al., 2006). Thus, 
autophosphorylation o f aCaMKII is essential for NMD A receptor-dependent CA1-LTP, 
but not required for the maintenance o f NMD A receptor-dependent DG-LTP.
3.1.2) Aim o f the project
A major goal in neuroscience is the elucidation of the molecular mechanisms underlying 
learning processes and memory formation. Generally, it has been established that 
protein phosphorylation, protein synthesis and de novo gene transcription are essential 
for learning and memory (see for review Reymann & Frey, 2006). However, the precise 
molecular machinery and its integral functioning require further characterisation.
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One aim of this study was to identify novel molecular mechanisms involved in learning 
and memory. I investigated changes in protein phosphorylation levels after behavioural 
training or electrophysiological stimulation to induce LTP in the hippocampus o f WT 
mice. An important first step for this experiment was the establishment o f suitable 
techniques to induce physiological protein phosphorylation and to detect these changes 
in phosphorylation levels.
A next aim o f this study was to get more information on the function o f aCaMKII, 
which has been characterised as a key molecule for learning and memory. For this I 
used the T286A mutant mouse line, in which the autonomous aCaMKII activity is 
blocked and, as a result exhibits impaired synaptic plasticity and hippocampal learning 
and memory. In the hippocampus o f these aCaMKII T286A mutants I analysed changes 
in protein phosphorylation levels after behavioural training or electrophysiological 
stimulation.
A final aim was to assess the role of the p-isoform of CaMKII in synaptic plasticity. 
Compensatory activation o f pCaMKII has been suggested to partially rescue activity- 
dependent potentiation in hippocampal area CA1 in an aCaMKII KO mouse line 
(Elgersma et al., 2002). To test this possibility I assayed the levels of 
autophosphorylated pCaMKII after electrophysiological stimulation.
3.2) Results
3.2.1) Evaluation o f  an approach to detect phosphorylation changes o f CaMKII 
substrates in hippocampus after fear conditioning
Molecular mechanisms including protein phosphorylation, protein synthesis and gene 
transcription have been identified as underlying processes o f learning and memory. It 
has been observed that behavioural training triggers changes in protein phosphorylation,
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protein expression and de novo gene transcription. In this experiment, I have 
investigated changes in protein phosphorylation occurring after contextual fear 
conditioning, a hippocampus-dependent, single trial learning task (see section 1.4.2). As 
aCaMKII is important for synaptic plasticity, learning and memory, I focussed on 
phosphorylation o f CaMKII substrates by using a phospho-specific antibody raised 
against the consensus motif o f CaMKII and AKT substrates. Analysis from 
immunoblots o f hippocampal synaptosome lysates from naive and trained WT mice did 
not reveal any obvious changes in phosphorylation levels between the two conditions 
(Fig 3-1). Furthermore, an anti-phospho-Cdk5/MAPK substrate antibody did not reveal 
any changes in phosphorylation between the naive and trained WT mice. To distinguish 
specific phosphorylation changes induced by fear conditioning from baseline 
phosphorylation, I also analysed the phosphorylation levels in naive and trained 
aCaMKII T286A mutants. In the T286A mutants the autonomous Ca2+-independent 
aCaMKII activity is disenabled, which results in the impairment o f hippocampal 
learning and memory (Giese et al., 1998). Hence, it is likely that behavioural training 
induces phosphorylation changes in aCaMKII substrates in WT mice but not in the 
T286A mutants. However, as there were no phosphorylation changes in trained WT 
mice, one would expect to detect no alterations in phosphorylation levels in trained 
T286A mutants. Consistent with this notion, no changes in phosphorylation levels were 
observed between naive and trained aCaMKII T286A mutants (Fig 3-1). Comparison of 
the immunoblot signals from naive WT and T286A mutants revealed several changes in 
phosphorylation levels (Fig 3-1). The intensity o f bands with the molecular weight 35, 
42 and 50 kDa was reduced in the T286A mutants. Both, naive and trained T286A 
mutants displayed reduced signal within in the same subset o f bands. Interestingly, an 
anti-phospho-Cdk5/MAPK substrate antibody did not detect any phosphorylation 
changes between T286A mutants and WT mice, indicating that the changes observed 
with the anti-phospho-AKT/CaMKII substrate antibody are due to the lack of 
autonomous aCaMKII activity in the T286A mice. The band at 50 kDa was absent in 
the T286A mutants (Fig 3-1). Re-probing the blots with anti-aCaMKII antibody
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showed that the 50 kDa band corresponded to phospho-Thr286-aCaMKII (data not 
shown). Because o f the point mutation in the T286A mutants, the anti-phospho- 
AKT/CaMKII substrate antibody could not bind to the autophosphorylation site o f 
aCaMKII anymore. Consistently, immunoblot analysis o f hippocampal lysate from 
T286A mutants probed with phospho-Thr286-aCaMKII antibody detected no signal, 
confirming the complete abolition o f the Thr286 autophosphorylation in the T286A 
mutants (Fig. 3-7).
Together, these results indicate that the current conditions used to detect 
phosphorylation changes in the hippocampus after contextual fear conditioning are not 
optimal and further studies will be required to improve this approach. The reduction in 
phosphorylation levels between T286A mutants and WT mice shows that the point 
mutation affects the basal phosphorylation level of several proteins. As the point 
mutation disenables autonomous activity of aCaMKII, it is conceivable that these 
proteins are phosphorylated specifically by aCaMKII in the autonomous activity state.
3.2.2) Evaluation o f an in vivo LTP approach to induce and detect phosphorylation 
changes in hippocampal subfields
The breeding o f  the T286A mutant mice and in vivo stimulation has been carried out by 
Dr Sam F. Cooke in the laboratory o f  Dr Tim VP. Bliss at the National Institute for  
Medical Research (NIMR), Mill Hill. At this point, I would like to thank Dr Bliss and Dr 
Cooke for the fruitful and inspiring collaboration and for their enormous engagement in 
this project.
Studies in the hippocampus, a brain structure central to the processing and temporary 
storage of information established LTP as the primary experimental model for 
investigating the molecular and cellular basis of learning and memory (see, for example,
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Bliss & Collingridge, 1993). The use o f kinase inhibitors in electrophysiological and 
behavioural studies demonstrated the requirement o f protein phosphorylation in long­
term potentiation, as well as learning and memory. Moreover, activity-dependent 
synaptic potentation has been shown to induce changes in phosphorylation levels of 
specific molecules such as aCaMKII and CREB (Barria et al., 1997; Ouyang et al., 
1997; Impey et al., 1996). In order to investigate changes in protein phosphorylation 
after synaptic potentiation, an in vivo LTP approach was developed in collaboration 
with Drs Sam F. Cooke and Tim V.P. Bliss. An in vivo LTP protocol was employed to 
induce synaptic potentiation in the hippocampal subfields, CA1 and DG, and 
subsequently phosphorylation changes were investigated using standard 
immunoblotting methods. First, it had to be ensured that the sensitivity o f the in vivo 
LTP assay was sufficient to observe changes in phosphorylation levels after the 
induction of LTP. This was tested by monitoring phosphorylation levels o f well- 
characterised marker molecules. I focused on the presynaptic protein synapsin I, the 
NMDA receptor subunit NR2B and the transcription factor CREB, for which an 
increase in phosphorylation after LTP induction has been reported (see, for example, 
Nayak et al., 1996; Rostas et al., 1996; Impey et al., 1996). In anaesthetised WT mice 
CA1-LTP was induced at Schaffer commissural-pyramidal cell synapses or respectively 
DG-LTP was induced at medial perforant path-granule cell synapses. The relevant 
hippocampal subregion, either CA1 or DG, was microdissected at 15 minutes or one 
hour after LTP induction and used for lysate preparation. As a control, either the 
unstimulated contralateral DG from the same mouse or CA1 from another unstimulated 
mouse were used. The lysates were separated by SDS-PAGE and immunoblotted. The 
blots were probed with phospho-specific antibodies to detect changes in 
phosphorylation levels o f synapsin I at Ser603, NR2B at Tyrl472 and CREB at Seri 33. 
In lysates from the DG of WT mice harvested 15 min after in vivo stimulation 
phosphorylation levels o f synapsin I, NR2B and CREB at Seri 33 were significantly 
increased (Fig. 3-2; see also Table 3-1 for overview) (phospho-synapsin I: 158%, n= 8, 
F\-\4r~ 30.0, p<  0.001, phospho-NR2B: 135%, n= 4, F\.6= 783, p<  0.001; phospho-
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CREB: 154%, n= 8; F\.\4= 25.8; p<  0.001). In addition, increased phosphorylation 
levels o f synapsin I at Ser603, NR2B at Tyrl472 and CREB at Serl33 were also 
observed in DG lysates of WT mice harvested one hour after stimulation (Fig. 3-2; see 
also Table 3-1 for overview) (phospho-synapsin I: 122%, n= 4, F\^= 9.63, p<  0.02; 
phospho-NR2B: 146%, n= 5, Fi_8= 20.6, p<  0.002; phospho-CREB: 151%, n= 6, Fi_io= 
26.8, p<  0.001). Moreover, the phosphorylation levels of synapsin I at Ser603 and 
CREB at Seri 29/133 were significantly elevated in hippocampal area CA1 of WT mice 
harvested one hour after LTP stimulation (Fig. 3-3; see also Table 3-1 for overview) 
(phospho-synapsin I: 171%, n= 4, F\^= 8.27, p< 0.05; phospho-CREB: 172%, n= 4, F\. 
6= 8.58, p< 0.05). Interestingly, the phosphorylation levels of NR2B at Tyrl472 were 
not increased in area CA1 of WT mice one hour after LTP induction (Fig. 3-3) 
(phospho-NR2B: 108%, n= 4, FU6= 0.68, p> 0.05).
Table 3-1. Overview of the results from the in vivo LTP approach testing 
phosphorylation changes in marker molecules.
WT CA1 lh DG lh DG 15 min
phospho- 
Ser603-Synapsin I
171 %
(p< 0.05)
121 %
(p< 0.05)
158 %
(p< 0.001)
phospho-
Tyrl472-NR2B
108 %
(p> 0.05)
146 %
(p< 0.002)
135 %
(p< 0.001)
phospho-
Serl33-CREB
172 %
(p< 0.05)
151 %
(p< 0.001)
154 %
(p< 0.001)
These results show that our in vivo LTP approach can be used to induce robust, 
persistent physiological phosphorylation changes in both CA1 and the DG. 
Furthermore, the lysate preparation and the immunoblot methods are suitable and the 
sensitivity of the assay is high enough to detect changes in phosphorylation levels after 
in vivo LTP induction in CA1 and DG. The results confirm that the tested marker 
molecules can be used as controls for efficient LTP stimulation in CA1 and the DG.
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3.2.3) Autophosphorylation o f aCaMKII is induced by LTP stimulation in CA1 and DG
The a-isoform o f CaMKII is one o f the most abundant proteins in the post-synaptic
* 2+densities o f excitatory neurons and is thought to be central to the regulation of Ca - 
mediated signal transduction (see for review Lisman et al., 2002). Autophosphorylation 
o f Thr286 switches aCaMKII into an autonomous Ca2+-independent state o f activity, a 
process shown to be important for synaptic potentiation and learning and memory. 
Biochemical and immunohistochemical studies on electrophysiologically stimulated 
brain slices demonstrated that LTP induction increases the levels o f autophosphorylated 
aCaMKII in hippocampal area CA1 (Barria et al., 1997; Ouyang et al., 1997). A 
disadvantage o f studies using stimulated brain slices is that the slice preparation and 
preservation may induce molecular changes, which lead to an increased background 
noise and provokes artefacts (see, for example, Taubenfeld et al., 2002). To minimise 
confounding molecular changes, an in vivo LTP approach was used to investigate the 
autophosphorylation level o f aCaMKII. The immunoblots o f lysates from in vivo 
stimulated CA1 or DG from WT mice and their relevant controls were probed with a 
phospho-specific antibody recognising the aCaMKII autophosphorylation site at 
Thr286. Autophosphorylation o f aCaMKII was elevated in CA1 tissue taken from WT 
mice one hour after the induction of LTP at Schaffer commissural-pyramidal cell 
synapses as compared to controls (150%, n= 5, Fi.g= 13.5,p <  0.02) (Fig. 3-4; see also 
Table 3-2 for overview). In the DG the aCaMKII autophosphorylation was significantly 
elevated after in vivo LTP induction at medial perforant path-granule cell synapses in 
anaesthetised WT mice at 15 minutes (145%, n= 8, F\.u= 14.6, p<  0.01). The increased 
autophosphorylation was sustained for one hour after in vivo LTP induction in DG 
(162%, n= 5, Fi_8= 435, p<  0.001) (Fig. 3-4; Table 3-2). These results confirm previous 
in vitro findings in area CA1 showing that the autophosphorylation levels o f aCaMKII 
at Thr286 increase upon stimulation and that this increase is sustained for a prolonged 
period o f time. In addition, I show that LTP induction also triggers autophosphorylation 
of aCaMKII in the DG.
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3.2.4) LTP stimulation in CA1 and the DG induces autophosphorylation o f  fCaMKH
Along with aCaMKII, the (3-isoform of CaMKII is expressed at high levels in neurons 
(see for review Hudmon & Schulman, 2002; Lisman et al., 2002). As with the a- 
isoform, pCaMKII can also be switched into an autonomous Ca2Mndependent state of 
activity through autophosphorylation at Thr287.
To test whether the autophosphorylation o f pCaMKII is also regulated by LTP 
induction, I examined the levels of PCaMKII autophosphorylation at Thr287 in CA1 or 
the DG after LTP stimulation in WT mice in vivo. The application o f a phospho-specific 
antibody detecting the autophosphorylation sites (Thr286/287) on both CaMKII 
isoforms demonstrated that the autophosphorylation of aCaMKII as well as PCaMKII 
were significantly increased in CA1 and the DG (Fig. 3-5; Table 3-2). I observed a 
significant increase in pCaMKII autophosphorylation in CA1 lysates from WT mice 
one hour after the induction of LTP at Schaffer commissural-pyramidal cell synapses 
(132%, n= 5, F\_8=  7.45, p<  0.05). In the DG the pCaMKII autophosphorylation was 
elevated 15 minutes after in vivo LTP induction in WT mice (153%, n= 8, F\.\a= 39.3, 
p<  0.001). The increased autophosphorylation of PCaMKII was sustained for one hour 
after LTP induction in the DG (132%, n= 5, Fi_8= 14.6, p<  0.01).
These findings demonstrate that the autophosphorylation o f pCaMKII is also regulated 
by LTP induction in both hippocampal subfields, CA1 and DG. Furthermore, the 
increased pCaMKII autophosphorylation is also sustained for a prolonged period of 
time, similar to the autophosphorylation of aCaMKII.
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3.2.5) LTP induction increases pCaMKII autophosphorylation in the T286A mutants
LTP recordings on transverse hippocampal slices o f the aCaMKII T286A mutant 
mouse line demonstrated that the loss of aCaMKII autophosphorylation completely 
prevents NMD A receptor-dependent CA1-LTP at Schaffer commissural-pyramidal cell 
synapses (Giese et al., 1998). Recently, we found that the loss of aCaMKII 
autophosphorylation did not block LTP at medial perforant path-granule cell synapses 
in the DG in vivo and in vitro in the T286A mutants (Cooke et al., 2006). Thus the 
aCaMKII autophosphorylation is essential for NMD A receptor-dependent CA1-LTP, 
but is not required for NMDA receptor-dependent DG-LTP at medial perforant path- 
granule cell synapses. To date it is not known, which signalling pathways are involved 
in DG-LTP. As described above, I found that LTP induction in area CA1 and DG 
increases the autophosphorylation of PCaMKII along with aCaMKII. Therefore, it is 
possible that the spared DG-LTP in the T286A mutants is mediated by autonomous 
PCaMKII activity in the autophosphorylated state. Furthermore, pCaMKII has been 
implicated in the partial compensation of LTP deficits in area CA1 in an aCaMKII KO 
mouse line (Elgersma et al., 2002). To check this hypothesis, I analysed the 
autophosphorylation o f PCaMKII in potentiated DG tissue from T286A mutants. The 
level o f autophosphorylated PCaMKII was significantly increased in the tetanised DG 
one hour after stimulation as compared to the unpotentiated control tissue (Fig. 3-6) 
(136%, 7i= 5, F\.%— 48.7, p<  0.001). The increase of PCaMKII autophosphorylation in 
the DG of T286A mutants one hour after stimulation (136% of control) was comparable 
to the levels observed in WT mice (132% of control) (Table 3-2). Based on this result, it 
could be assumed that that PCaMKII activity compensates for the lack o f autonomous 
aCaMKII activity in the T286A mutants and the T286A mutation does not have a 
dominant-negative effect on pCaMKII autophosphorylation.
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Table 3-2. Overview of the results analysing the level o f autophosphorylation of 
aCaMKII and PCaMKII after LTP induction.
WT CA1 lh DG lh DG 15 min
phospho-
Thr286-aCaMKII
150 %
(p< 0.05)
162 %
(p< 0.001)
145 %
(p< 0.01)
phospho-
Thr287-pCaMKII
132 %
(p< 0.05)
132 %
(p<0.01)
153 %
(p< 0.001)
T286A mutants DG lh
phospho-
Thr287-pCaMKII
136 %
(p< 0.001)
3.2.6) Normal fiCaMKII levels in crude synaptosomal fraction from T286A mutant mice
The pCaMKII compensation observed in aCaMKII null mutants has been attributed to 
a mislocalisation of PCaMKII into post-synaptic densities (Elgersma et a l 2002). 
Therefore, I checked whether there is an up-regulation o f PCaMKII or 
autophosphorylated pCaMKII in crude synaptosomal fractions of aCaMKII T286A 
mutant mice (Fig. 3-7). No differences were observed in pCaMKII levels or 
autophosphorylated PCaMKII levels in synaptosomal lysates from T286A mutants as 
compared to WT mice (Fig. 3-7).
This result shows that PCaMKII is not mislocalised and translocated to the post- 
synaptic densities in the T286A mutants, suggesting no compensatory role for pCaMKII 
in the T286A mutants. Nevertheless, it is still possible that PCaMKII participates in the 
compensation o f aCaMKII via alternative mechanisms other than translocation to the 
post-synaptic densities. Further studies will be required to elucidate the role of 
pCaMKII in synaptic plasticity.
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3.2.7) Level o f  inhibited GSK3 is increased after LTP stimulation in CA1 and the DG
The evaluation o f the in vivo LTP approach showed that it is suitable to detect changes 
in phosphorylation levels after induction o f LTP. Thus, I wanted to exploit the assay to 
test the regulation o f signalling molecules that might be important for learning and 
memory. A recent study has demonstrated that mutants with conditional GSK3p over­
expression have impaired spatial learning (Hernandez et al., 2002). Hence, I tested 
whether GSK3p activity is regulated by LTP induction in CA1 and DG. GSK3P is 
constitutively active, but phosphorylation at Ser9 leads to inhibition o f GSK3p (Grimes 
& Jope, 2001). The phosphorylation levels at the inhibitory Ser9 phosphorylation site 
were significantly increased one hour after in vivo LTP induction in CA1 (134%, n= 4, 
F\.e= 6.29, p<  0.05) as well as in the DG (156%, n -  6, F m o =  16.5,p <  0.003) (Fig. 3-8). 
The same result was observed in DG tissue harvested 15 minutes after LTP induction 
(134%, n= 8, F\.\4= 10.2, p<  0.007) (Fig. 3-8). Interestingly, the phosphorylation at the 
inhibitory site on GSK3P was also elevated in DG from aCaMKII T286A mutant mice 
harvested one hour after stimulation (123%, «= 5, Fi_8= 5.31, p<  0.05) (Fig. 3-9). 
Together, these results reveal that inhibition of GSK3p is regulated by LTP induction 
and therefore may be important for synaptic plasticity, learning and memory processes. 
Furthermore, it shows that GSK3 inhibition is mediated independently of the 
autonomous aCaMKII activity in the DG.
3.2.8) Summary
In the present study, I have established an approach in collaboration with Drs Sam F. 
Cooke and Tim V.P. Bliss to study biochemical changes after electrophysiological in 
vivo stimulation of hippocampal subfields in anaesthetised mice. I demonstrate that 
well-characterised molecules including synapsin I, NR2B and CREB that exhibit 
increased levels o f phosphorylation after in vitro LTP induction, undergo stimulation-
CHAPTER 3: Biochemical analysis of the aCaMKII T286A mutants 110
induced phosphorylation changes in this in vivo LTP approach. This confirms that the in 
vivo LTP approach is suitable to investigate molecular changes relevant for synaptic 
plasticity, learning and memory. I then employed this in vivo LTP approach to 
investigate the regulation o f the autophosphorylation of aCaMKII and pCaMKII after 
stimulation in area CA1 and the DG of aCaMKII T286A mutants and WT mice. I find 
that autophosphorylation o f aCaMKII at Thr286 and PCaMKII autophosphorylation at 
Thr287 are both significantly increased after LTP stimulation in vivo in the DG of WT 
mice at 15minutes and one hour as well as in hippocampal area CA1 at one hour. In 
T286A aCaMKII mutant mice, in which the autophosphorylation of aCaMKII at 
Thr286 is disenabled, autophosphorylation levels at Thr287 on pCaMKII were also 
elevated one hour after in vivo LTP induction. These results suggest that autonomous 
PCaMKII activity could, possibly, compensate for the lack o f autonomous aCaMKII 
activity in the T286A mutants. However, the protein levels of PCaMKII in the crude 
synaptosomal fraction were unaltered between T286A mutants and WT mice, 
suggesting that there is no compensation by PCaMKII. Furthermore, I find that the 
phosphorylation levels at the inhibitory site of GSK3p display a stimulation-dependent 
increase. This increase in inhibitory phosphorylation is also observed in aCaMKII 
T286A mutants. These results suggest that regulation of GSK3p is involved in synaptic 
plasticity and also that this regulation occurs independent o f the autonomous aCaMKII 
activity.
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3.3) Discussion
3.3.1) An approach using electrophysiological in vivo stimulation to induce biochemical 
changes
In order to detect functional molecular changes triggered by learning and memory 
processes, I investigated changes in protein phosphorylation levels in the hippocampus 
o f WT mice after behavioural training. These pilot experiments using the hippocampus- 
dependent, single trial learning task, contextual fear conditioning, did not reveal any 
obvious changes in protein phosphorylation between naive and trained WT mice. 
Equally, the analysis of phosphorylation levels between naive and trained T286A 
mutants did not detect any changes. Possible explanations as to why no changes have 
been observed, may include limitations of the stimulation o f learning and memory 
processes by behavioural training. It is likely that only a relative limited number of 
synapses undergo simultaneously learning-induced changes after the behavioural 
training. Thus, it may be expected that only small changes in protein phosphorylation 
levels occur as a result o f the behavioural training. Subsequently, the immunoblotting 
method using phospho-specific antibodies might not provide sufficient sensitivity to 
detect these subtle changes in protein phosphorylation levels. Furthermore, there is 
generally a high degree of variation within the results of behavioural studies, which 
further complicates the identification o f changes in phosphorylation levels.
To overcome some of the problems encountered with the behavioural training, I decided 
to use electrophysiological stimulation to induce biochemical changes. Thankfully, Drs 
Sam F. Cooke and Tim V.P. Bliss from the National Institute for Medical Research, 
Mill Hill, were willing to collaborate on establishing an approach to 
electrophysiologically stimulate CA1 and the DG, and analyse resulting changes in 
protein phosphorylation. We focussed on phosphorylation changes in the hippocampus, 
because it is a well-characterised brain region implicated in learning and memory
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processes. As LTP has been shown to trigger changes in protein phosphorylation levels 
comparable to physiological phosphorylation changes observed after behavioural 
training, we opted to use electrical stimulation to induce long-term synaptic 
potentiation. A major advantage of using electrophysiological stimulation to trigger 
activity-dependent phosphorylation changes is that a relatively large number of  
synapses within a neuronal field can be simultaneously activated. This induction method 
is likely to result in pronounced changes of protein phosphorylation levels. The results 
presented here, demonstrate that the in vivo LTP induction produced robust and 
persistent phosphorylation changes in marker molecules including synapsin I, aCaMKII 
and CREB in both hippocampal subfields, CA1 and the DG (see Tables 3-1 and 3-2). 
Further advantages are a high level o f reproducibility and a low degree o f variation 
between different experiments as many important parameters can be controlled. 
Consistently, our approach produced reproducible data (see Table 3-1 and 3-2) and the 
variance within the values is relatively small. This allows us to produce conclusive data 
with a lower number o f samples.
LTP studies are commonly carried out in vitro in transverse hippocampal slices. 
However, the disadvantages o f the analysis of activity-dependent biochemical changes 
in vitro in stimulated brain slices include possible introduction o f artefacts and 
background noise resulting from the slice preparation and slice preservation (see, for 
example, Taubenfeld et al., 2002). A further disadvantage is that the lysate preparation 
from a single brain slice yields only small amounts of protein lysate and therefore 
several stimulated brain slices have to be pooled. To overcome some o f these limitations 
we decided to use in vivo LTP to induce activity-dependent synaptic potentiation in the 
hippocampal subfields, CA1 and the DG. The advantages o f using the in vivo LTP 
method include the presence of the unstimulated contralateral DG as an intrinsic control 
for the potentiated DG. Furthermore, there is a reduced likelihood o f inducing artefacts 
and background noise by damaging hippocampal tissue. A previous study on aCaMKII 
autophosphorylation using rat hippocampal slice homogenates observed an approximate
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increase o f 120% in phosphorylation levels one hour after in vitro CA1-LTP induction 
(Barria et al., 1997). In comparison, I detect an increase o f approximately 150 % in 
phospho-Thr286-aCaMKII in area CA1 using our in vivo LTP approach. This 
observation indicates that the in vivo LTP approach has a higher sensitivity in detecting 
phosphorylation changes. This is possibly due to less background noise and the fact that 
the whole hippocampus can be processed and individual hippocampal subfields micro­
dissected. Because each hippocampal subfield (either CA1 or the DG) is potentiated 
individually, the relative amount of protein phosphorylation increases, when the tissue 
from the stimulated subfield alone is isolated. Furthermore, each o f the hippocampal 
subfields employ distinct activity-dependent molecular mechanisms. Hence, it is crucial 
to investigate biochemical changes for each subfield separately. A drawback of in vivo 
LTP stimulation is the application of anaesthetic to the mouse during the LTP 
stimulation protocol. The administration of anaesthesia might interfere with molecular 
mechanisms underlying synaptic plasticity, learning and memory.
3.3.2) Regulation o f the autophosphorylation o f aCaMKII and fCaMKII
The present study demonstrates that autophosphorylation o f aCaMKII at Thr286 is 
increased after induction of in vivo LTP in both hippocampal subfields, CA1 and the 
DG. This finding is consistent with in vitro hippocampal slice studies that observed a 
persistent increase in aCaMKII Thr286 autophosphorylation in area CA1 after LTP 
induction (Barria et al., 1997; Ouyang et al., 1997). Moreover, increased aCaMKII 
Thr286 autophosphorylation has been observed after contextual fear conditioning 
(Kouzu et al., 2000). These results, in conjunction with studies in various aCaMKII 
mutant mouse lines, established a fundamental role for aCaMKII Thr286 
autophosphorylation in synaptic plasticity, learning and memory (see for review Lisman 
et al., 2002). Autophosphorylation o f aCaMKII at Thr286 switches the kinase into an
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autonomously active state. However, the function o f this autophosphorylation switch of 
aCaMKII is not yet understood.
In vitro and in vivo work demonstrated that CA1-LTP was abolished in aCaMKII 
T286A mutant mice, where the switch into autonomous aCaMKII activity is disenabled 
(Giese et al., 1998; Cooke et al., 2006). In contrast, DG-LTP at medial perforant path- 
granule cell synapses can be sustained over days in awake T286A mutant mice (Cooke 
et al., 2006). Therefore, the aCaMKII Thr286 autophosphorylation is essential for CA1- 
LTP, but not required for DG-LTP. This raises the question as to which molecular 
mechanisms sustain DG-LTP. Here I show that phospho-Thr286-aCaMKII is increased 
in the DG both 15 minutes and one hour after induction of in vivo LTP in WT mice. The 
persistence and the level of the increase in aCaMKII autophosphorylation in the DG 
resemble the autophosphorylation changes in CA1 (Table 3-2). Thus, it is likely that 
aCaMKII autophosphorylation can support DG-LTP, but additional molecular 
mechanisms either are simultaneously activated or can compensate in case aCaMKII is 
inactivated. Consistent with this idea, application o f the Ca2+/CaM-dependent kinase 
(CaMK) inhibitor, KN62, does not affect the induction of DG-LTP (Cooke et al., 2006). 
One obvious candidate to support DG-LTP is the p-isoform of CaMKII, as it shares 
high homology with aCaMKII and is also abundant in neurons (see for review Hudmon 
& Schulman, 2002). In fact, pCaMKII has been involved in the compensation of 
aCaMKII by partially rescuing CA1-LTP in an aCaMKII KO mouse line (Elgersma et 
al., 2002). Consistent with a compensatory role o f PCaMKII, I observe an increase in 
pCaMKII autophosphorylation after in vivo LTP induction in both hippocampal 
subfields; CA1 and the DG. This increase in phospho-Thr287-pCaMKII persists for at 
least one hour. Further, I find that pCaMKII autophosphorylation is also increased after 
induction o f in vivo LTP in the DG of T286A mutants. Together, these results show that 
pCaMKII autophosphorylation is regulated in an activity-dependent manner, indicating 
that autonomous PCaMKII activity is implicated in molecular mechanisms underlying
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synaptic plasticity. Moreover, these results could support the idea o f a compensatory 
role o f pCaMKII. However, there is also evidence against a compensatory role of 
PCaMKII. The mechanism by which pCaMKII compensation occurs in the aCaMKII 
KO mouse line is thought to involve translocation o f pCaMKII into post-synaptic 
densities (Elgersma et al., 2002). Here, I show that there is no compensatory 
translocation of pCaMKII into the post-synaptic densities in T286A mutants. 
Accordingly, recent pharmacological studies demonstrate conclusively that pCaMKII 
does not compensate for autonomous aCaMKII activity (Cooke et a l , 2006; Wu et al., 
2006). Application of the CaMK inhibitor, KN62, had no effect on DG-LTP in both WT 
mice and T286A mutants, demonstrating that other molecules than CaMKs support DG- 
LTP. These studies then show that DG-LTP in T286A mutants can be reduced by 
application o f PKA and MAPK inhibitors. However, some residual LTP can still be 
induced in the DG of T286A mutants. In contrast, CA1-LTP induction is completely 
blocked in T286A mutants or in WT mice with application o f KN62 (Cooke et al., 
2006). These findings demonstrate a dissociation between the molecular mechanisms 
for LTP in CA1 and the DG. These results indicate that CA1-LTP is mediated via 
aCaMKII. In contrast, DG-LTP at medial perforant path-granule cell synapses can be 
supported by parallel signalling pathways, one including aCaMKII and the other 
including PKA and MAPK. In addition, further mechanisms might be involved in the 
induction o f DG-LTP, as suggested by the residual LTP after simultaneous application 
of KN62 and PKA or MAPK inhibitors (Wu et al., 2006). The finding that there is a 
dissociation between the molecular mechanisms of LTP in CA1 and DG has important 
implications for further studies. It shows that future molecular studies need to be 
performed in a subfield-specific manner. The identification of the distinct molecular 
mechanisms implicated in LTP of the two subfields will help to understand the role of 
the hippocampus in learning and memory.
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3.3.3) The role o f GSK3 in synaptic plasticity, learning and memory.
The present study shows that inhibitory phosphorylation o f GSK3P at Ser9 is increased 
in both hippocampal subfields, CA1 and the DG, after in vivo LTP induction. This 
increase in phosphorylation of GSK3(3 on Ser9 persists for at least one hour. Increased 
inhibitory phosphorylation of GSK3 has previously been linked to pharmacological 
induced activity-dependent conditions. Interference with serotonergic activity by 
pharmacological means was shown to significantly increase the level of inhibitory 
phosphorylation o f GSK3P in hippocampus, cerebral cortex and striatum of mouse in 
vivo (Li et al., 2004). In vivo treatment o f mice with pilocarpine, a muscarinic agonist 
commonly used to induce seizures, resulted also in increased inhibitory phosphorylation 
in both GSK3p at Ser9 and GSK3a at Ser21 in hippocampus, cerebral cortex and 
striatum (De Samo et al., 2006). The induction o f the GSK3 inhibitory phosphorylation 
occurred rapidly between 5 and 15 minutes, persisted for at least 90 minutes and was 
back to baseline two hours after induction. Interestingly, I observe a comparable time 
course o f inhibitory GSK3p phosphorylation after DG-LTP in vivo. The signal is 
increased after 15 minutes and persists for at least one hour after LTP induction. A 
similar time course has been observed for molecules involved in processes during the 
early phase o f synaptic plasticity. Thus, it is conceivable that inhibition of GSK3 is 
involved in molecular mechanisms underlying the early phase o f synaptic plasticity. As 
GSK3 has been implicated in the negative regulation o f multiple transcription factors, it 
is likely that GSK3 may affect synaptic plasticity via the control o f transcription. This 
hypothesis is supported by an elegant study in cell cultures demonstrating that electrical 
activation of L-type VGCC triggers translocation of the transcription factor NF-ATc4 
from the cytoplasm into the nucleus (Graef et al., 1999). The translocation step is 
regulated via GSK3J3 activity, which promotes nuclear export o f NF-ATc4 and in turn 
inhibits NF-ATc4-induced transcription (Graef et al., 1999). Furthermore, over­
expression of GSK3 in cell culture blocked BDNF-induced CREB phosphorylation and 
pharmacological inhibition can subsequently revert this effect and facilitate activation of
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CREB (Grimes & Jope, 2001; Mai et al., 2002). In addition, these studies highlight a 
major problem of investigating GSK3 functions. GSK3 is ubiquitously localised within 
a cell. However, functionally different subcellular pools o f GSK3 co-exist, which are 
probably regulated by alternative complexes, and this complicates the study of one 
individual GSK3 pool.
To date there are only few data available on the involvement o f GSK3 in learning and 
memory processes. The most conclusive results come from a study analysing TG mice 
conditionally over-expressing GSK3(3 in hippocampal and cortical neurons (Hernandez 
et al., 2002). The GSK3p over-expression resulted in enhanced GSK3P activity, which 
coincided with impaired spatial learning in the MWM. This result indicates that 
persistent activation of GSK3 impairs learning and memory processes and suggests that 
inhibition of GSK3 is important for the expression o f learning and memory. Obviously, 
more detailed research will be required to untangle the diverse functions o f GSK3 and 
to elucidate the involvement of GSK3 in synaptic plasticity and learning and memory.
3.4) Conclusion
In the present study I have established that the in vivo LTP approach can be applied to 
detect protein phosphorylation changes after synaptic potentiation in both CA1 and the 
DG. The findings show increased levels o f protein phosphorylation after in vivo LTP 
induction in much-researched molecules including synapsin I, NR2B, aCaMKII and 
CREB, which have been consistently reported to exhibit increased phosphorylation after 
in vitro LTP. Thus, this approach may be used to investigate molecular and cellular 
processes important for synaptic plasticity, learning and memory. Moreover, in this 
study I show that the in vivo LTP approach can be used to assess activity-dependent 
changes in phosphorylation levels in the T286A mutant mice, where the autonomous
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activity o f aCaMKII is disenabled. Further characterisation o f the T286A mutants with 
this approach will help to understand the function o f aCaMKII in learning and memory 
processes. In the future application of this in vivo LTP approach to analyse other 
genetically-modified mouse lines with learning and memory impairments promises to 
yield new insights o f the molecular processes underlying learning and memory.
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CHAPTER 4: Analysis of a transgenic mouse line expressing the Cdk5 
activator p25
4.1) Introduction
4.1.1) The p25 expressing transgenic mouse line
Dr Marco Angelo generated a transgenic mouse line in the C57BL/6 genetic 
background carrying an autosomal, single-copy integration o f the mouse p25 transgene 
(Angelo et al., 2003). The transgene includes two copies o f the coding region head to 
tail oriented and a FLAG epitope. In this p25 TG mouse line the expression of the 
transgene is under the control o f the aCaMKII promoter, which restricts the expression 
to excitatory neurons in the forebrain. Consistently, in adult TG mice at 12 month o f age 
the highest level o f p25 expression is in the hippocampus, where it averaged at 
approximately 33% of endogenous p35 expression (Fig. 4-1; Angelo et al., 2003). 
Further, p25 is detected in neocortex, striatum and low amounts in spinal cord, but not 
in cerebellum (Fig. 4-1; Angelo et al., 2003). The TG mouse line had low levels o f p25 
expression as compared to the p25 expression in other TG mouse lines (Table. 1-6). 
Most o f the other TG mouse lines have a p25 transgene expression that is equal or 
higher than the levels o f endogenous p35 expression (Table. 1-6). No p25 expression 
was observed in brains o f TG mice at postnatal day 1. p25 was detected in the 
hippocampus of 18 days old TG mice, although at slightly lower levels (approximately 
25% of endogenous p35 expression) than in adult TG mice (Angelo et al., 2003). These 
findings suggest that the expression o f p25 starts between the first and second postnatal 
week. The expression of p25 did not interfere with the expression of p35 and Cdk5 
(Angelo et al., 2003; see results). Further, p25 and endogenous p35 levels were 
unchanged between male and female p25 TG mice (Ris et al., 2005). Finally, no
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obvious signs o f neurodegeneration were observed in the p25 TG mice even at an old 
age (Angelo et al., 2003). The basic characterisation o f the p25 TG mice demonstrates 
that the mouse line is suitable for further analysis o f biochemical changes, synaptic 
plasticity, learning processes and memory formation. The p25 transgene expression 
starts postnatally. Hence, embryonic developmental artefacts can be excluded. As the 
interest focused on the impact o f the presence o f p25 in the hippocampus, a brain area 
affected in many tauopathies, including AD, a strategy to restrict the p25 expression to 
excitatory forebrain neurons was selected. The analysis o f the expression pattern in the 
p25 TG mice showed that the p25 transgene expression is mainly forebrain restricted 
(Angelo et al., 2003). The electrophysiological and behavioural characterisation of the 
p25 TG mice revealed that the expression of p25 enhanced CA1 LTP in female, but in 
contrast CA1 LTP was reduced in male p25 TG mice (Ris et al., 2005). Spatial learning 
was improved in female p25 TG mice as compared to female WT controls, but it was 
not affected in male p25 mice (Ris et al., 2005). Furthermore, tone fear conditioning 
was improved in female p25 TG mice in the 129B6F1 background, as well as in male 
and female p25 TG mice in the C57BL/6 background. Together, these results implicate 
the p25/Cdk5 holoenzyme in synaptic plasticity, learning and memory, possibly in a 
sex-specific manner (see for review Angelo et al., 2006).
4.1.2) Aim o f the project
Previous studies have implicated formation of p25 and p25-induced Cdk5 over­
activation with molecular changes characteristic for neurodegenerative diseases 
including AD (see for review Shelton & Johnson, 2004). In fact, formation of p25 has 
been reported to occur specifically in sporadic AD patients, but not healthy individuals 
(Patrick et al., 1999). Over-activation of Cdk5 by p25 has been proposed to trigger 
abnormal tau hyperphosphorylation and alter APP processing (see, for example, Cruz et 
al., 2003; Lee et al., 2003). Thus, one aim of this study was to investigate whether p25
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expression and subsequently p25-induced Cdk5 over-activation leads to tau 
hyperphosphorylation and altered processing of APP in the p25 TG mouse line. For this 
I analysed the phosphorylation levels of tau at several disease-associated sites by using 
phospho-specific tau antibodies in young and old p25 TG mice. Further, I tested 
whether APP processing was affected in young and old p25 TG mice by using a range 
of antibodies detecting different parts of APP.
Another aim was the identification of Cdk5 substrates and in turn to acquire more 
information on what molecular mechanisms p25/Cdk5 is involved in. For this, I 
assessed changes in phosphorylation levels between p25 TG and WT mice by using a 
two dimensional gel electrophoresis (2DE) approach.
Finally, as behavioural and electrophysiological analysis of the p25 TG mice indicated 
an involvement of the p25/Cdk5 holoenzyme in synaptic plasticity, learning and 
memory, this study aimed to acquire some information on the molecular mechanisms 
underlying the changes in synaptic plasticity and behaviour in the p25 TG mice.
4.2) Results
4.2.1) Constant p25 expression in p25 TG mice
Previous results have shown that the p25 TG mouse line has postnatal, forebrain- 
restricted expression of the Cdk5 activator p25 (Angelo et al., 2003). Here, 1 find that 
the expression of p25 stayed constant in young (3 months) and old (18 months) p25 TG 
mice (Fig. 4-2). I observed no expression of p25 in young and old WT controls (Fig. 4- 
2). This finding indicates that no proteolytic degradation occurred during the lysate
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preparation and that the protease inhibitor cocktail used during the lysate preparation is 
suitable to prevent proteolytic degradation. Furthermore, no change in Cdk5 levels 
could be observed in young and old TG mice when compared to WT controls (Fig. 4-2). 
Studies in cell cultures have reported that p25 is not present at the synapse and therefore 
might delocalise Cdk5 from the synapse (Patrick et al., 1998). However, I find p25 in 
crude synaptosomal fractions o f TG mice and detect no changes in Cdk5 protein levels 
in synaptosomal lysate o f TG mice (Fig. 4-3; Angelo et al., 2003) indicating that Cdk5 
is not mislocalised in our TG mice. Taken together, these results demonstrate that the 
p25 transgene expression and the Cdk5 protein levels are not altered during the lifespan 
of the TG mouse suggesting a constant over-activation o f Cdk5 in TG mice.
4.2.2) Constant increase in Cdk5 activation by p25 expression
I tested whether the low-level expression of p25 in our mouse line resulted in an over­
activation of Cdk5. For this I carried out a Cdk5 immunoprecipitation kinase assay. I 
found that the Cdk5 activity was increased by approximately 2-fold in young and old 
TG mice as compared to WT littermates (Fig. 4-4). This result shows that Cdk5 is 
constantly over-activated in the TG mice. This is consistent with the unaltered 
expression of p25 and Cdk5 protein level in young and old TG mice. Interestingly, in 
most studies using other TG mouse lines expressing p25 an approximately 2-fold 
increase in Cdk5 activity was observed, independently o f the level of p25 expression 
(Table 1-6).
4.2.3) 2DE screen for changes in phosphorylation at proline-directed sites in p25 mice
Cdk5 is a proline-directed kinase that phosphorylates a broad range of substrates with 
diverse functions (Table 1-3). In order to see whether the p25-induced Cdk5 over­
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activation is functional in vivo, I screened for changes in phosphorylation levels at 
proline-directed phosphorylation sites. First I focused on changes in phosphorylation 
levels of synaptic proteins. A 2DE immunoblot of crude synaptosomal protein from 
hippocampus was probed with a phospho-specific Cdk/MAPK substrate antibody. I 
observed distinct and reproducible changes in signal intensities of individual spots and 
spot trains that were controlled for with phospho-tyrosine antibody (see also section
2.3.4). Several spots and spot trains displayed higher intensity in TG mice as compared 
to WT controls (Fig. 4-5). A protein with a molecular mass o f 160 kDa and an 
isoelectric point o f 4.5 showed a 2.5-fold increase in TG mice (Fig. 4-5). This protein 
was identified as neurofilament M, a prime substrate o f Cdk5 (Fig. 4-5). Interestingly, 
our screen could not detect elevated phosphorylation of neurofilament H, even though 
neurofilament M as well as neurofilament H contain repeats of the same Cdk5 
phosphorylation motif. This finding suggests that the activated kinase complex 
Cdk5/p25 is directed towards a specific subset of substrates. Together, these results 
show that the over-activation of Cdk5 is functional in vivo in the TG mice and leads to 
increased phosphorylation of the Cdk5-specific substrate, neurofilament M, amongst 
others.
4.2.4) Age-dependent increase in tau hyperphosphorylation in p25 TG mice
After demonstrating that the expression of p25 induced over-activation o f Cdk5 in our 
TG mice, I studied the phosphorylation levels o f the microtubule-associated protein tau 
at disease-associated sites. Abnormal hyperphosphorylation o f tau at proline-directed 
serine/threonine phosphorylation sites is characteristically found in neurodegenerative 
tauopathies including AD (see for review Buee et al., 2000, Lee et al., 2001). 
Previously, we have shown a non-significant trend of increased tau phosphorylation in 
hippocampal lysates from 13 month-old TG mice (Angelo et al., 2003). Here, I 
examined the impact o f p25-induced Cdk5 over-activation on tau hyperphosphorylation
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in young (3 month) and old (18 months) TG mice. For this, I probed immunoblots of 
hippocampal lysates from TG mice and WT littermates with the phospho-specific tau 
antibodies AT8 (Ser202/Thr205), AT100 (Ser214 and/or Ser212), PHF-1 (Ser396/404) 
and TG3 (Thr231/Ser235). These antibodies recognise disease-associated epitopes 
around proline-directed phosphorylation sites on tau and are commonly used in studies 
o f human pathology to detect NFTs. Protein levels o f tau were assessed with the pan-tau 
antibodies BR134 and TAU5. In the TG mice an age-dependent accumulation of 
hyperphosphorylated tau was detected with the AT8 and the PHF-1 antibodies (Fig. 4- 
6). In young TG mice no changes in tau hyperphosphorylation were observed with any 
of the phospho-tau antibodies, even though Cdk5 activity was constantly elevated (Fig. 
4-4). In contrast, old TG mice displayed significantly increased tau
hyperphosphorylation by approximately 90% using the AT8 and PHF-1 antibodies (Fig.
4-6). The results of the PHF-1 antibody were confirmed using the phosphorylation- 
dependent neurofilament antibody, SMI31, which cross-reacts with tau
hyperphosphorylated at the PHF-1 site (Lichtenberg-Kraag et al., 1992). The SMI31 
antibody revealed increased tau hyperphosphorylation in old TG mice comparable to the 
PHF-1 antibody (Fig. 4-6). The phospho-specific tau antibodies ATI00 and TG3 did not 
detect differences in tau hyperphosphorylation levels between genotypes at old ages. 
Interestingly, by 18 months o f age the WT' mice also had increased tau 
hyperphosphorylation at the AT8 and PHF-1 site as compared to young age, albeit with 
larger variation between individuals than in the p25 mutants (Fig. 4-6).
4.2.5) Involvement o f other proline-directed kinases in tau hyperphosphorylation
There were no age-dependent changes in expression of p25 and Cdk5, nor in Cdk5
activity in the TG mice that could account for the increased levels of tau
hyperphosphorylation at the AT8 and PHF-1 sites. Therefore, I tested the involvement 
of other proline-directed kinases that have been linked to tau hyperphosphorylation
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including extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal kinase 
(JNK), and MAPK/ERK kinase 1/2 (MEK1/2) (see for review Billingsley & Kincaid, 
1997; Buee et al., 2000). No changes in the phosphorylation levels at the activatory sites 
of JNK (Thrl83/Tyrl85) and MEK1/2 (Ser217/Ser221) were observed between TG and 
WT mice. The phosphorylation levels at the activatory site o f ERK1/2 were reduced in 
TG mice as compared to WT mice suggesting that ERK activity is decreased in TG 
mice (Fig. 4-7). This is consistent with the finding that Cdk5 regulates the activity of 
ERK via the inhibition of MEK1 (Sharma et al., 2002). Together, these results indicate 
that proline-directed kinases ERK, JNK and MEK are not responsible for the increased 
tau hyperphosphorylation observed in old TG mice. However, the activity of GSK3, 
another proline-directed kinase and prime candidate for mediating tau phosphorylation, 
was differentially regulated in TG mice (Fig. 4-8).
4.2.6) Age-dependent inhibitory regulation o f GSK3 activity by p25 expression
GSK3 is known to phosphorylate proline-directed serine/threonine sites similarly to 
Cdk5 (Mandelkow et al., 1992; Reynolds et al., 2000), and has been linked to tau 
hyperphosphorylation (Hanger et al., 1992; Mandelkow et al., 1992; for review, see 
Buee et al., 2000). GSK3 is constitutively active, but can be inhibited by 
phosphorylation at Ser9 in the (3-isoform and at Ser21 in the a-isoform (Stambolic & 
Woodgett, 1994). I found that the inhibitory phosphorylation at the serine residue of 
GSK3 was increased by approximately 80% in the young TG mice as compared to WT 
controls (Fig. 4-8). This result indicates that p25-induced Cdk5 over-activation leads to 
inhibitory control of GSK3. However, no increased phosphorylation at the inhibitory 
serine site was observed in old TG mice (Fig. 4-8), suggesting loss of inhibitory 
regulation in old TG mice. Interestingly, this loss of regulatory control coincides with 
the increased levels o f tau hyperphosphorylation in old TG mice.
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4.2.7) Inhibitory regulation o f GSK3 is not mediated by AKT and p90Rsk activity
The inhibitory phosphorylation of GSK3a/p at the serine residue (Ser21/9) is regulated 
by antagonistic kinase and phosphatase activity (Grimes & Jope, 2001). Several kinases, 
including AKT, p90Rsk, PKA as well as some isoforms o f PKC and phosphatases, 
including PP1 and PP2A have been implicated in this inhibitory regulation of GSK3 
(Fig. 4-9; Grimes & Jope, 2001; Morfini et al., 2004). Because Cdk5 does not directly 
phosphorylate GSK3 at the inhibitory site (Morfini et al., 2004), I checked whether 
Cdk5 mediates the inhibition o f GSK3 via the control o f AKT and p90Rsk. I assessed 
the phosphorylation levels on their activation sites with phospho-specific antibodies and 
detected no altered regulation in the TG mice (Fig. 4-9). This suggests that the 
modulation evoked by p25 expression is not mediated by AKT and p90Rsk.
4.2.8) Age-dependent increase in activated GSK3/3 protein in old TG and WT mice
Phosphorylation of GSK3 at the Tyr279 in the a-isoform and Tyr216 in the p-isoform, 
respectively, is essential for activation of GSK3 (Hughes et al., 1993). I used a phospho- 
specific GSK3 antibody recognising the phosphorylated activatory sites, to check 
whether p25-induced Cdk5 over-activation impacts on the activating phosphorylation. 
No alterations in phosphorylation at the activating tyrosine site (Tyr279/216) were 
detected between the genotypes at any age (Fig. 4-10). Interestingly, whereas the 
protein level of the a-isoform remained constant between young and old mice, the 
amount o f GSK3p protein is increased in both old WT and old TG mice. Further, the 
phosphorylation at the activating Tyr216 site of the P-isoform was also elevated in old 
mice as compared to young mice (Fig. 4-10). In contrast, the phosphorylation level of 
the activating Tyr279 site on the a-isoform remained constant in young and old mice. 
These findings show that p25-induced Cdk5 over-activation does not impact on the 
phosphorylation levels at the activating site. Furthermore, it is conceivable that the age-
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dependent increase of GSK3(3 protein phosphorylated at the activatory site confers 
increased GSK3P activity in old mice.
4.2.9) GSK3J3 activity is reduced in young, but increased in old TG mice
The phosphorylation level at the inhibitory site o f GSK3 was elevated in young TG 
mice suggesting decreased GSK3 activity. However this inhibitory phosphorylation was 
lost in old TG mice and coincided with an increase in GSK3P protein. I tested the levels 
of GSK3p activity by using a GSK3p immunoprecipitation kinase assay. In young TG 
mice the GSK3p activity was significantly decreased by approximately 25% confirming 
the immunoblot results of the inhibitory phosphorylation levels (Fig. 4-11). Further, in 
old TG mice the GSK3P activity was increased by approximately 70% (Fig. 4-11). 
These results suggest that the inhibitory regulation of GSK3P is altered in old TG mice 
leading to enhanced GSK3p activity, which correlates with tau hyperphosphorylation at 
the AT8 and PHF-1 sites in old TG mice. Thus, it is likely that the increase in GSK3 
activity is responsible for the tau hyperphosphorylation in the old TG mice.
4.2.10) Chronic lithium treatment reduced the level o f tau hyperphosphorylation in old 
p25 TG mice
To test whether the increased GSK3 activity is responsible for the age-dependent tau 
hyperphosphorylation at the AT8 and PHF-1 sites, old TG mice were treated chronically 
with lithium, a commonly used reversible inhibitor o f GSK3 (see, for example, Hong et 
al., 1997; Klein et al. 1996) and the level of tau hyperphosphorylation at the AT8 and 
PHF-1 sites was assessed. At low concentrations lithium is an inhibitor o f GSK3, but 
does not affect significantly the activity of other kinases (Phiel & Klein, 2001; Davies et 
al., 2000). The phospho-specific tau antibodies, PHF-1 and AT-8, showed a marked
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reduction of the tau hyperphosphorylation level in the lithium treated old TG mice as 
compared to old TG controls (Fig. 4-12). The tau hyperphosphorylation could be 
reversed close to levels observed in young TG mice. Chronic lithium treatment in 18 to 
19 month old WT mice induced a non-significant reduction o f phosphorylation levels at 
the PHF-1 site, but did not alter phosphorylation levels at the AT8 site (Fig. 4-13). The 
inhibitory effect o f lithium on GSK3 was confirmed by assessing the protein levels o f p- 
catenin. Phosphorylation o f p-catenin by GSK3 targets the protein for degradation via 
the ubiquitin-proteosome pathway (Grimes & Jope, 2001). The level o f P-catenin was 
increased in lithium treated WT and TG mice as compared to untreated controls (Fig. 4- 
12 and 4-13), indicating reduced GSK3 activity. Interestingly, no differences in P~ 
catenin levels were observed between untreated TG and WT mice, both at young and 
old age, despite the changes in GSK3p kinase activities between genotypes (Fig. 4-14). 
To assess whether Cdk5 activity was affected by the lithium treatment, the 
phosphorylation level of amyloid precursor protein (APP) at Thr668 was monitored. 
APP is phosphorylated at the proline-directed Thr668 in the cytosolic domain 
specifically by Cdk5 (Iijiama et al., 2000; see also section 4.2.12). No differences in 
APP phosphorylation at Thr668 were observed in lithium treated TG and WT mice as 
compared to untreated controls (Fig. 4-12 and 4-13) suggesting Cdk5 activity is not 
affected by lithium treatment.
4.2.11) Interaction ofCdk5, GSK3 andPP2A
The inhibitory cross-talk of Cdk5 and GSK3 suggests that these two molecules are 
localised in proximity of each other or even aggregate together. To test whether Cdk5, 
GSK3 and protein phosphatases interact with each other, 1 carried out co- 
immunoprecipitation in hippocampal lysates of TG mice using anti-GSK3|3 antibody. 
The presence o f GSK3p protein in the precipitate fraction showed that the antibody was 
suitable for pull-down assays (Fig. 4-15). The co-immunoprecipitation with the anti-
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GSK3p antibody also pulled down Cdk5 and PP2A as tested by immunoblotting (Fig. 4- 
15). Interestingly, the immuno-precipitate pulled down with an anti-Cdk5 antibody 
contained Cdk5, p25 and p35; however, no GSK3, nor PP2A could be detected (data not 
shown). These results show that GSK3, Cdk5 and PP2A can aggregate within the same 
complex. However only a small subset of all Cdk5 molecules participates in this 
complex. Further evidence for association of these molecules comes from GSK3p 
immunoprecipitation kinase activity assays (Fig. 4-16). The GSK3p activity assay 
showed similar levels o f kinase activity for TG mice and WT littermates when okadaic 
acid, a specific inhibitor of PP1 and PP2A, was omitted from the kinase reaction buffer. 
Addition o f okadaic acid to the kinase reaction buffer had no significant effect on kinase 
activity levels in WT mice, but produced a marked reduction in TG mice (Fig. 4-16). 
These results indicate that protein phosphatases co-immunoprecipitate with GSK3p, as 
the GSK3P activity is differentially regulated by phosphatase activity in TG mice as 
compared to WT mice. These observations further demonstrate the necessity of 
application of suitable kinase and phosphatase inhibitors in immunoprecipitation kinase 
activity assays. As I found that Cdk5, GSK3 and PP2A co-immunoprecipitate and 
GSK3 activity is inhibited by Cdk5 over-activation, it is necessary that Cdk5 inhibitors, 
such as roscovitine, as well as phosphatase inhibitors, such as okadaic acid, are used in 
GSK3 activity assays.
4.2.12) Constant increase in APP phosphorylation by p25 expression
I assessed whether other well-characterised, specific Cdk5 substrates showed an age- 
dependent increase in phosphorylation similar to that observed for tau. The membrane- 
associated protein APP is phosphorylated at the proline-directed site Thr668 (as per 
APP695) in the cytosolic domain specifically by Cdk5 (Iijiama et al., 2000). The anti- 
phospho-Thr668-APP antibody predominantly recognised an immature 62 kDa APP 
isoform (Fig. 4-17 and 4-18). The phospho-Thr668-APP level was significantly
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increased by approximately 60% in TG mice as compared to WT mice (Fig. 4-17). This 
increase was detected in young and old TG mice (Fig. 4-17). No changes in total APP 
expression were observed with antibodies recognising the unphosphorylated epitope 
around Thr668 (APP) and the extreme carboxy-terminal region of APP (CT-15) (Fig. 4- 
17 and 4-18). The constantly elevated phospho-Thr668-APP levels are consistent with 
the results o f the in vitro Cdk5 kinase assay that demonstrate increased Cdk5 activity in 
young and old TG mice. These results confirm that Cdk5 activity is constantly increased 
in TG mice in vivo. Hence, specific substrates o f the p25/Cdk5 holoenzyme display 
elevated phosphorylation levels in the TG mice.
4.2.13) 2DE analysis o f APP isoforms and phosphorylated APP at Thr668
APP is the product of a single gene, but a large number of APP isoforms is generated by 
alternative splicing, post-translational modifications and complex proteolytic processing 
(Fig. 1-8 to 1-11; see for review, Turner et al., 2003). APP isoforms can be grouped in 
mature and immature isoforms according to their electromobility in SDS PAGE. 
Immature APP isoforms are lacking post-translational modifications and run at around 
70-90 kDa, whereas mature APP isoforms, which are highly glycosylated have an 
apparent molecular mass weight o f about 110-130 kDa. To investigate the various APP 
isoforms and explore the impact of the APP phosphorylation at Thr668 on the 
electromobility o f the molecule, 2DE-gels were immunoblotted and probed with 
different APP antibodies. I used an antibody raised against the Ap-peptide domain 
(4G8) and one against the carboxy-terminus of APP (CT-15) on 2DE immunoblots from 
hippocampal lysates (Fig. 4-18). Both antibodies recognised a similar complex signal 
pattern o f myriads o f immature and mature APP isoforms with various molecular mass 
weights and isoelectric points (Fig. 4-19). The data from the 2DE immunoblot o f the 
two antibodies were combined to generate a composite picture that just included signals 
recognised by both antibodies. The resulting composite picture is likely to exclusively
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represent APP isoforms; however some isoforms (e.g. those lacking the carboxy- 
terminus) might have been omitted. The composite picture was overlaid with the signal 
from the immunoblot probed with anti-phospho-Thr668-APP antibody. This overlay 
reveals that only a well-defined subset of APP isoforms displays phosphorylation at 
Thr668 (Fig. 4-20). This result implies that only a specific pool of APP isoforms with a 
characteristic electromobility (possibly due to similar post-translational modifications) 
undergoes phosphorylation at Thr668, which might correlate with a specific function of 
this subset of APP isoforms.
4.2.14) Age-dependent alterations in APP processing in p25 TG mice
The alternative splice variants o f APP are subjected to numerous post-translational 
modifications and complex proteolytic processing that give rise to a large number o f  
APP isoforms and fragments, including the Ap-peptide and carboxy-terminal fragments 
(CTF) (Fig. 1-9 to 1-11; see for review Turner et a l , 2003). Much research has focused 
on the production of AP-peptides, because of their involvement in AD. Ap-peptides 
constitute the main component o f senile plaques. The APP phosphorylation at Thr668 
has been thought to be important for the processing of APP and possibly the generation 
of Ap-peptides (Suzuki et al., 1994; Iijama et al., 2000; Lee et al., 2003). As p25 
expression caused increased APP phosphorylation at Thr668, I investigated the 
processing o f APP in the TG mice. Levels of different APP isoforms and fragments 
were assessed in immunoblots of hippocampal lysate probed with an antibody 
recognising the Ap-domain of APP (4G8). The anti-Ap antibody detected a 57 kDa 
fragment in old (18 and 26 month), but not in young (3 month) TG mice (Fig. 4-21). 
The quantification of the immunoblot signal revealed a significant age-dependent 
accumulation of this 57 kDa fragment in old TG mice (Fig. 4-21). Interestingly, the 
pattern of APP isoforms detected by the anti-Ap antibody is altered between the tested 
age-points, implying that the post-translational modifications on APP are affected in an
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age-dependent manner (Fig. 4-21). Unprocessed APP runs normally at molecular mass 
weights higher than 57 kDa. Thus, it is conceivable that parts of the APP have been 
cleaved off resulting in a 57 kDa fragment. To assess what parts the 57 kDa fragment is 
lacking, I tested whether the band at 57 kDa can be detected with antibodies against the 
amino- and carboxy-terminus o f APP (Fig. 4-22). Surprisingly, neither the amino- 
terminus, nor the carboxy-terminus-specific anti-APP antibody recognised a band at 57 
kDa (Fig. 4-22).
Taken together, these results indicate that APP processing is altered in old but not in 
young TG mice. Moreover, the 57 kDa fragment does not contain the amino- and 
carboxy-terminal portion o f APP. Thus, further studies will be required to reveal the 
identity o f the 57 kDa fragment.
4.2.15) No changes in carboxy-terminal fragments o f APP in p25 TG mice
To investigate whether the altered APP processing has an impact on the levels of other 
fragments than the 57 kDa species, I assessed the levels of CTFs and Ap-peptides in 
high resolution tris-tricine gels. The analysis of CTF levels is commonly used as an 
indicator of secretase activity and AP-peptide production, because CTFs are released as 
a by-product of Ap-peptide processing.
Hippocampal lysates o f old TG mice and WT controls were separated on tris-tricine 
gels, immunoblotted and probed with anti-Ap antibody (4G8), anti-phospho-Th668- 
APP antibody and an antibody against the carboxy-terminus o f APP (CT-15) (Fig. 4- 
18). All of the antibodies detected several bands in the molecular mass weight range of
5-25 kDa (Fig. 4-23). Some of the bands were consistently found with all three 
antibodies (i.e. 16, 19, 23 kDa) indicating that these bands are CTFs of APP. However, 
the antibodies did not detect any differences in signal intensity o f bands between TG 
mice and WT controls (Fig. 4-23). This suggests that there are no differences in CTF
CHAPTER 4: Analysis of a transgenic mouse line expressing the Cdk5 activator p25 133
production/accumulation, and therefore in A(3-peptide production in old TG mice as 
compared to old WT littermates. Consistent with this observation, the anti-Ap antibody 
(4G8) did not detect any changes in band intensity in the molecular mass weight range, 
where Ap-peptides migrate (3-6 kDa; data not shown). However, it is possible that the 
detection level o f tris-tricine immunoblots is not sufficient to assess subtle changes in 
low AP-peptide levels. Hence, a more accurate analysis o f Ap-peptide production in the 
TG mice using the ELISA technique will be required. The results so far show that there 
is an age-dependent accumulation of a 57 kDa fragment indicating that APP processing 
is altered in old TG mice. But no evidence for altered Ap-peptide generation in old TG 
mice could be produced. In order to understand the effect of the p25/Cdk5 holoenzyme 
on APP processing, it will be important to characterise the 57 kDa fragment.
4.2.16) Summary
Here, I analysed biochemical changes in the TG mouse line expressing the Cdk5 
activator p25. I examined the impact of p25-induced Cdk5 over-activation on the 
phosphorylation levels o f specific substrates, including the microtubule associated 
protein tau and APP.
First, I demonstrated that in the TG mouse line p25 is constantly expressed at low- 
levels. This p25 expression leads to a persistent, two-fold increase in Cdk5 activity and 
consistently to a constant elevation o f the phosphorylation levels o f APP at Thr668. 
However, the p25-induced Cdk5 over-activation did not result in tau 
hyperphosphorylation in young TG mice. In fact, over-activation o f Cdk5 was 
associated with increased phosphorylation levels at the inhibitory site on GSK3. This 
result indicates that Cdk5 negatively regulates GSK3 activity. However, in old TG mice 
the inhibitory regulation of GSK3 is lost. Further, I observed an age-dependent increase 
in tau phosphorylation at disease-associated sites, including ATS and PHF-1 sites, that
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coincides with enhanced GSK3 activity. These results suggest that the increased tau 
hyperphosphorylation observed in old TG mice is mediated by GSK3, but not Cdk5 
activity. Accordingly, in old TG mice the level of increased tau hyperphosphorylation 
could be reduced by chronic treatment with lithium, a GSK3 inhibitor.
Moreover, p25 expression was found to influence APP processing such that a 57 kDa 
fragment o f APP accumulates in an age-dependent manner. These results suggest that 
long-term exposure to low-level p25 expression can induce biochemical changes 
characteristic o f AD. Further, our findings show that key molecular players of AD are 
linked by regulation through common intersecting signalling pathways involving Cdk5 
and GSK3.
4.3) Discussion
4.3.1) The roles o f Cdk5 and GSK3 in tau hyperphosphotylation
Hyperphosphorylation o f tau is a characteristic feature o f neurodegenerative tauopathies 
including AD. Therefore, many studies tried to identify the protein kinases and protein 
phosphatases that are involved in the abnormal hyperphosphorylation o f tau. Numerous 
studies, both in vitro and in vivo, demonstrate that these sites are phosphorylated by 
proline-directed protein kinases, including Cdk5, ERK, GSK3, JNK and MAPKs (see, 
for example, Mandelkow et al., 1992; Reynolds et al., 2000; see for review Billingsley 
& Kincaid, 1997; Buee et a l,  2000). In addition, protein phosphatases including PP1, 
PP2A, PP2B and PP5 have been implicated in the regulation of the phosphorylation 
level o f tau (see, for example, Liu et al., 2005; for review, see Billingsley & Kincaid, 
1997; Buee et a l,  2000). However, at present, the results implicating the various kinases
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and protein phosphatases in the regulation of the many phosphorylation sites on tau are 
inconsistent.
The proline-directed serine/threonine kinase Cdk5 has been identified as prime 
candidate for phosphorylating tau at disease-associated sites characteristic for 
neurodegenerative tauopathies (see for review Shelton & Johnson, 2004). Cdk5 co- 
localises with filamentous tau deposits and has enhanced activity in several tauopathies, 
including AD (Augustinack et al., 2002b; Lee et al., 1999). Numerous in vitro studies 
implicate Cdk5 in the phosphorylation o f tau at several proline-directed sites (see, for 
example, Liu et al., 2002; Hamdane et al., 2003). In vivo studies using TG mouse lines 
expressing the Cdk5 activator p25 report tau hyperphosphorylation as tested by 
antibodies recognising disease-associated phospho-epitopes such as AT8 and PHF-1 
(Alijahnian et al., 2001, Cruz et al., 2003; Plattner et al., 2006). Therefore, it is 
currently believed that Cdk5 directly induces hyperphosphorylation o f tau at disease- 
associated sites and that this may subsequently trigger neurofibrillary tangle formation 
in tauopathies (see, for example, Cruz et al., 2003).
The results presented in this study do not support a direct role for Cdk5 in tau 
hyperphosphorylation at disease-associated sites. The p25 TG mice show no tau 
hyperphosphorylation at young age despite a persistent two-fold increase in Cdk5 
activity. Consistently, other TG mouse lines expressing p25 do not exhibit tau 
hyperphosphorylation, even though Cdk5 activity is enhanced (Takashima et al., 2001; 
Noble et al., 2003). However, I observe increased tau hyperphosphorylation at the AT8 
and PHF-1 epitopes in our p25 TG mice at an old age. This raises the question as to why 
in the p25 mouse line, tau hyperphosphorylation only becomes apparent with advancing 
age. One possibility is that long-term exposure to p25 is required to induce tau 
hyperphosphorylation. Thus, initial Cdk5 over-activation may be compensated by 
phosphatases and degradation of hyperphosphorylated proteins by proteases. However, 
this compensation may not be maintained over long periods or in old age.
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Another possibility is that Cdk5 is not directly involved in the hyperphosphorylation of 
tau and additional factors are required, triggered only in old age. In fact, I found that the 
activity o f the proline-directed kinase, GSK3, is reduced in young TG mice, but 
increased in old TG mice. Hence, the elevated GSK3 activity correlates with the age- 
dependent increase in tau hyperphosphorylation at the AT8 and PHF-1 site. GSK3 is 
another major candidate for mediating tau hyperphosphorylation and has been shown to 
phosphorylate proline-directed serine/threonine sites similarly to Cdk5 (Mandelkow et 
al., 1992; Hanger et al., 1992; Hong et al., 1997, Lucas et al., 2001;). GSK3 has been 
observed to generate disease-associated phospho-epitopes on tau (Nishimura et al., 
2004) and co-localises with aggregated hyperphosphorylated tau (Ishizawa et al., 2003). 
In this study I demonstrate that chronic treatment with lithium, a GSK3 inhibitor, 
reduced the levels o f tau hyperphosphorylation at the AT8 and PHF-1 sites in the old 
TG mice strongly suggesting that GSK3 is a key mediator o f tau hyperphosphorylation 
at these sites. This contention is supported by a study in p35 null mutant mice (Hallows 
et al., 2003). The p35 null mutants have reduced Cdk5 activity, but enhanced GSK3p 
activity, which coincides with increased levels of tau hyperphosphorylation. 
Experiments using the fruit fly, Drosophila melanogaster, show that the PHF-1 
phospho-epitope on tau contains GSK3-specific phosphorylation sites, but is not 
modified by Cdk5 (Nishimura et a l ,  2004). Further evidence for an indirect 
involvement o f Cdk5 in tau hyperphosphorylation via the regulation o f GSK3 comes 
from a recent study using yeast expressing human tau (Vandebroek et al., 2006). In this 
model it has been observed that Mdsl, the GSK3 orthologue in yeast, mediates 
hyperphosphorylation o f tau at disease-associated phospho-epitopes. In contrast, the 
Cdk5 orthologue Pho85 does not phosphorylate tau, but in fact acts indirectly as a 
negative regulator of tau hyperphosphorylation. In line with the observation that GSK3 
is mediating tau hyperphosphorylation at disease-associated epitopes, the analysis of a 
TG mouse line over-expressing GSK3p, which displays enhanced GSK3 activity 
revealed that tau hyperphosphorylation at the AT8 and PHF-1 sites was significantly 
increased (Lucas et a l,  2001). Further, this study localises tau phosphorylated at the
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PHF-1 epitope at somatodendritic sites. However, no tau filament formation was 
observed in the GSK30 over-expressing TG mice (Lucas et al., 2001; Hernandez et al.,
2002). Taken together, these results indicate that GSK3 acts as a key mediator o f tau 
phosphorylation at the disease-associated sites, AT8 and PHF-1. Further these results 
consistently show that Cdk5 negatively regulates GSK3 activity and suggest that Cdk5 
indirectly affects tau hyperphosphorylation via the regulation of GSK3.
Some o f the GSK3-mediated tau phosphorylation requires priming by other kinases 
including Cdk5, PKA and PAR-1 kinase (Sengupta et a l ,  1997; Nishimura et al., 2004; 
Li & Paudel, 2006). It has been suggested that once a priming site on tau is modified, 
GSK3 can sequentially phosphorylate neighbouring sites and hence induce 
hyperphosphorylation (Cho & Johnson, 2003). Therefore, the priming of tau 
phosphorylation sites may constitute another mechanism, next to the inhibitory 
regulation of GSK3|3, by which over-activation of Cdk5 could affect tau 
hyperphosphorylation. Recent studies have involved Cdk5 in the priming o f tau at the 
individual sites Ser202 and Ser404 for GSK3p (Li & Paudel, 2006; Li et al., 2006). It is 
thought that priming of these sites by Cdk5 and subsequent phosphorylation at the 
neighbouring sites by GSK3P results in the generation o f the disease-associated 
phospho-epitopes, AT8 and PHF-1, respectively. Because Cdk5 and GSK3 are 
simultaneously over-activated in old p25 TG mice, the two kinases may synergise to 
trigger tau hyperphosphorylation at these sites. Consistent with this contention, the AT8 
and PHF-1 sites are hyperphosphorylated in old TG mice. In this context, I have 
proposed that the inhibitory regulation of GSK3 by Cdk5 might represent an important 
mechanism to regulate the level of tau phosphorylation and prevent excessive 
phosphorylation at primed sites (Plattner et al., 2006).
Numerous protein kinases have been implicated in the phosphorylation of tau at 
multiple individual serine/threonine residues (see for review Billingsley & Kincaid, 
1997; Buee et a l, 2000). However, it is not established, which individual residues on
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tau are phosphorylated under physiological conditions and which are the kinases that 
mediate the tau phosphorylation at the different residues. Further, it is unclear what 
functions, if  any, the phosphorylation of the individual sites on tau serves. Here, GSK3 
has been specifically implicated in the hyperphosphorylation of tau at the AT8 
(Ser202/Thr205) and PHF-1 (Ser396/Ser404) sites in vivo, possibly in conjunction with 
the priming o f these sites by Cdk5. Consistent with this finding, TG mice over­
expressing GSK3P exhibit tau hyperphosphorylation at the AT8 and PHF-1 site (Lucas 
et al., 2001). Interestingly, an in vivo study where PKA activity was altered by 
pharmacological means, found that PKA specifically phosphorylates the individual sites 
Ser202, Ser214 and Ser404 and primes tau for subsequent modification by GSK3 (Liu 
et al., 2004). Consistent with the notion that PKA mediates phosphorylation at the 
ATI00 (Ser214 and/or Ser212) site, the p25 TG mice do not display increased 
phosphorylation levels at the AT 100 site, suggesting that this site is not phosphorylated 
by Cdk5 or GSK3 in vivo. Together, these data suggest that distinct protein kinases 
mediate phosphorylation at specific sites on tau. Thus, it is conceivable that distinct 
kinases may regulate various physiological functions o f tau by differential 
phosphorylation of individual sites.
4.3.2) Regulatory cross-talk between Cdk5 and GSK3
The present study describes a regulatory cross-talk between Cdk5 and GSK3 (for 
proposed model see Fig. 4-24 and 4-25). In young TG mice this regulation appears to be 
dependent on phosphorylation of GSK3 at the inhibitory serine site. The 
phosphorylation of GSK3P at Ser9 is increased resulting in significantly reduced 
GSK3P activity. Hence, this finding implicates p25-induced Cdk5 over-activation in the 
inhibitory regulation of GSK3P by affecting the level of Ser9 phosphorylation. 
Consistently, a study in p35 null mutant mice shows that the reduction in Cdk5 activity 
coincided with increased GSK3 activity (Hallows et al., 2003). Moreover,
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pharmacological inhibition of Cdk5 with olomucine and roscovitine induces activation 
of GSK3 (Morfini et al., 2004). The molecular mechanisms that lead to inhibition of 
GSK3 by Cdk5 are not yet characterised. However, it is has been shown that the 
phosphorylation at the inhibitory serine site on GSK3 is not directly mediated by Cdk5 
(Morfini et al., 2004). Hence, it is conceivable that Cdk5 affects the inhibitory GSK3 
phosphorylation indirectly via intermediate protein kinases and phosphatases. My 
results suggest that Cdk5 does not act via AKT and p90Rsk, two kinases directly 
implicated in the inhibition o f GSK3. In fact, my data indicate that Cdk5 mediates its 
inhibitory control over GSK3 via the regulation o f protein phosphatases, including PP1 
and PP2A. Here, I observe that application of okadaic acid, a specific PP1 and PP2A 
inhibitor, reduces GSK3p activity in TG mice, but not WT controls. Consistently, a 
pharmacological study proposed the involvement o f PP1 in the inhibitory regulation of 
GSK3 (Morfini et al., 2004). This study demonstrated that inhibition o f Cdk5 led to 
increased levels o f GSK3 activity, which could be reversed by blocking PP1. Moreover, 
a functional link between Cdk5, GSK3p and PP2A is further supported by my finding 
that these molecules associate with each other in a complex. Accordingly, other studies 
report the association o f Cdk5 and GSK3P in a functional complex approximately 450 
kDa in mass weight, which contains tau (Li et al., 2006). These data implicate Cdk5 and 
GSK3 in the formation o f protein complexes with PP1, Inhibitor 2, and 14-3-3 
(Agarwal-Mawal & Paudel, 2001; Agarwal-Mawal et al., 2003). Within such protein 
complexes the associated proteins are often regulated via functional cross-talk. In fact, 
protein phosphatase activity is commonly regulated by association with regulatory 
partners. For example, for PP1 more than fifty regulatory subunits have been described 
(see for review Cohen, 2002). Furthermore, it has been demonstrated that the function 
of several regulatory subunits of PP1 is controlled directly via phosphorylation. 
Interestingly, Cdk5 and GSK3 have been implicated in the phosphorylation of 
phosphatase-regulating molecules including Inhibitor 1 and 2 as well as DARPP32 
(Bibb et al., 1999; Bibb et al., 2001; Agarwal-Mawal & Paudel, 2001). Similar 
molecular mechanisms have been implicated in the regulation of PP2A activity (Winder
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& Sweatt, 2001). From this, I propose that Cdk5 directly controls the activity of a 
regulatory subunit, which in turn exerts an effect on PP1 and/or PP2A and ultimately 
the activity o f GSK3.
In contrast to young TG mice, where GSK3 activity is reduced, old TG mice have 
increased levels o f GSK3 activity. Curiously, in old TG mice GSK3 activity is 
increased, despite equivalent phosphorylation levels at the inhibitory and activatory 
sites o f GSK3 in old TG mice and old WT littermates. This suggests that in old TG 
mice the inhibitory control o f GSK3 by Cdk5 is lost and additional mechanisms, other 
than phosphorylation o f the regulatory sites, regulate the activity o f GSK3p. Alternative 
mechanisms might include differences in protein complex formation involving GSK3 or 
alterations in subcellular localisation o f GSK3. It is conceivable that in young TG mice 
that the presence of p25 leads to an altered subcellular localisation and complex 
composition or to differences in the regulation within protein complexes. Consistently, I 
find that application o f okadaic acid, a specific PP1 and PP2A inhibitor, differently 
affects GSK3 activity in young TG mice and WT controls. This suggests that the protein 
complex containing GSK3, Cdk5 and PP2A is functionally different in young TG mice 
as compared to young WT littermates. Based on these results, I propose that the 
presence of p25 induces functional changes within protein complexes in young TG mice 
resulting in increased Ser9 phosphorylation and in turn reduced GSK3P activity 
(Plattner et al., 2006). Long-term exposure to p25 expression disrupts this altered 
regulatory control of GSK3 resulting in elevated GSK3 activity in old TG mice. 
Together, these findings suggest that GSK3 activity is regulated by an intricate inteiplay 
of protein phosphatases, kinases and possibly other associated proteins. Further studies 
will be required to characterise the molecular mechanisms by which Cdk5 regulates 
GSK3. As the age-dependent disruption of the regulatory cross-talk between GSK3 and 
Cdk5 may underlie tau hyperphosphorylation in neurodegenerative tauopathies, it will 
be paramount to elucidate this regulatory signalling pathways.
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4.3.3) Comparison o f the different p25 TG mouse lines
Several TG mouse lines with p25 expression have been generated (for a summary of 
p25 TG mouse lines, see Table 1-6). The expression of p25 resulted in an over­
activation of Cdk5 in all TG mouse lines. Subsequently, these p25 TG lines were used 
to test the involvement o f Cdk5 in tau hyperphosphorylation. The onset and the level of 
tau hyperphosphorylation varied markedly between the different p25 TG mouse lines. 
The trend observed in studies examining TG animals at older ages is of increased levels 
of tau phosphorylation. One study looking at young TG animals did observe no tau 
hyperphosphorylation (Takashima et al., 2001). These results imply that prolonged p25 
expression leads to higher levels o f tau hyperphosphorylation. Further, these results 
show that increased levels o f tau phosphorylation occur only after a certain period of 
p25 expression. Next to the age factor, the difference in p25 expression levels between 
the TG mouse lines might be responsible for the variation between the results. 
Transgenic mouse lines expressing higher levels of p25 display higher levels o f tau 
phosphorylation or an earlier onset o f tau hyperphosphorylation (Bian et al., 2002; Cruz 
et al., 2003). The analysis o f two TG mouse lines expressing p25 at different levels in 
young age, revealed tau hyperphosphorylation in the high level p25 expressing line, but 
not in the low level p25 expressing (Cruz et al., 2003). Interestingly, in most studies the 
presence o f p25 resulted in an approximately two-fold increase in Cdk5 activity, 
independently of the p25 level (Table 1-6). Hence, higher p25 expression did not 
correlate with higher Cdk5 over-activation in the TG mouse lines. This raises the 
concern that high levels of p25 expression might affect other molecular mechanisms 
next to over-activation of Cdk5. For example, it was suggested that high levels o f p25 
could also be toxic per se (Bian et al., 2002). Accordingly, a recent study has implicated 
the formation o f p25 in excitotoxicity and neuronal cell death via the regulation of  
nuclear processes (O’Hare et al. 2005). Two of the p25 TG mouse lines were reported 
to form aggregates o f hyperphosphorylated tau, similar to NFTs observed in AD 
patients (Nobel et al., 2003; Cruz et al., 2003). Further, in a inducible p25 TG mouse
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line immunoblot and immunohistological analyses revealed neurodegeneration and 
gliosis (Cruz et al., 2003). However, recent data indicates that the “neurodegeneration” 
in this inducible p25 TG line is not linked to increased levels of tau 
hyperphosphorylation (Fischer et al., 2005).
Together, these results indicate that the protein kinase complex p25/Cdk5 plays a role in 
the phosphorylation o f tau at proline-directed sites, where the duration of p25 exposure 
and the level of p25 are important parameters determining the degree of tau 
phosphorylation. However, these studies do not provide evidence that p25/Cdk5 directly 
mediates tau hyperphosphorylation and they cannot exclude that p25/Cdk5 is indirectly 
involved in tau phosphorylation by regulating other kinases or phosphatases. In fact, my 
data indicate that GSK3 mediates tau hyperphosphorylation, whereas Cdk5 acts as a 
modulator o f tau hyperphosphorylation via the inhibitory control over GSK3. However, 
prolonged exposure to p25 deregulates the cross-talk between Cdk5 and GSK3, leading 
to increased GSK3 activity and in turn to hyperphosphorylation of tau. It is conceivable 
that higher levels o f p25 or prolonged exposure to p25 are more likely to disrupt the 
regulatory cross-talk between Cdk5 and GSK3. Hence, this could explain why tau 
hyperphosphorylation was observed predominantly in high level p25 expressing TG 
mouse lines or in studies analysing p25 TG mouse lines at old ages. Further, this could 
explain the heterogeneity within the results from different p25 TG mouse lines and 
other studies on Cdk5 involvement in tau hyperphosphorylation (e.g. cell culture 
experiments; compare Kerokoski et al., 2002 and Hamdane et al., 2003). As the level of 
p25 and the duration of p25 exposure vary between the different studies, it is 
conceivable that different levels of tau phosphorylation are observed. Moreover, as a 
short period of high level p25 expression and a long period of low level p25 expression 
lead similarly to tau hyperphosphorvlation, it suggest that comparable processes are 
induced in both cases, independently of ageing factors. Further research will be required 
to elucidate the role of Cdk5 in intracellular signalling, aggregation of 
hyperphosphorylated tau and neurodegeneration. This question is complicated by the
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fact that the expression of p25 induces numerous other molecular changes, which might 
impact generally on protein phosphorylation, protein degradation and cell survival. To 
overcome these confounding factors, new research strategies need to be applied.
4.3.4) Implication o f Cdk5 in APP processing
APP is phosphorylated at the residue Thr668 specifically by Cdk5 (Iijima et al., 2000). 
Consistently, p25-induced Cdk5 over-activation increased the phosphorylation level of 
APP at Thr668 in the p25 TG mice. Interestingly, the increased phosphorylation 
occurred predominantly in an immature APP isoform running at approximately 62 kDa 
and to a lesser extend in mature isoforms running at 110-120 kDa in the p25 TG mice. 
In line with this, over-expression of p25 in cell cultures induces predominantly 
phosphorylation of immature APP isoforms, whereas over-expression o f p35 triggered 
phosphorylation of both mature and immature APP at Thr668 (Liu et al., 2003). The 
phosphorylation at Thr668 has been implicated in protein complex formation and 
protein localisation (Suzuki et al., 1994; Iijima et a l., 2000). Hence, it is possible that 
p25/Cdk5 and p35/Cdk5 phosphorylate different pools o f APP according to their 
cellular localisation and in turn regulate distinct functions o f APP. Further, recent in 
vitro studies link Thr668 phosphorylation with altered processing of APP (Liu et al., 
2003; Lee et al., 2003). These studies implicate increased APP phosphorylation and 
Cdk5 activity with elevated APP processing resulting in enhanced Ap-peptides 
production and secretion o f sAPPa as well as sAPPp. However, these studies are 
contradictory to another finding showing that inhibition of Cdk5 stimulates AP 
production in vitro and in vivo (Ryder et al., 2003). Consistent with this, I find that 
despite increased APP phosphorylation levels and Cdk5 over-activation, APP 
processing is not changed in young p25 TG mice. Nevertheless, APP processing is 
altered in old p25 TG mice, where both Cdk5 and GSK3 activity are increased; I 
observed an age-dependent accumulation of a 57 kDa fragment containing the AP-
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peptide domain. Because p25-induced Cdk5 over-activation did not lead to altered APP 
processing in young p25 TG mice, it is conceivable that the accumulation o f the 57 kDa 
fragment in old p25 TG is due the enhanced activity of GSK3. Consistent with this 
assumption are data showing the involvement of GSK3 in APP processing (Phiel et al., 
2003; Ryder et a l , 2003). These data demonstrate that inhibition of GSK3 
(pharmacological agents or siRNA) reduces the production of Ap-peptides in vitro and 
in vivo. Because o f the regulatory cross-talk between Cdk5 and GSK3, inhibition of 
Cdk5 results in enhanced GSK3 activity. Hence, it is possible that in the studies, in 
which Cdk5 inhibitors are used, the increased APP processing actually is due to 
enhanced GSK3 activity.
The 57 kDa fragment could not be detected with antibodies against the amino- and 
carboxy-terminal parts of APP. This observation suggests that the 57 kDa fragment 
lacks the amino-terminal and carboxy-terminal parts. There are several cleavage sites 
for proteases and secretases in the carboxy-terminal portion of APP. Thus, it is possible 
that the carboxy-terminus is cleaved off, but this would not release a 57 kDa APP 
fragment. Further, in the outer amino-terminal part there are no cleavage sites known, 
that can lead to the generation of a 57 kDa APP fragment. As this fragment could only 
be detected with Ap-specific antibody, it is also possible that the band running at 57 
kDa constitutes of an aggregate o f multiple AP-peptides. Consistent with this idea, a 
recent study reports the accumulation of an multimeric 56 kDa Ap-peptide complex in 
TG mice over-expressing mutant APP (Lesne et a l,  2006). This 56 kDa Ap-complex is 
stable under normal denaturing conditions used in common immunoblotting protocols. 
Interestingly, as this study links the presence of the 56kDa Ap-complex to memory 
impairments, the authors suggest that this Ap-complex might be responsible for the 
cognitive decline in AD.
Together, these results indicate an interplay between Cdk5 signalling and APP 
processing. Further evidence for such cross-talk comes from the study of the Tg2576
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transgenic mice expressing mutated human APP, which display formation of p25 (Otth 
et al., 2002). Moreover, a recent study describes the formation o f p25 in presenilin 1/2 
double mutants (Saura et al., 2004). Mutations in APP, as well as in presenilin 1 and 2 
have been identified as cause for inherited familial forms o f AD. Over 100 mutations in 
these three genes can each trigger the early onset of pathology apparently via over­
production of AP-peptides (Tanzi & Bertram, 2001). Thus, it is intriguing to speculate 
that APP and presenilin share common signalling pathways that involve Cdk5 and 
GSK3. Further, disruption of these signalling pathways might constitute underlying 
mechanisms in the onset o f AD pathology.
4.3.5) Involvement o f p25/Cdk5 in molecular processes underlying synaptic plasticity, 
learning and memory
Previously, p25/Cdk5 has been implicated in synaptic plasticity, learning and memory 
(Angelo et al., 2003; Ris et al., 2005). Electrophysiological characterisation of the p25 
TG mice revealed that CA1 LTP was elevated in female, but decreased in male TG mice 
(Ris et al., 2005). Consistent with this observation, spatial learning was enhanced in 
female p25 TG mice as compared to female WT controls, but it was not affected in male 
TG mice (Ris et al., 2005). Another study analysing inducible p25 TG mice has 
reproduced these findings, that p25-expression triggers enhanced CA1-LTP and 
improved learning and memory (Fischer et a l , 2005). However, it is yet not understood 
how p25/Cdk5 expression might induce enhancement of LTP and memory. One 
candidate mechanism is the regulation of NMD A receptor function by Cdk5. 
Phosphorylation of the NMDA receptor subunit NR2A by Cdk5 was shown to enhance 
the conductance o f the channel (Li et al., 2001; Wang et al., 2003). Further, as p25- 
expression has been implicated in spine density increases, it was hypothesised that Cdk5 
affects plasticity and memory-related processes via the regulation of spine numbers 
(Fischer et al., 2005).
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The biochemical characterisation of the p25 TG mice presented here, identifies several 
alterations in molecular mechanisms, which may underlie the changes observed in 
synaptic plasticity and memory in the p25 TG mice. I found that ERK activity is 
significantly reduced in the p25 TG mice. ERK is part o f the MAPK signalling pathway 
that regulates numerous cellular processes such as transcription and ion channel 
modulation (Sweatt, 2004). In fact, the MAPK pathway including ERK has been 
involved in synaptic plasticity and memory (Sweatt, 2004). The idea that p25/Cdk5 
affects synaptic plasticity and memory via the control of the MAPK pathway are 
supported by preliminary electrophysiological studies. The deficits in CA1 LTP in male 
p25 TG mice can be reversed by treatment with anisomycin, which is an activator of 
ERK (Laurence Ris, unpublished observation). Hence, it is conceivable that inhibition 
of ERK by Cdk.5 is implicated in the impairment of CA1 LTP in male TG mice. 
Another interesting link is the involvement of ERK in oestrogen signalling pathways. 
As oestrogens have been implicated in sex-specific plasticity changes, it is conceivable 
that the male/female divergence in p25 TG mice results from the modulation of 
oestrogen signalling via the regulation of ERK.
The regulation of GSK3 activity might constitute another mechanism by which 
p25/Cdk5 affects synaptic plasticity and memory. The inhibitory phosphorylation at 
Ser9 of GSK3 is significantly increased in young p25 TG mice, which consequently 
resulted in reduced GSK3(3 activity. As described in section 3.3.3, GSK3 is an emerging 
molecular player in plasticity and memory-related processes. Consistently, increased 
activity o f GSK3 has been reported to impair spatial learning (Hernandez et al., 2002). 
Hence, it is conceivable that increased inhibition of GSK3 may lead to an enhancement 
of some forms of synaptic plasticity and memory. Obviously, further biochemical and 
electrophysiological characterisation of the p25 TG mice will be required to elucidate 
the molecular changes underlying the alteration in synaptic plasticity, learning and 
memory in the TG mice.
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4.4) Conclusion
The biochemical analysis o f the p25 TG mouse line revealed that p25-induced Cdk5 
over-activation, surprisingly, did not generally perturb cellular function, despite the 
critical involvement o f Cdk5 in various processes from synaptic plasticity to cell 
survival (see for review Dhavan & Tsai, 2003; Angelo et a l,  2006). Instead subtle and 
well-demarcated molecular changes were observed. This underscores the high degree of  
regulatory and compensatory capacity o f the involved molecular mechanisms. The 
findings presented here, show that long-term exposure to Cdk5 over-activation 
undermines these well-balanced processes, which subsequently results in increased tau 
hyperphosphorylation and altered APP processing. The findings that the 
phosphorylation level o f tau as well as the processing o f APP are affected by the 
p25/Cdk5 holoenzyme is indicative that both o f these processes are regulated by 
common underlying molecular mechanisms. This observation may be important to 
understand neurodegenerative diseases, especially AD. The neuropathological 
characteristics o f AD include the accumulation of hyperphosphorylated tau in tangles 
and of Ap-peptides in plaques. Hence, it is conceivable that the derangement o f similar 
common molecular mechanisms are equally responsible for the formation of tangles and 
plaques in AD. It will be paramount to elucidate the molecular mechanisms that become 
deranged in the p25 TG mice in order to understand the processes underlying 
accumulation o f hyperphosphorylated tau and the processing of APP and investigate the 
relevance o f these mechanisms in neurodegenerative diseases including AD.
The present study establishes distinct roles o f Cdk5 and GSK3 in tau 
hyperphosphorylation. Increased levels o f tau hyperphosphorylation at the disease- 
associated AT8 and PHF-1 sites was linked to enhanced GSK3 activity. The p25- 
induced Cdk5 over-activation was not found to directly hyperphosphorylate tau, but was 
implicated in the inhibitory regulation of GSK3. In fact, these findings indicate that 
GSK3 acts as a key mediator o f tau hyperphosphorylation at the AT8 and PHF-1 sites,
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whereas Cdk5 indirectly affects tau hyperphosphorylation via the regulation of GSK3. 
Moreover, these observations may have important implications for the development of 
therapeutic treatments of neurodegenerative tauopathies. The application of 
pharmacological inhibitors of Cdk5 may not be an effective treatment for tau 
hyperphosphorylation, as the results suggest that inhibition of Cdk5 induces GSK3 
activity and this may subsequently lead to enhanced tau phosphorylation. In fact, these 
findings support the idea that GSK3 inhibitors may be a useful tool for therapeutic 
intervention to reduce tau hyperphosphorylation and possibly the burden of tau 
aggregates in neurodegenerative tauopathies. Moreover, inhibition of GSK3 was also 
reported to lead to reduced A(3-peptide formation (Phiel et al., 2003). Hence, in 
conjunction, these data make GSK3 a prime therapeutic target in AD.
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CHAPTER 5: General discussion and outlook
5.1) General discussion
The characterisation of genetically-modified mouse strains by behavioural, biochemical, 
electrophysiological and pharmacological techniques allows investigation of the 
function of specific molecules at different levels of organisation within the brain. This 
multilevel analysis of genetically-modified mouse lines has greatly furthered the 
understanding of the molecular mechanisms underlying synaptic plasticity and helped to 
explore the molecular processes implicated in neurodegenerative diseases.
In the study presented here, biochemical changes were analysed in two different lines of 
genetically-modified mice. One mouse line carries a point mutation in the aCaMKII 
gene, disenabling the autophosphorylation at Thr286. The other mouse line expresses 
the Cdk5 activator p25 at low levels predominantly in forebrain. Previous evaluation of 
these genetically-modified mouse lines demonstrated that they are suitable for further 
analysis, as the genetic modifications did not interfere with their viability or fertility 
(see, for example, Giese et al., 1998; Angelo et al., 2003). In addition, the two lines 
displayed no obvious developmental abnormalities and exhibited gross normal anatomy 
of the brain structures. Subsequently, both mouse strains were assessed in behavioural 
assays that showed that the genetic alterations had significant effects on behavioural 
performance of these mouse lines (see, for example, Giese et al., 1998; Angelo et al.,
2003). Further, electrophysiological characterisation of the mouse lines revealed that the 
genetic modifications affected synaptic plasticity (see, for example, Giese et al., 1998; 
Ris et al., 2005). These findings suggest that aCaMKII as well as p25/Cdk5 are 
implicated in molecular mechanisms underlying synaptic plasticity as well as learning 
and memory processes. Accordingly, the analysis of numerous other genetically-
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modified mouse lines have correlated synaptic plasticity changes with altered 
acquisition and storage of memory. Further, these studies greatly helped to advance the 
knowledge on molecular mechanisms underlying synaptic plasticity and provided ample 
evidence that the molecular mechanisms implicated in the induction and maintenance of 
synaptic plasticity changes might also play critical roles in learning and memory 
processes (see for review Martin & Morris, 2002; Silva, 2003). Many mouse lines have 
been characterised, where the genetic modification induced LTP deficits that coincided 
with behavioural impairments (see for review Bockamp et al., 2002; Martin & Morris, 
2002; Silva, 2003). As with the p25 TG mice, other genetically-modified mouse lines 
exhibit increased LTP, correlated with memory enhancements (see, for example, Jeon et 
al. 2003 and Madani et a l 1999). Despite the most results from genetically-modified 
mouse lines support the notion that changes in synaptic efficacy underlie learning and 
memory processes. However, the relationship of synaptic plasticity and memory is still 
correlative.
The aCaMKII T286A mutant mouse line as well as the p25 TG mouse line 
simultaneously display changes in synaptic plasticity and altered learning and memory. 
Therefore, I assessed these two mouse lines for biochemical changes, in order to get 
more information on the underlying molecular mechanisms that lead to alterations in 
synaptic plasticity and in memory. The analysis of basal phosphorylation levels of 
CaMKII substrates revealed changes between the aCaMKII T286A mutants and WT 
mice indicating that the autonomous aCaMKII activity mediates phosphorylation of 
specific substrates. To investigate biochemical changes induced by activity-dependent 
synaptic plasticity changes, we established an in vivo LTP approach. Consistent with 
previous studies, induction of LTP triggered increased phosphorylation levels of several 
marker proteins including CREB in the hippocampal subfields, CA1 and DG in vivo. 
This result confirms that the in vivo LTP approach is suitable to investigate molecular 
mechanisms underlying synaptic plasticity changes in different mouse lines.
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Furthermore, I assessed phosphorylation changes in p25 TG mice. The p25-induced 
Cdk5 over-activation induced enhanced phosphorylation on several proteins including 
ERK, which has been implicated in synaptic plasticity (Sweatt, 2004). Together, the 
biochemical analysis revealed that both genetically-modified mouse lines exhibit subtle 
and well-demarcated alterations in phosphorylation levels. The genetic alterations did 
not affect critical cellular processes in a manner that it would induce severe 
malfunctions. These observations demonstrate that the two mouse lines are suitable 
models to investigate the functions of autonomous aCaMKII and p25/Cdk5 activity and 
their further analysis promises to yield critical new insights. Interestingly, recent 
advances revealed an intriguing relationship between CaMKII and the p35/Cdk5 
holoenzyme, which might have important implications for synaptic plasticity and 
memory. It was observed that inhibition of Cdk5 resulted in enhanced CaMKII 
autophosphorylation and subsequently increased CaMKII activation (Hosokawa et al., 
2006). Consistent with such molecular interplay is the finding that CaMKII associates 
with the Cdk5 activators p35 and p39 in an Ca2+-dependent manner (Dhavan et al., 
2002). The fact that CaMKII and Cdk5 seem to be involved in common synaptic 
processes, puts an interesting spin on the analysis of the two genetically-modified 
mouse lines presented here. Hence, these two mouse lines can be utilised to investigate 
the role of the molecular relationship between CaMKII and Cdk5 in synaptic plasticity 
and memory.
In recent years, genetically-modified mouse lines were commonly used to model aspects 
of neurodegenerative diseases. The identification of molecules carrying mutations 
responsible for inherited forms of neurodegenerative diseases and the characterisation of 
pathological proteins from post-mortem tissue allowed the generation of mouse models 
of neurodegenerative diseases (see for review Ashe, 2001; Lee et al., 2005). Because 
the Cdk5 activator p25 has been found to accumulate specifically in brains of AD 
patients but not healthy individuals, it was postulated that p25 is implicated in AD 
(Patrick et al., 1999). In the present study, I analysed a TG mouse line expressing p25,
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in order to asses the involvement of p25/Cdk5 in molecular processes underlying 
tauopathies including AD. I found that p25-induced Cdk5 over-activation affects both 
the level of tau hyperphosphorylation and APP processing in an age-dependent manner. 
These observations show that the p25 TG mouse line models some aspects of 
tauopathies and hence represent a useful tool to study the molecular mechanisms of 
tauopathies including AD.
In summary, my studies validate the use of genetically-modified mouse lines for 
investigating the molecular mechanisms underlying activity-dependent synaptic 
changes. Further, genetically-modified mice are an adequate tool to model 
neurodegenerative diseases and hence, study the molecular mechanisms implicated in 
the ontogeny of the diseases.
5.2) Outlook
The biochemical analysis of the two genetically-modified mouse lines presented here, 
revealed a number of interesting molecular changes. These data provide a good 
fundament for future experiments to further characterise the two mouse lines and 
subsequently get more insights on the molecular mechanisms involving CaMKII and the 
p25/Cdk5 holoenzyme.
Currently, there is only limited knowledge as to which proteins are phosphorylated by 
aCaMKII and which of these substrates are critically involved in activity-dependent 
synaptic plasticity changes. The data presented here, showed that the disenabling point 
mutation of aCaMKII affects the basal phosphorylation level of several proteins in 
T286A mutant mice. Hence, the identification of the proteins with altered 
phosphorylation levels can reveal substrates, which undergo phosphorylation
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specifically mediated by autonomous aCaMKII activity and which are possibly 
implicated in synaptic plasticity and memory processes.
In order to study biochemical changes after synaptic potentiation, I established an in 
vivo LTP approach in collaboration with Dr Sam F. Cooke and Prof. Tim V.P. Bliss. 
The data presented here, confirmed that this approach is suitable to investigate 
molecular mechanisms underlying activity-dependent synaptic plasticity changes. The 
induction of LTP in area CA1 is abolished by the T286A point mutation indicating that 
autonomous aCaMKII activity is essential for CA1 LTP. Thus, future studies can 
exploit the in vivo LTP approach to detect biochemical changes in T286A mutants and 
WT mice after CA1 LTP induction. The comparison of protein phosphorylation levels 
after CA1 LTP induction between T286A mutants and WT mice can be used to 
characterise proteins, which are regulated by autonomous aCaMKII activity and which 
may be required for the induction and expression of CA1 LTP. The present study also 
showed that LTP induction in the two hippocampal subfields DG and CA1 is supported 
by distinct molecular mechanisms. The in vivo LTP approach can therefore be applied 
to investigate the different molecular mechanisms underlying LTP in DG and CA1.
The analysis of the p25 TG mouse line presented here, revealed several biochemical 
changes. Low-level expression of p25 interfered with APP processing and tau 
hyperphosphorylation, two molecular processes affected in neurodegenerative diseases. 
A 57 kDa APP fragment was observed to accumulate in an age-dependent manner in the 
p25 TG mice. The role for Cdk5 in APP processing can be studied by characterising the 
57 kDa fragment and investigating the molecular mechanisms involved in the formation 
of this fragment. The data presented here indicate that there is cross-talk between Cdk5 
and GSK3, which is involved in the hyperphosphorylation of tau at the AT8 and PHF-1 
site. As tau hyperphosphorylation at these sites might serve cellular functions, the 
analysis of the p25 TG mice may be used to investigate the physiological roles of tau 
and the hyperphosphorylation of tau. The characterisation of the molecular mechanisms
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underlying the inhibitory regulation of GSK3 by Cdk5 will help to elucidate the link 
between these two kinases and tau hyperphosphorylation. Moreover, the 
characterisation of these molecular mechanisms might also reveal suitable candidate 
molecules as targets for drug development.
Electrophysiological and behavioural analysis of the p25 TG mouse line revealed a sex- 
specific increase in LTP and improved learning and memory (Ris et al., 2005). Thus, 
further investigation of the p25 TG mice may reveal the molecular mechanisms 
underlying the alterations in LTP and the behavioural phenotype. A detailed 
electrophysiological characterisation might be used to evaluate, which signalling 
processes are altered in the TG mice. Moreover, activity-dependent changes could be 
assessed applying the in vivo LTP approach in the p25 TG mice. The data presented 
here and elsewhere, support a physiological role for p25, possibly in synaptic plasticity. 
Hence, the in vivo LTP approach can also be employed to investigate whether there is 
activity-dependent formation of p25, and if so to study its physiological function. 
Furthermore, analysis of the p25 TG mice might be used to characterise substrates, 
which are specifically phosphorylated by the p25/Cdk5 holoenzyme.
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Figure 1-1. The trisynaptic circuit in hippocampus. Schema of a transverse section through the 
hippocampus of a mouse. The principal hippocampal subfields include the dentate gyrus (DG) 
with the granule cells, the area CA3 and CA1 with the pyramidal cells. The main excitatory 
afferent projections include the perforant path from entorhinal cortex to granule cells, the mossy 
fibre projection from granule cells to CA3 cells and the Schaffer collateral-commissural pathway 
that connects ipsilateral and contralateral CA3 cells to CA1 cells. (Adapted from Bliss & 
Collingridge, 1993)
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Figure 1-2. Organisation of functional domains of aCaMKII. The aCaMKII protein (Swiss 
Prot|P11798|KCC2A_MOUSE) can be broadly divided into three functional parts, the catalytic 
(1-272), the regulatory (273-314) and the self-association domain (315-478). The regulatory 
domain contains the autoinhibitory site (282-300) and the calmodulin-binding site (293-308). 
Several variable inserts can be introduced into the self-association domain o f aCaMKII by 
alternative splicing. Phosphorylation at Thr286 switches aCaMKII into an autonomous activity 
mode that is Ca2+-independent (e.g. Miller & Kennedy, 1986). Phosphorylation at Thr305/306 
blocks activation of CaMKII by Ca2+/CaM and prevents the translocation of CaMKII to the post- 
synaptic density (e.g. Elgersma et al., 2002). Phosphorylation at Thr253 enhances the binding to 
the post-synaptic density (e.g. Migues et al., 2006) (Adaptedfrom Lisman et al., 2002)
FIGURES: Chapter 1
Inactive aCaMKII
Influx of
Ca2+
Autophosphorylation 
site (Thr286)
273
Ca2+/Calmodulin
Autoinhibitory 
Pseudosubstrate j /  domain 
segment ^ 3 1 4
1 Catalytic 
domainSubstrate 
binding site
Activated by 
Ca2+/Calmodulin
NR2B
Persistent activation by 
Thr286 autophosphorylation
P ersisten t activation through  
interaction (e.g. NMDA receptor)
Figure 1-3. The aCaMKII autophosphorylation switch. Under basal conditions the pseudo­
substrate region of aCaMKII is binding to its catalytic site and thereby inhibiting its enzymatic 
activity. Rise in Ca2+-levels triggers association o f the Ca2+/calmodulin (Ca2+/CaM) complex, 
which in turn binds to aCaMKII on a site overlapping with the pseudosubstrate region. This 
exposes the catalytic domain and renders aCaMKII active (asterix). In this Ca2+-activated state 
Thr286 can be autophosphorylated by neighbouring aCaMKII subunits. Once Thr286 is 
phosphorylated aCaMKII can not revert back in the inactive conformation, even after Ca2+-levels 
drop and Ca2+/CaM dissociates from the kinase. Hence, aCaMKII is in a persistent, autonomous 
state of activity that is Ca2+-independent and which can only be reversed via dephosphorylation of 
Thr286 by phosphatases. Alternatively, in the Ca2+-activated state aCaMKII can interact with 
proteins (e.g. NMDA receptor subunit NR2B), which in turn lock the kinase in the active 
conformation even after dissociation of Ca2+/CaM. (Adaptedfrom Lisman et al., 2002)
FIGURES: Chapter 1
(f^) Ca2+/calmodulin ^  Active catalytic site □  Phosphatase
Figure 1-4. Different activation modes in the CaMKII complex. A) The CaMKII holoenzyme 
consists of 12 subunits that associate in two stacks o f hexameric rings via their self-association 
domains (green). In the absence of Ca27calmodulin (Ca2+/CaM) the catalytic site (red) is 
inactivated by interaction with the regulatory domain (blue). Low Ca2+-levels trigger the 
formation of Ca2+/CaM complexes, which in turn bind to the regulatory domain o f some subunits 
within the holoenzyme. This interaction releases the catalytic domain and triggers the kinase 
activity. After the Ca2+-levels drop the CaMKII complex reverts back into the inactive state. B) 
Higher levels of Ca2+-influx and formation of more Ca2+/CaM complexes lead to the activation of  
several CaMKII subunits within a holoenzyme. This increases the probability that two 
neighbouring subunits become bound to Ca2+/CaM simultaneously. Coincident binding of 
Ca2+/CaM to two adjacent subunits allows one subunit to autophosphorylate the Thr286 site of its 
neighbouring subunit. The phosphorylation at Thr286 switches the subunit into an autonomous 
activity mode. Even after Ca2+-levels drop, this subunit retains its activity, until it becomes 
dephosphorylated. One implication o f the autophosphorylation switch is that during the next Ca2+- 
influx the binding of only one Ca2+/CaM, adjacent to the already autophosphorylated subunit, is 
required to autonomously activate the subunit. Hence, coincident Ca2+/CaM binding is no longer 
needed. This constitutes a mechanism that allows subunits in the autonomous activity state to 
switch even at lower Ca2+-levels. Another implication o f this Thr286 switch is that an entire 
holoenzyme can be switched into the autonomous mode, if  there is sufficient Ca2+/CaM to bind all 
subunits within a holoenzyme and trigger their autophosphorylation. This activated state o f the 
CaMKII holoenzyme has been proposed as a mechanism involved in the long-term storage of 
memory. (Adoptedfrom Lisman et al., 2002)
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Figure 1-5. The isoforms of the microtubule-associated protein tau. (A) Schematic 
representation of the six tau isoforms expressed in the central nervous system in the adult human 
(Swiss Prot|P10636|TAU_HUMAN). In the amino-terminus part exon 2 and 3 (E2 and E3) are 
alternatively spliced. The carboxy-terminus contains 4 repeats (R1-R4). Alternative splicing of 
exon 10 (E10) results in the formation of the 3R or 4R isoforms respectively. (B) Schematic 
representation of fetal-tau and peripheral nervous system (PNS) tau isoforms. Fetal-tau is the 
shortest isoform with 315aa. It contains an alternative amino-terminus and lacks exons 2, 3 and 
10. PNS-tau is the longest isoform with 757aa containing exons 2, 3 and 10. In addition, two large 
portions can be spliced into PNS-tau, a 250aa part at residue 124 encoded by exon 4A and 
possibly a 65aa part at residue 142.
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Figure 1-6. Organisation of domains on the microtubule-associated protein tau. Schematic 
representation of the human tau 441aa isoform (also tau-F or hTau40) containing exons 2, 3 and 
10 (Swiss-Prot: Tau-F, P10636-8). The projection domain contains an acidic and a proline-rich 
region and serves for interaction with cytoskeletal proteins and the plasma membrane. The 
carboxy-terminally located microtubule-binding domain containing the 4 repeats is involved in the 
regulation of microtubule polymerisation and the binding o f proteins including PP2A and 
presenilin. (Adoptedfrom Buee et al., 2000)
FIGURES: Chapter 1
1 MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT
51 PTEDG SEEPG
©
S ETSD A K STP TAEDVTAPLV
101 TTAEEAGIGD
©
TPSLEDEAAG HVTQARMVSK
151
©
IATPRGAAPP GQ^GQANATR
V©
IP A K T P P A P K
201
©  ©
GSPGTPGSR S
®  ©  ®  
R T P S L P T P P T
V
REPKKVAVVR
251 PDLKNVKS^I
©
GSTENLKHQP G G G K V Q IIN ^
301
©
PGGGSVQIVY KPVDLSKVTS
©
KCGSLGNIHH
351
V  ©
Q S K IG S L D N I t h v p g g g n I k IE T H K L T F R E
401
©  ©
GDTSPRHLSN
©
VSSTGSIDM V
©
DSPQLATLAD
® ©
CSPLQT
SKDGTGSDDK KAKGADGKTK
® ®
T P P S S G E P P K  SGDRSGYSSP
© V©
T P P K S P S S A K  SRLQTAPVPM 
V  ©
©
© proline-directed phosphorylation site 
© site phosphorylated by MARKs 
© site phosphorylated by CaMKII 
© site phosphorylated by PKA 
V  glycation
Figure 1-7. Post-translational modifications on tau. Amino acid sequence o f the tau-F isoform 
(Swiss-Prot entry TAU HUMAN PI0636). The tau-F isoform contains 441 amino acids and can 
be post-translationally modified at numerous sites via phosphorylation and glycation. Letters in 
bold indicate serine/threonine residues, for which phosphorylation has been reported.
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Figure 1-8. Organisation of functional domains in APP isoforms. APP is transcribed from a 
single gene, which subsequently gives rise to multiple isoforms by alternative splicing (Swiss 
Prot|P 12023|A4^MOUSE). The three major APP isoforms are APP770, APP751 and APP695 
(with the name indicating the number o f amino acids within the isoform). APP is a single 
transmembrane protein with a large extracellular amino-terminal part and a short intracellular 
carboxy-terminal portion. The extracellular part contains domains binding copper, zinc, heparin 
and collagen. The heparin and collagen binding domains have been implicated in the adhesion 
function of APP. Furthermore, it contains a kunitz protease inhibitor domain, which is spliced out 
in APP695 and two phosphorylation sites, possibly modified by casein kinase. There are two 
extracellular protease cleavage sites immediately adjacent to the transmembrane domain o f APP. 
One site (M672/D673) is cleaved by the (3-secretase, the other (K687/L688) by the a-secretase 
(see also Fig 1-10). The intracellular portion contains also several different functional domains, 
protease cleavage sites and phosphorylation sites (see Fig 1-9).
transmembrane 
domain of APP
710 720 730 740 750 760 770
-G rM LKKKQYTSIH HG W E  VI PEERHLSKMQQNGYENPTYKFFEQMQN- COOH
Cdk5caspase
y-secretase Dab1, 
MAPK8IP1, 
Numb, X11
PAT1
FE65
(© -d e p e n d e n t)
she  A/C
(© -d e p e n d e n t)
Figure 1-9. Functions within the carboxy-terminal portion of APP. APP is a single membrane-spanning protein containing a 
short (47 amino acids) intracellular carboxy-terminal portion, which is the same for all splice isoforms. The intracellular portion has 
been implicated in the binding of several proteins including Dabl, Fe65, MAPK8Ibl (Jiplb), PAT1, she A1C and X I1. Within the 
intracellular portion several Ser, Thr and Tyr residues can be phosphorylated. Interestingly, phosphorylation at Thr743 on APP770 
(Thr668 in APP695) within the binding domain of Fe65 abolishes the interaction. This phosphorylation is mediated by Cdk5. 
Likewise, phosphorylation at Tyr757/Tyr762 affects association with she A/C. Processing of APP generates numerous different 
carboxy-terminal fragments (CTFs) from the intracellular part (see Fig. 1-7). APP can be cleaved within the transmembrane domain 
at several sites by y-secretase resulting in different-sized CTFs. Moreover, caspases can cleave the intracellular portion of APP. 
(adaptedfrom Kerr & Small, 2005)
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Figure 1-10. Processing of APP involving P-secretase. APP can be cleaved by the p-secretase in 
the extracellular part proximal to the membrane between the residues 671/672 (as per APP770). 
The processing of APP by the P-secretase releases the soluble APP-P amino-terminal part (sAPP- 
P) and the P-carboxy terminal fragment (P-CTF or C99; 99aa). The cleavage site of the y- 
secretase is within the transmembrane domain of P-CTF between residues 711/712, 713/714 or 
720/721. The cleavage o f the P-CTF by the y-secretase produces Ap-peptides including ApM0 
(residues 672 to 711) and APM2 (residues 672 to 713) and y-carboxy-terminal fragments (y-CTFs; 
depending on cleavage site, the y-CTF fragment is 59, 57 or 50aa). Furthermore, caspases cleave 
APP at several sites within the cytosolic part of APP giving rise to multiple different cleavage 
products. For example, caspases cleave APP at the residues 739/740 and release the neurotoxic 
C31 peptide. As all cleavage sites are present in all APP iso forms, the processing of each APP 
isoform results in sAPP-a fragments o f characteristic size.
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Figure 1-11. Processing of APP involving a-secretase. APP can be cleaved by the a-secretase 
in the extracellular part proximal to the membrane between the residues 687/688 (as per 
APP770). The cleavage site lies within the Ap-domain and consequently prevent the production 
o f Ap-peptides. Processing by the a-secretase generates the soluble APP-a amino-terminal part 
(sAPP-a) and the a-carboxy terminal fragment (a-CTF or C83; 83aa). Subsequent cleavage o f a- 
CTF by y-secretase leads to the production of y-CTFs (depending on the cleavage site the y-CTF 
fragments are 59, 57 or 50aa) and p3 peptides (depending on the cleavage site the p3 fragments 
are 24, 26 or 33aa). Moreover, sAPP-a can be cleaved by caspases between residues 673 and 674. 
As all cleavage sites are present in all APP isoforms, the processing of each APP isoform results 
in sAPP-a fragments of characteristic size.
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Figure 2-1. Separation of hippocampal lysate by two-dimensional electrophoresis.
Representative silver stain o f a two-dimensional electrophoresis (2DE) gel o f hippocampal 
synaptosome lysate from a 3 month old WT BL6 mouse. The silver stained gel revealed a high 
number of protein spots and protein spot trains. The proteins display a good separation in the 
range of 20-90 kDa and between the isoelectric points (pi) of 4 and 8. In the higher molecular 
weight range above 90 kDa many spot trains can be detected. These results show that the applied 
method for the 2DE is adequate to separate proteins from complex lysates. The apparent 
molecular weight is indicated in kDa on the left side o f the gel and the pi range is indicated at the 
bottom of the gel.
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Figure 2-2. Evaluation of the methodology used for immunoblotting. Immunoblots o f  
hippocampal lysates from p25 TG mice and one WT control were probed with antibodies against 
synaptotagmin, phospho-GSK3a/{3 (Ser21/9), protein phosphatase 1 (PP1), a-synuclein and C-19 
antibody recognising p35 as well as p25. Different amounts of protein were loaded (5, 10 and 20 
pg/lane) as indicated on top of the blot. The signal o f the bands increased corresponding to the 
higher protein loading demonstrating that the ECL system is suitable to reproducibly detect 
changes in protein concentration. These results suggest that the signal intensities are in the linear 
range. For most blots loading o f 10-20 pg o f protein per lane resulted in an good signal intensity, 
where the band is not saturated or too weak. All o f the blots shown above have been stripped at 
least once prior to incubation with the named antibody. This shows that the stripping of the blots 
does not significantly affect the quality o f the immunoblot signal. The blot probed with the anti- 
phospho-Ser9-GSK3 antibody indicates that changes in phosphorylation levels can be reliably 
detected with the ECL system also using phospho-specific antibodies. Apparent molecular weight 
is indicated in kDa on the right side of the blots.
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Figure 3-1. Phosphorylation pattern of synaptosomal lysate from naive and trained 
aCaMKII T286A mutants and WT mice. Representative immunoblots and quantification from 
hippocampal synaptosome lysates (20 fig protein/lane) o f naive and fear conditioned T286A 
mutants and WT mice. Immunoblots were probed with phospho-specific antibodies raised against 
A) the CaMKII/AKT substrate motif K-K/L-x-S/T(phospho) and B) the Cdk5/MAPK substrate 
motif x-S/T(phospho)-P-x. No obvious changes could be observed between the nai've and trained 
mouse groups with either phospho-specific substrate antibody. The phospho-CaMKII/AKT 
substrate antibody revealed changes in phosphorylation levels between WT and T286A mutants at 
35, 42 and 50 kDa (arrow heads). The changes at 50 kDa correspond to the lack of aCaMKII 
autophosphorylation in the T286A mutants (data not shown).
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Figure 3-2. Marker molecules exhibit increased phosphorylation levels 15 minutes and one 
hour after induction of LTP in DG in vivo. A) Representative immunoblots and quantifications 
from lysates (20 pg protein/lane) o f tetanised and control DG tissue of BL6 WT mice harvested 
15 min after LTP induction. Immunoblots were probed with antibodies against phospho-synapsin 
I (Ser603: 158%, n= 8; F^u = 30.0, * * * / K  0.001), phospho-NR2B (Tyrl472: 135%, n= 4; F ^ =  
783; ***p< 0.001) and phospho-CREB (Serl33: 154%, «= 8; Fv u = 25.8; ***p< 0.001). B) 
Quantifications from lysates (20 pg protein/lane) o f tetanised and control DG tissue of BL6 WT 
mice harvested one hour (lh) after LTP induction. Immunoblots were probed with antibodies 
against phospho-synapsin I (Ser603: 122%, n= 4, 7r1_6= 9.63, *p< 0.05), phospho-NR2B 
(Tyrl472: 146%, n= 5, F ^ =  20.6, **p< 0.01) and phospho-CREB (Serl33: 151%, n= 6, F^mW— 
26.8, ***p< 0.001). (taken from Cooke et al., 2006)
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Figure 3-3. Phosphorylation levels of marker molecules are elevated after in vivo 
potentiation in area CA1. Representative immunoblots and quantification from lysates (20 pg 
protein/lane) of tetanised and control CA1 tissue of BL6 WT mice harvested one hour (lh) after 
LTP induction. Immunoblots were probed with antibodies against phospho-synapsin I (Ser603: 
171%, n= 4, F ^=  8.27, *p< 0.05), phospho-NR2B (Tyrl472: 108%, n= 4, F ^=  0.68, p>  0.05) 
and phospho-CREB (Serl33: 172%, n= 4, 8.58, *p< 0.05).
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Figure 3-4. Autophosphorylation of aCaMKII is elevated after LTP induction in 
hippocampal area CA1 and DG in vivo. Quantification of immunoblots from lysates (20 pg 
protein/lane) of tetanised and control CA1 or DG tissue of WT mice. Immunoblots were probed 
with an antibody recognising phospho-Thr286-aCaMKII. The levels of aCaMKII 
autophosphorylation at Thr286 were increased one hour after tetanisation in hippocampal area 
CA1 (150%, n= 5, F ^=  13.5, *p< 0.05) as well as DG (162%, «= 5, F ^ =  435, ***p< 0.001) and 
in DG 15 minutes after tetanisation (145%, n= 8, F^ _u = 14.6, **p< 0.01). (taken from Cooke et 
al, 2006)
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Figure 3-5. Autophosphorylation of P-isoform of CaMKII is increased after LTP induction 
in hippocampal area CA1 and DG in vivo. Quantification of immunoblots from lysates (20 pg 
protein/lane) of tetanised and control CA1 or DG tissue of WT mice. Immunoblots were probed 
with an antibody recognising phospho-Thr287-pCaMKII. The levels in pCaMKII 
autophosphorylation at Thr287 were increased one hour after tetanisation in hippocampal area 
CA1 (132%, n= 5, F ^=  7.45, *p< 0.05) as well as DG (132%, n= 5, F ^ =  14.6, **p< 0.01) and 
in DG 15 minutes after tetanisation (153%, n= 8, F 1.14= 39.3, ***p< 0.001). (taken from Cooke et 
al., 2006)
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Figure 3-6. LTP induction in DG of T286A mutants leads to increased autophosphorylation 
of PCaMKII in vivo. Quantification of immunoblots from lysates (20 pg protein/lane) of 
tetanised and control CA1 or DG tissue of WT mice. Immunoblots were probed with an antibody 
recognising phospho-Thr287-pCaMKII. The levels in PCaMKII autophosphorylation at Thr287 
were increased one hour after tetanisation in DG of aCaMKII T286A mutants (136%, n= 5 ,^ .8=  
48.7, ***p< 0.001). (taken from Cooke et al., 2006)
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Figure 3-7. Normal PCaMKII levels in crude synaptosomal fraction of aCaMKII T286A 
mutants. A) Representative immunoblots from hippocampal synaptosome lysates (20 pg 
protein/lane) of T286A mutants and WT mice assayed with antibodies against aCaMKII, 
PCaMKII and a phospho-specific antibody detecting the autophosphorylation sites on both 
aCaMKII (Thr286) as well as PCaMKII (Thr287). B) Quantification of immunoblots showed no 
difference between T286A mutants and WT mice in the normalised ratio of phospho-Thr287- 
pCaMKII /pCaMKII (n= 3, F M= 6.90, p>  0.05) and in the normalised ratio PCaMKII /aCaMKII 
(»= 3, F m= 6.27, p> 0.05). (taken from Cooke et al., 2006)
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Figure 3-8. Increased phosphorylation at the inhibitory Ser9 site of GSK3 after in vivo LTP 
induction in area CA1 and DG in WT mice. A) Representative immunoblot from hippocampal 
lysates (20 pg protein/lane) of tetanised and control tissue from DG of WT mice harvested 15 
minutes after LTP induction. Immunoblots were probed with an antibody recognising phospho- 
GSK3a/p (Ser21/9). B) The quantification of immunoblots of lysates from hippocampal area 
CA1 of WT mice harvested one hour after in vivo LTP induction revealed a significant increase in 
phospho-Ser9-GSK3p signal (134%, n= 4, FU6= 6.29, *p< 0.05). C and D) The quantification of 
immunoblots of lysates from DG of WT mice harvested 15 minutes and one hour after in vivo 
LTP induction showed a significant increase in phosphorylation of GSK3P at Ser9 (15 min: 
134%, n= 8, F ,.14= 10.2, **p< 0.01; lh: 156%, n= 6, F ,.10= 16.5, **p< 0.01 )
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Figure 3-9. The inhibitory site of GSK3 shows enhanced phosphorylation after induction of 
LTP in DG of aCaMKII T286A mutants in vivo. The quantification of immunoblots from 
hippocampal lysates (20 pg protein/lane) of tetanised and control tissue from DG of T286A 
mutants assayed with an anti-phospho-GSK3a/p (Ser21/9) antibody revealed a significant 
increase in phosphorylation of GSK3P at Serf) one hour after LTP induction (123%, n= 5, Fj.8= 
5.31, *p< 0.05).
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Figure 4-1. Analysis of p25 expression in the p25 TG mice. A) Immunoblots from hippocampal 
lysates o f p25 TG and WT mice probed with antibodies recognising synaptotagmin and the 
carboxy-terminus of p35 (both p35 and p25). No changes in endogenous p35 expression are 
detected between genotypes. Expression of p25 is detected in TG mice, but not in WT mice. B) In 
TG mice p25 expression was detected in neocortex (CX), striatum (SR), and spinal cord (SC), but 
not in cerebellum (CB). C) Quantification o f p25 immunoblot signal in relation to endogenous 
p35 signal in hippocampus (HP, n= 5), CX (n= 2), SR, (n= 2) and SC (n= 2). (Taken from Angelo 
etaL, 2003)
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Figure 4-2. Level of p25 expression is constant in young and old TG mice. Immunoblots from 
hippocampal lysates o f  young (3 month) and old (18 month) TG mice and WT littermates were 
assayed with C-19 (recognising p35 as well as p25), anti-Cdk5 and anti-(3-actin antibodies. The 
immunoblot analysis showed that p25 expression persists in young and old TG mice and that no 
p25 could be detected in hippocampal lysates from WT mice. (Taken from Plattner et al., 2006)
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Figure 4-3. Crude synaptosomal fractions from TG mice contain p25 and unaltered levels of 
Cdk5. Immunoblots o f A) crude synaptosomal fractions and B) whole hippocampal lysates o f  TG 
mice and WT littermates probed with an antibody recognising p35 as well as p25 and a Cdk5- 
specific antibody. The results reveal the presence o f  p25 in crude synaptosomal lysates from 
hippocampi o f TG mice, but not WT controls. The levels o f  Cdk5 in the synaptosomal fractions 
were equal in TG and WT mice, indicating no re-localisation o f Cdk5 away from the synapse.
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Figure 4-4. Expression of p25 induces overactivation of Cdk5 at 3 and 18 month.
Quantification o f Cdk5 immunoprecipitation kinase activity assays from hippocampal lysates o f  
TG mice and WT controls at A) young (3 month) and B) old (18 month) age. Cdk5 activity was 
increased by approximately 2-fold in both young and old TG mice as compared with WT mice (3 
month: n= 4, F w = 29.0, **p< 0.01; 18 month: n= 4, FU6= 33.2, **p< 0.01). (Takenfrom Plattner 
etal., 2006)
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Figure 4-5. Increased phosphorylation of neurofilament M in p25 TG mice. 2-DE immunoblots of crude 
hippocampal synaptosomes fractions of A) WT mice and B) p25 TG mice probed with a phospho-specific 
Cdk/MAPK substrate antibody revealed multiple changes in spot intensities (arrow heads). The spot X (160 
kDa, pi 4.5) showed a 2.5-fold change in TG mice as compared to WT controls. Insets: reprobing the 2-DE 
blots with an antibody (RT97) recognising neurofilament M (NF-M; 160 kDa, pi 4.5) and neurofilament H 
(NF-H; 200 kDa, pi 4.3) demonstrated that NF-M corresponded to spot X. (Taken from Angelo et al., 2003)
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Figure 4-6. Age-dependent increase in tau hyperphosphorylation at the AT8 and PHF-1 sites 
in the hippocampus of p25 TG mice. A) Representative immunoblots o f hippocampal lysates 
from young and old p25 TG mice and WT controls assayed with phospho-specific tau antibodies 
AT-8 (phospho-Ser202/Thr205), AT 100 (phospho-Thr212 and/or Ser214), TG3 (phospho- 
Thr231/Ser235) and PHF-1 (phospho-Ser396/404), pan-tau antibody BR134 and SMI31, a 
phospho-specific neurofilament antibody cross-reacting with the hyperphosphorylated PHF-1 
epitope. B) Quantification o f immunoblots probed with AT8, ATI00, TG3, PHF-1 and SMI31 
(mean ± SEM). At 18 months o f  age tau hyperphosphorylation at the AT8 and PHF-1 sites was 
significantly increased by approximately 90% in TG mice as compared with WT littermates (n= 4; 
AT-8: F,_6= 55.4, ***p< 0.001; PHF-1: F1j6= 31.2, **p< 0.01, SMI31: F ^=  27.1, **p< 0.01). 
Tau hyperphosphorylation at the AT100 and TG3 site were not different between genotypes at 
young and old age (AT100: 3 month: n= 4; Flm6-  0 .02,p>  0.5; 18 month: n= 4; F{_6= 3.31, p>  0.1; 
TG3: 3 month: rt= 4; Flm6= 0.06, p>  0.5; 18 month: n= 4; Fl_6= 0.12, p>  0.5). (Taken from Plattner 
etal., 2006)
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Figure 4-7. Assessment of phosphorylation levels at the activatory sites of the proline-directed kinases 
ERK, MEK1/2 and JNK in p25 TG mice. Representative immunoblots from hippocampal lysates of young 
and old TG and WT mice probed with phospho-specific antibodies raised against the activatory 
phosphorylation sites of ERK1/2 (Thr202/Tyr204), MEK1/2 (Ser217/221) and JNK (Thrl83/Tyrl85). 
Quantification of the immunoblot signals revealed a reduction in the phosphorylation levels on A) ERK (3 
month: n= 8, Jr1.l4:= 5.08, *p< 0.05; 18 month: n= 4, F^= 3.78, p= 0.07), but no changes in B) JNK (3 
month: n= 4, F^= 0.76, p> 0.1; 18 month: n= 4, F^= 0.77, p> 0.1), and C) MEK1/2 (3 month: n= 5, Fu%-  
0.31, p> 0.1; 18 month: n= 4, F^= 0.01 ,p> 0.1). (Taken from Plattner et al., 2006)
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Figure 4-8. Age-dependent changes in phosphorylation levels at the inhibitory site of GSK3 
in p25 TG mice. A) Representative immunoblots from hippocampal lysates o f  young and old TG 
and WT mice probed with antibodies recognizing the inhibitory phosphorylation sites on 
GSK3a/p (Ser21/9) and total GSK3a/p protein. B) Quantification o f data from phospho-Ser9- 
GSK3P immunoblots revealed an approximately 80% increase in 3 month-old TG mice («= 6; F}_ 
]0-  13.0, **p< 0.01). Phospho-Ser9-GSK3p levels were not different between genotypes at old 
age. (Taken from Plattner et al., 2006)
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Figure 4-9. Phosphorylation at the inhibitory site on GSK3 is not mediated by AKT and 
p90RSK in TG mice. A) Representative immunoblots from hippocampal lysates o f  young TG 
and WT mice probed with phospho-specific antibodies raised against activatory phosphorylation 
sites o f AKT (Thr308) and p90RSK (Thr359/Ser363). B) Quantification o f the immunoblot 
signals showed no changes in phosphorylation levels o f  AKT (Thr308: n= 4 ,F ^ =  1.17, p>  0.1) 
and of p90RSK (Thr359/Ser363: n= 4 , F ,.6= 0.06,p>  0.1).
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Figure 4-10. Age-dependent increase in GSK30 phosphorylation at the activatory site in TG 
mice. A) Representative immunoblots from hippocampal lysates o f  young and old TG and WT 
mice probed with antibodies recognising the activatory phosphorylation sites o f GSK3a/p 
(Tyr279/216) and total GSK3a/p protein. B) Quantification o f  the immunoblot signals detected no 
changes in phosphorylation o f Tyr216 on GSK3P between genotypes at 3 month («= 4, Fx^ = 0.06, 
p>  0.5) and at 18 month (n= 4, F1_6= 0.12, p>  0.5). C) GSK3P displays higher level o f  
phosphorylation at the activatory sites in old TG as well as old WT mice. Quantification o f signals 
from the activatory sites on GSK3a/p (Tyr279/216) revealed that GSK3a displays a constant 
level o f Tyr279 phosphorylation, whereas the level o f phosphorylation o f Tyr216 on GSK3P is 
increased in both TG and WT mice at old age (WT: n= 4, F}_6= 90.7, ***p< 0.001; TG: n= 4, F;_ 
6= 73.9, ***p< 0.001). (Taken from Plattner et al., 2006)
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Figure 4-11. GSK30 activity is reduced in young, but increased in old p25 TG mice.
Quantification of GSK3P immunoprecipitation kinase assays from hippocampal lysates o f  TG 
mice and WT controls at A) young (3 month) and B) old (18 month) age. GSK3(3 activity was 
significantly reduced by approximately 25% in young TG mice (n= 5, F U8= 16.8, **p< 0.01), but 
it was significantly increased by approximately 70% in old TG mice (n= 3, FlA= 13.8, *p< 0.05). 
(Taken from Plattner et al., 2006)
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Figure 4-12. Chronic in vivo lithium treatment reduced tau hyperphosphorylation in aged 
p25 TG mice. Immunoblot analysis and signal quantification from hippocampal lysates from 
aged, 22-24 month old, lithium treated TG mice and untreated aged TG mice (control) probed 
with PHF-1, AT8, phospho-Thr668-APP and P-catenin antibodies. The quantification showed that 
tau hyperphosphorylation was significantly reduced in lithium treated TG mice as compared to 
TG controls A) at the AT8 site («= 4, F 16= 5.99, *p< 0.05) and B) at the PHF-1 site (n= 4, F 16= 
26.4, ***p< 0.001). C) Levels o f  phospho-Thr668-APP were unaltered (n = 4, F{ 6= 1.06, p>  0.1) 
suggesting the lithium treatment did not effect Cdk5 activity. D) Levels o f P-catenin were 
increased in lithium treated mice («= 4, F 16= 6.23, *p< 0.05) demonstrating reduced GSK3 
activity. (Taken from Plattner et al„ 2006)
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Figure 4-13. Effects of chronic lithium treatment in vivo in aged WT mice. Immunoblot 
analysis and signal quantification from hippocampal lysates from aged, 18-19 month old, lithium 
treated WT mice and untreated aged WT controls probed with PHF-1, AT8, phospho-Thr668-APP 
and p-catenin antibodies. The quantification showed that tau hyperphosphorylation was affected 
non-significantly in lithium treated WT mice as compared to WT controls A) at the AT8 site («= 
3, Fm= 0.64, p>  0.1) and B) at the PHF-1 site (n= 3; FlA= 6.18,p >  0.05). C) Levels o f phospho- 
Thr668-APP were unaltered (n= 3; FlA= 0.02, p>  0.5) suggesting the lithium treatment did not 
effect Cdk5 activity. D) Levels o f  p-catenin were increased in lithium treated WT mice (n= 3; Fu 
4= 16.7, *p< 0.05) demonstrating reduced GSK3 activity. (Taken from Plattneret al., 2006)
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Figure 4-14. Levels of P-catenin are not altered between genotypes. Representative 
immunoblots from hippocampal lysates o f  young and old TG and WT mice probed with an anti-P- 
catenin antibody. Quantification o f the immunoblot signals revealed no changes in P-catenin 
protein levels between genotypes A) at young age (/i= 4, F 16= 2.26, p>  0.1) and B) at old age (n=
4, F m= 0.00, p> 0.1). (Taken from Plattner et al., 2006)
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Figure 4-15. Association of Cdk5, GSK3 and PP2A. Co-immunoprecipitation experiments with 
hippocampal lysates from TG mice and WT littermates were carried out using either anti-GSK3p 
antibody or non immune antibody as a control. Immune pellets were analysed by immunoblotting 
using A) anti-GSK3p antibody, B) anti-Cdk5 antibody as well as antibodies recognizing C) the 
catalytic subunit o f PP2A (PP2Ac) and D) the scaffolding/ regulatory subunit o f PP2A (PR65/A). 
The molecular weight standards are shown on the right. Immunoreactive bands o f interest are 
indicated by arrow heads. The band running at approximately 50 kDa in C) and D) and at 28 kDa 
in B) results from cross-reactivity with the immunoprecipitating IgG. These immunoblots are 
representative o f  n= 4 independent experiments. (Takenfrom Plattneret al., 2006)
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Figure 4-16. Okadaic acid affects GSK30 activity differently in TG mice and WT controls.
GSK30 immunoprecipitation kinase assay o f  hippocampal lysates from young TG (n= 4) and WT 
mice (n= 4) were carried out in presence or absence o f  okadaic acid (OA), a PP1 and PP2A 
inhibitor. Addition o f okadaic acid reduced the GSK30 activity in TG mice, but not WT controls. 
(Taken from Plattner et al., 2006)
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Figure 4-17. Persistent increase in APP phosphorylation at Thr668 in p25 TG mice. A)
Representative immunoblots from hippocampal lysates o f  young and old TG mice and WT 
controls probed with a phospho-specific antibody recognising APP (pAPP) phosphorylated at 
Thr668 (as per APP695). Total APP protein levels were detected with antibodies against the 
unphosphorylated epitope around Thr668 on APP (APP) and the carboxy-terminus o f APP (CT- 
15). B) Quantification o f phospho-Thr668-APP signal revealed a significant increase o f  
approximately 60% in TG mice at 3 months (n= 6, FI10= 11.1, **p< 0.01) and 18 months (n= 4, 
Fj_6= 175, ***p< 0.001). (Taken from Plattneret al., 2006)
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Figure 4-18. Schematic representation of antibody epitopes on APP. APP is a single 
transmembrane protein. In this study different antibodies were used that recognise distinct 
epitopes within the extracellular and intracellular part o f APP. On the extracellular side are the 
epitopes o f an antibody raised against the amino-terminal sequence o f APP (APP N-term) and an 
antibody recognising a site adjacent to the transmembrane domain within the A^-peptide domain 
at residues 686-695 (4G8). Within the intracellular portion are the epitopes o f the anti-phospho- 
Thr668-APP antibody (as per APP695). Further, an antibody recognising the epitope around 
Thr668 on APP in the unphosphorylated state (APP) and an antibody raised against the carboxy- 
terminus of APP (CT-15).
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Figure 4-19. 2DE immunoblot analysis of APP isoforms and fragments. Representative one­
dimensional SDS PAGE blots (left o f marker) and two-dimensional electrophoresis (2DE) 
immunoblots (right o f marker) of hippocampal lysate from a 3 month-old WT mouse probed with 
A) an antibody recognising the carboxy-terminus o f APP (CT-15) and B) assayed with an anti- 
Ap-peptide antibody (4G8). 2DE analysis with both antibodies reveals the existence o f a large 
number of APP isoforms, possibly generated by alternative processing and post-translational 
modifications. Comparison of the 2-DE blots show that both antibodies detect a similar spot 
pattern. Protein spots detected by both antibodies are likely to be APP isoforms. Mature (mt) and 
immature (im) isoforms of APP are indicated left of the one-dimensional blot.
FIGURES: Chapter 4 197
H  phospho-Thr668-APP 
: |  APP (composite)
Figure 4-20. Subset of APP isoforms display Thr668 phosphorylation. A composite picture 
from 2DE immunoblots assayed with anti-Ap-peptide antibody and the CT-15 antibody was 
overlaid with a 2-DE immunoblot probed with anti-phospho-Thr668-APP antibody. In the 
composite picture spots without communality between the anti-Ap-peptide antibody and the CT- 
15 antibody were omitted. The overlay reveals that only a well-defined subset o f APP isoforms 
displays phosphorylation at Thr668.
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Figure 4-21. Age-dependent changes in APP processing in p25 TG mice. A) Representative 
immunoblots from hippocampal lysates o f  3, 18 and 26 month-old TG mice and WT littermates 
probed with an anti-Af} antibody (4G8). The immunoblots reveal an age-dependent accumulation 
o f a 57 kDa fragment (arrow head) in TG mice after 18 months o f age. B) Quantification o f signal 
from the 57 kDa fragment showed a significant increase in TG mice at 18 month (n= 4,
15.9, **p< 0.01) and 26 month (n= 4, FJm6= 44.6, ***p< 0.001). In 3 month-old TG mice and WT 
controls no signal was observed at 57 kDa.
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Figure 4-22. The 57 kDa fragment is recognised by anti-AP antibody, but not amino- and 
carboxy-terminal anti-APP antibodies. Representative immunoblots from hippocampal lysates 
of 18 month-old TG mice and WT littermates probed with antibodies recognising the Ap-peptide 
domain (4G8), the amino-terminal part o f APP and the carboxy-terminus o f APP (CT-15). The 57 
kDa band (arrow head) is only detected with the anti-Ap antibody, but not with antibodies against 
the amino- and carboxy-terminus of APP.
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Figure 4-23. No changes in carboxy-terminal fragments of APP in TG mice. Representative 
immunoblots from hippocampal lysates o f old TG mice and old WT controls separated on a 16% 
tris tricine gel. The immunoblots were probed with anti-Ap-peptide antibody (4G8), anti-phospho- 
Thr668-APP antibody (pAPP) and antibody against the carboxy-terminus o f APP (CT-15). None 
of the antibodies detected any changes in signal intensity between genotypes.
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Figure 4-24. Proposed model of the inhibitory cross-talk of p25/Cdk5 and GSK3 as observed 
in young p25 TG mice. In 3 month-old p25 TG mice Cdk5 is over-activated by association with 
p25. The p25-induced Cdk5 over-activation leads to the inhibition o f GSK3, possibly by indirectly 
regulating the phosphorylation level at the inhibitory site o f GSK3. Numerous protein kinases and 
protein phosphatases have been directly involved in the regulation of the inhibitory 
phosphorylation o f GSK3 (see for review Grimes & Jope, 2001). Hence, it is conceivable that 
Cdk5 controls GSK3 activity via some o f these protein kinases and phosphatases. In line with this 
hypothesis, my results indicate that Cdk5 acts via protein phosphatases such as PP1 and PP2A, 
possibly by affecting their regulatory subunits. However, Cdk5 seems not to act via AKT and 
p90RSK, two kinases linked to the regulation o f GSK3 activity (see for review Grimes & Jope, 
2001). Interestingly, in the p25 TG mice at 3 month o f age the two-fold increase in Cdk5 activity 
does not lead to hyperphosphorylation of tau at disease-associated epitopes. This finding suggest 
that Cdk5 is not directly mediating hyperphosphorylation o f tau, but in feet might affect tau 
hyperphosphorylation by regulation of other kinases, such as GSK3. (Taken from Plattner et al., 
2006)
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Figure 4-25. Model of the disruption of the cross-talk between p25/Cdk5 and GSK3 in old 
p25 TG mice. In 18 month-old p25 TG mice Cdk5 is over-activated by the expression of p25. 
However, the p25-induced Cdk5 over-activation does not inhibit GSK3 any longer, possibly 
because o f the disruption o f the regulatory mechanism by which Cdk5 controls GSK3. 
Consequently, in old TG mice GSK3 activity is increased, which correlates with elevated levels of 
tau hyperphosphorylation at the disease-associated epitopes AT8 and PHF-1. Pharmacological 
inhibition of GSK3 by chronic lithium-treatment reduces the levels o f tau hyperphosphorylation at 
the AT8 and PHF-1 sites in old TG mice.
Together, these results suggest that GSK3 is directly hyperphosphorylating tau at the AT8 and 
PHF-1 sites. Furthermore, the data indicate that pharmacological GSK3 inhibitors, such as 
lithium, can reduce the levels o f tau hyperphosphorylation at the AT8 and PHF1 sites and thus 
may be useful as a treatment in tauopathies including AD. (Taken from Plattner et al., 2006)
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APPENDIX I: Sequence alignment of tau from mouse, human and rat origin
Aligned sequences:
1) sp|P1063 7|TAU_MOUSE
2) sp j P10636 j TAU_HUMAN
3) sp j P19332 j TAU-RAT
length:
732aa
757aa
751aa
Please note that only upper-case letters are considered to be aligned.
Alignment (DIALIGN format):
sp|P10637|TAU 
sp j P10636 j TAU 
sp j P19332 j TAU
1 ADPRQEFDTM EDHAGD ------ YTL LQDQEGDMDH GLKESPPQPP
1 AEPRQEFEVM EDHAGtyglg drkdqggYTM HQDQEGDTDA GLKESPLQTP
1 AEPRQEFDTM EDQAGD  ------ YTM LQDQEGDMDH GLKESPPQPP
* * * * * * * * * *  * * * * * *  
* * * * * * * * * *  * * * * * *  
* * * * * * * * * *  * * * * *
* * *  * * * * * * * * * *  * * * * * * * * * *
* * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  
* * *  * * * * * * * * * *  * * * * * *  * * *
spIP10637|TAU 40 ADDGAEEPGS ETSDAKSTPT AEDVTAPLVD ERAPDKQAAA QPHTEIPEGI
sp j P10636 j TAU 51 TEDGSEEPGS ETSDAKSTPT AEDVTAPLVD EGAPGKQAAA QPHTEIPEGT
sp j P19332 j TAU 40 ADDGSEEPGS ETSDAKSTPT AEDVTAPLVE ERAPDKQATA QSHTEIPEGT
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * *  * * * * *  *  * * * * * * * *
sp|P10637|TAU 90 TAEEAGIGDT PNQEDQAAGH VTQ   G RREGQAPDLG
sp| P10636 j TAU 101 TAEEAGIGDT PSLEDEAAGH VTQEPESGKV VQEGFLREPG ppgls----
sp j P19332 j TAU 90 TAEEAGIGDT PNMEDQAAGH VTQEPQKVEI FSQSLLVEPG RREGQAPDSG
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  
* * * * * * * * * *  * * * * * * * * * *  * * *  *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * *
* * * * * * *
sp|P10637 | TAU 124 TSDWTRQQVS SMSGAPLLPQ GLREATCQPS GTRPEDIEKS HPASELLRR-
sp j P10636 j TAU 146 ----- HQLMS GMPGAPLLPE GPREATRQPS GTGPEDTEGG RHAPELLKhq
sp j PI93 32 | TAU 140 ISDWTHQQVP SMSGAPLPPQ GLREATHQPL GTRPEDVERS HPASELLWQ-
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * *
* *  * * * * * * * * * *  * * * * * *  * * *  * * * * * * * * * *  * * * * *
sp|P10637 j TAU 173 -------- GP PQKEGWGQDR LGSEEEVDED LTVDESS-QD SPPSQASLTP
sp j P10636 j TAU 191 llgdlhqeGP PLKGAGGKER PGSKEEVDED RDVDESSpQD SPPSKASPAQ
sp j P19332 j TAU 189 -------- ES PQKEAWGKDR LGSEEEVDED ITMDESS-QE SPPSQASLAP
* *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * *  * *  * * * * * * * * * *  
* *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * *
Sp |P1063 7|TAU 214 GRAAPQAGSG SVCG ETA SVPGLPTEGS VPLPADFFSK VSAETQASQP
sp j P10636 j TAU 241 DGRPPQTAAr EAT SIPGFPAEGA IPLPVDFLSK VSTEIPASEP
sp j P19332 j TAU 23 0 GTATPQARSV SASGvsgETT SIPGFPAEGS IPLPADFFSK VSAETQASPP
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sp|P10637|TAU 
sp|P10636 j TAU 
sp j P19332 j TAU
261 EGPGTGPmEE GHEAAPEFTF HVEIKASTPK EQD---- LE GATWGVPGE
284 DGPSVGra-K GQDAPLEFTF HVEITPNVQK EQahseehLG RAAFPGAPGE 
280 EGPGTGPsEE GHEAAPEFTF HVEIKASAPK EQD---- LE GATWGAPAE
* * * * * * *  * *  * * * * * * * * * *  * * * * * * * * * *  * * *  
* * * * * * *  * *  * * * * * * * * * *  * * * * * * * * * *  * * *  
* * * * * *
* * * * * *
* *  * * * * * * * * * *  
* *  * * * * * * * * * *  
* * * * *
sp | P10637|TAU 306 EQKAQtqGPS VGKGTKEASL QEPPGKQPAA GLPGRPVSRV PQLKARVa--
sp j P10636 j TAU 333 GPEAR--GPS LGEDTKEADL PEPSEKQPAA APRGKPVSRV PQLKARMVSK
sp j P19332 j TAU 325 EQKAR--GPS VGKGTKEASL LEPTDKQPAA GLPGRPVSRV PQLKARVAGV
* * * * *  * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * *  * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * *
* * *  * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * *
* * * * * * *  * * * * * * *
sp| P10637|TAU 354 SKDRTGNDEK KAKTSTPSCA KAPSHRPCLS PTRPTLGSSD PLIKPSSPAV
sp j P10636|TAU 381 SKDGTGSDDK KAKTSTRSSA KTLKNRPCLS PKLPTPGSSD PLIQPSSPAV
sp j P193 3 2 j TAU 373 SKDRTGNDEK KAKTSTPSCA KTPSNRPCLS PTRPTPGSSD PLIKPSSPAV
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * *  * * * *  *  * * * * * *
* * * * * * * * *  * * * * * * * * * *  * *  * * * * * *  * * * * *  * * * * * *
sp I P1063 7 ITAU 404 SPEPATSPKH VSSVTPRNGS PGTKQMKLKG ADGKTGAKIA TPRGAASPAQ
sp | P10636|TAU 431 CPEPPSSPKH VSSVTSRTGS SGAKEMKLKG ADGKT--KIA TPRGAAPPGQ
sp j P19332 j TAU 423 CPEPATSPKY VSSVTPRNGS PGTKQMKLKG ADGKTGAKIA TPRGAATPGQ
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * *  * * *  * * * * * * * *  *  
* * * *  * * * * *  * * * * * * * * * *  * * * *  *
Sp | P10637|TAU 454 KGTSNATRIP AKTTPSPKTP PGSGEPPKSG ERSGYSSPGS PGTPGSRSRT
sp j P10636 j TAU 479 KGQANATRIP AKTpPAPKTP PSSGEPPKSG DRSGYSSPGS PGTPGSRSRT
sp |P19332 jTAU 473 KGTSNATRIP AKTTPSPKTP PGSGEPPKSG ERSGYSSPGS PGTPGSRSRT
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  
* * * * * * * * * *  * * *  * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  
* * * * * * * * * *  * * *  * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  
* * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
sp | P10637 | TAU 504 PSLPTPPTRE PKKVAWRTP PKSPSASKSR LQTAPVPMPD LKNVRSKIGS
sp | P10636 j TAU 529 PSLPTPPTRE PKKVAWRTP PKSPSSAKSR LQTAPVPMPD LKNVKSKIGS
sp j PI93 32 j TAU 523 PSLPTPPTRE PKKVAWRTP PKSPSASKSR LQTAPVPMPD LKNVRSKIGS
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
sp|P10637| TAU 554 TENLKHQPGG GKVQIINKKL DLSNVQSKCG SKDNIKHVPG GGSVQIVYKP
sp j P10636 j TAU 579 TENLKHQPGG GKVQIINKKL DLSNVQSKCG SKDNIKHVPG GGSVQIVYKP
sp | P19332|TAU 573 TENLKHQPGG GKVQIINKKL DLSNVQSKCG SKDNIKHVPG GGSVHIVYKP
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
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sp|P10637|TAU 
sp j P10636 j TAU 
sp j P19332|TAU
604 VDLSKVTSKC GSLGNIHHKP GGGQVEVKSE KLDFKDRVQS KIGSLDNITH
629 VDLSKVTSKC GSLGNIHHKP GGGQVEVKSE KLDFKDRVQS KIGSLDNITH
623 VDLSKVTSKC GSLGNIHHKP GGGQVEVKSE KLDFKDRVQS KIGSLDNITH
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
sp|P1063 7|TAU 
sp|P10636 j TAU 
sp j P19332|TAU
654 VPGGGNKKIE THKLTFRENA KAKTDHGAEI VYKSPWSGD TSPRHLSNVS
679 VPGGGNKKIE THKLTFRENA KAKTDHGAEI VYKSPWSGD TSPRHLSNVS
673 VPGGGNKKIE THKLTFRENA KAKTDHGAEI VYKSPWSGD TSPRHLSNVS
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * *
sp|P10637|TAU 
sp j P10636|TAU 
sp j P193 3 2 j TAU
704 STGSIDMVDS PQLATLADEV SASLAKQGL
729 STGSIDMVDS PQLATLADEV SASLAKQGL
723 STGSIDMVDS PQLATLADEV SASLAKQGL
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * *
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * *
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APPENDIX II: Protocol for the use of Silver Stain Plus reagents (BioRad)
For all handling use clean containers. After use wash the containers with 50% nitric 
acid.
1. Rinse Gel with Milipore water and incubate for at least 20 min in fixative 
solution (200ml for one 20x20cm gel or two mini-gels).
Fixative Enhancer Solution
Methanol 100 ml 50 %v/v
Acetic acid 20 ml 10%v/v
Fixative Enhancer
Concentrate 20 ml 10%v/v
Millinore H2Q________ 60 ml_______ 30% v/v
Total 200 ml 100% v/v
In this solution the gel can be stored for longer period of time.
Therefore, the fixative step is a good stopping point.
2. Rinse Step: Decant Fixative solution and rinse gel with Millipore water for 10 
min. Change water and rinse at least for another 10 min. Adjust rinse time for 
larger and thicker gels (see BioRad protocol).
3. Staining step: Prepare staining solution within 5 min of use (Use special 250 ml 
bottle). Take Development Accelerator Solution out of fridge and bring to RT.
50 ml of staining solution are enough for one 20x20cm gel or two mini-gels.
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Staining Solution
Millipore H20 18 ml
Add in following order:
Silver Complex Solution 2.5 ml
Reduction Moderator Solution 2.5 ml
Image Develoment Reagent 2.5 ml
Immediately before use quickly add:
Development Accelerator Solution 25 ml
50 ml
Stain until desired staining intensity is reached. It may take at least 10 min 
before bands become visible.
4. After desired staining is reached, place the gel in 5 % acetic acid for a minimum 
of 15 min to stop the reaction. Rinse the Gel with Millipore water and 
photograph or dry it.
Destaining
Silver stain plus gels can be completely destained in 1% Hydrogen Peroxide.
Question?
For all further question please consult BioRad protocol.
